




- (51) **International Patent Classification:**
A61K 31/64 (2006.01) A61K 39/395 (2006.01)
A61K 45/06 (2006.01)
- (21) **International Application Number:** PCT/US2016/015964
- (22) **International Filing Date:** 1 February 2016 (01.02.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 62/109,918 30 January 2015 (30.01.2015) US
- (71) **Applicant:** TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad & Montgomery Avenue, Philadelphia, PA 19122 (US).
- (72) **Inventor:** YANG, Xiaofeng; 1612 Reading Circle, Huntingdon Valley, PA 19006 (US).
- (74) **Agents:** NGUYEN, Quang D. et al.; Riverside Law, LLP, Glenhardie Corporate Center, 1285 Drummers Road, Suite 202, Wayne, PA 19087 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) **Title:** EARLY HYPERLIPIDEMIA PROMOTES ENDOTHELIAL ACTIVATION VIA A CASPASE-1-SIRTUIN 1 PATHWAY

(57) **Abstract:** The present invention provides compositions and methods for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including but not limited to cardiovascular diseases and inflammatory disorders.



Figures 1A – 1E



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

TITLE OF THE INVENTION

EARLY HYPERLIPIDEMIA PROMOTES ENDOTHELIAL ACTIVATION VIA A
CASPASE-1-SIRTUIN 1 PATHWAY

5 CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 62/109,918 filed January 30, 2015, the content of which is incorporated by reference herein in its entirety.

10 STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

This invention was made with government support under RO1 HL 094451-01A1 and RO1 HL 108910-01, awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.

15

BACKGROUND OF THE INVENTION

Hyperlipidemia, a risk factor for cardiovascular disease, is defined as pathologically elevated plasma concentrations of cholesterol and other lipids, which are commonly found in patients with atherosclerosis (Libby et al., 2011, Nature 473:317-25). It has been reported that hyperlipidemia, proinflammatory mediators, and other risk factors promote endothelial cell (EC) activation and atherosclerosis via several mechanisms, which include inducing endothelial activation and injury (Mestas and Ley, 2008, Trends Cardiovasc Med 18:228-32; Jiang et al., 2005, Arterioscler Thromb Vasc Biol 24:2515-21), increasing monocyte recruitment and differentiation (Zhang et al., 2009, Circulation 120:1893-902; 20 Combadière et al., 2008, Circulation 117:1649-57), and decreasing regulatory T cell population (Xiong et al., 2009, Atherosclerosis. 203:401-8; Ait-Oufella et al., 2006, Nat Med 12:178-80).

ECs that line the inner surface of vessel wall are the first cells exposed to metabolite-related endogenous danger signals in the circulatory system (Libby et al., 2011, Nature 473:317-25). Endothelial activation is, therefore, defined as the initial event responsible for monocyte recruitment in atherogenesis (Chowienzyk et al., 1992, Lancet 340:1430-2). However, questions such as how hyperlipidemia can be sensed by ECs and how hyperlipidemia-induced vascular inflammation is initiated remain largely unanswered.

The cellular receptors, which can recognize the risk factors for atherogenesis, such as hyperlipidemia, have been under intensive search. The role of receptors for pathogen-associated molecular patterns has been characterized recently as bridging innate immune sensory systems for exogenous infectious agents and endogenous metabolic danger signals associated molecular patterns (DAMPs) to initiation of inflammation (Yang et al., 2008, *Drug Discov Today Ther Strateg* 5:125-42). The toll-like receptors, mainly located in the plasma membrane, recognize a variety of conserved microbial pathogen-associated molecular patterns and metabolic DAMPs and promote inflammatory gene transcription. As we described previously (Yin et al., 2009, *Int J Immunopathol Pharmacol* 22:311-22), for inflammation-privileged tissues in which inflammasome component genes are not constitutively expressed, toll-like receptors also work in synergy with cytosolic sensing receptor families, including nod-like receptors (NLRs; NOD [nucleotide binding and oligomerization domain]-like receptors) in recognizing endogenous DAMPs and in mediating upregulation and activation of a range of inflammatory genes (Yin et al., 2013, *Front Biosci* 18:638-49). Caspase-1, a member of the cysteine protease family of caspases, is present in the cell cytosol as pro-caspase-1, an inactive zymogen, and requires the assembly of an NLR family member-containing protein complex called inflammasome for activation. Activated caspase-1 is required for cleaving/processing pro-interleukin-1 β (IL-1 β) and pro-IL-18 into mature proinflammatory cytokines IL-1 β and IL-18, respectively, and activation of other inflammatory pathways. However, it remains unclear whether in early atherosclerosis, the caspase-1-inflammasome pathway in ECs can sense elevated lipids as a DAMP and promote endothelial activation.

Previous reports showed that cholesterol crystals activate NLRP3 inflammasome in macrophages (Duewell et al., 2010, *Nature* 464:1357-61; Rajamäki, 2010, *PLoS One* 5:e11765), suggesting that NLRP3 inflammasome in macrophages can sense cholesterol crystals formed in advanced stage of atherosclerosis (Lim et al., 2011, *J Lipid Res* 52:2177-86). However, monocyte migration into the aorta after 3 weeks of high fat (HF) diet feeding is detected in atherosclerotic apolipoprotein E (ApoE)^{-/-} mice (Nakashima et al., 1994, *Arterioscler Thromb* 14:133-40), suggesting that before cholesterol crystal formation in the vessels, ECs may respond to hyperlipidemia and activate caspase-1 precedent for monocyte recruitment. It has been reported that in response to various proinflammatory stimuli, including lipopolysaccharide, human ECs secrete IL-1 β , resulted from the cleavage of pro-IL-1 β by activated caspase-1. However, IL-1 β secretion from human ECs, detected by ELISA, are 70.6-folds lower than that secreted from human monocytes (Wilson et al., 2007,

Br J Pharmacol 151:115-27), suggesting that IL-1 β role in ECs as functional consequence of caspase-1 activation may not be as significant as that in monocytes. Thus, additional roles of caspase-1 in ECs need to be further explored. Although proatherogenic functions of caspase-1 (Gage et al., 2012, Can J Cardiol 28:222-9), NLRP3 (Duewell et al., 2010, Nature
5 464:1357-61), IL-1 β (Merhi-Soussi et al., 2005, Cardiovasc Res 66:583-93), and IL-18 (Whitman et al., 2002, Circ Res 30:E34-8) have been reported, important knowledge gaps remain, such as (1) whether caspase-1 sensing system in ECs can sense early hyperlipidemia (noncholesterol crystals lipid stimulus) and (2) whether caspase-1 activation in ECs can promote endothelial activation, monocyte recruitment, and atherogenesis.

10 It has been reported that caspase-1 can have >70 protein substrates (Shen et al., 2010, Atherosclerosis 201:422-9), the list of which is getting longer. A recent report showed that caspase-1 specifically cleaves sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide-dependent protein/class III histone deacetylase, in adipose tissue during metabolic stress (Chalkiadaki and Guarente, 2012, Cell Metab 16:180-8). However, the
15 question of whether caspase-1 cleaves Sirt1 in aortic ECs remains unanswered.

Thus, there is a need in the art for compositions and methods for treating hyperlipidemia. The present invention satisfies this unmet need.

SUMMARY OF THE INVENTION

20 In one aspect, the invention provides a method for treating or preventing a disease or disorder associated with at least one of endothelial activation, inflammation and atherogenesis in a subject in need thereof. In one embodiment, the method comprises administering to the subject an inhibitor of caspase-1-Sirt1-AP-1 pathway.

In one embodiment, the inhibitor is an inhibitor of at least one of the group
25 consisting of caspase-1 activity and caspase-1 expression. In one embodiment, the inhibitor is a non-cleavable Sirt1 peptide inhibitor. In another embodiment, the inhibitor is a human non-cleavable Sirt1 peptide inhibitor.

In one embodiment, the the non-cleavable Sirt1 peptide inhibitor comprises a cell membrane permeable protein transduction sequence. In another embodiment, the non-
30 cleavable Sirt1 peptide inhibitor is at least one of Mouse nc-Sirt1:

RQIKIWFQNRRMKWKKGYRDNLLLTAGLLTNGFHSC (SEQ ID NO: 1); or Human nc-Sirt1: RQIKIWFQNRRMKWKKGYRDNLLFGAEIITNGFHSC (SEQ ID NO: 2).

In one embodiment, the inhibitor is selected from the group consisting of a nucleic acid, a siRNA, an antisense nucleic acid, a ribozyme, a peptide, a small molecule, an antagonist, an aptamer, and a peptidomimetic.

In another aspect, the invention provides an inhibitor of caspase-1 activity comprising a non-cleavable Sirt1 peptide inhibitor. In one embodiment, the inhibitor is a human non-cleavable Sirt1 peptide inhibitor. In another embodiment, the non-cleavable Sirt1 peptide inhibitor comprises a cell membrane permeable protein transduction sequence. In yet another embodiment, the non-cleavable Sirt1 peptide inhibitor is at least one of Mouse nc-Sirt1: RQIKIWFQNRRMKWKKGYRDNLLTAGLLTNGFHSC (SEQ ID NO: 1); or Human nc-Sirt1: RQIKIWFQNRRMKWKKGYRDNLLFGAEIITNGFHSC (SEQ ID NO: 2).

BRIEF DESCRIPTION OF THE DRAWINGS

The following detailed description of preferred embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.

Figure 1, comprising Figure 1A through Figure 1E, depicts experimental results showing early hyperlipidemia induces caspase-1 (casp-1) expression and activation in mouse aorta. Figure 1A depicts plasma levels of cholesterol and triglycerides in wild-type mice (WT) and apolipoprotein E gene-deficient mice (ApoE^{-/-}) after 0 week (ND), 3 weeks (HF3w), or 6 weeks (HF6w) of high fat (HF) diet (n=5 for each group). Figure 1B depicts the protein expression of pro-casp-1 and active casp-1 p20 subunit in mouse aorta lysate of WT and ApoE^{-/-} mice after 0, 3, or 6 weeks of HF diet (n=2 for each group). Figure 1C depicts the correlation of caps-1 activation and plasma lipid levels (of A and B). Figure 1D depicts Casp-1 mRNA expression in aortas of WT and ApoE^{-/-} after 0, 3, or 6 weeks of HF diet (n=3 for each group). Figure 1E depicts the protein expression of pro-IL-1 β and active IL-1 β in mouse aorta lysate of WT and ApoE^{-/-} mice with or without HF diet for 3 weeks. Data are expressed as mean $\pm$ SE. *P<0.05, changes with the statistical significance.

Figure 2, comprising Figure 2A through Figure 2C, depicts experimental results showing genotyping and characterization of ApoE^{-/-} Casp-1^{-/-} mice. Figure 2A depicts Polymerase chain reaction (PCR) analysis of ApoE and caspase-1 (casp-1) gene expressions in ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice (left panel). Western blot analysis of pro-casp-1

expression in the aortas of ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice (right panel) (n=2).

Figure 2B depicts General phenotype of Casp-1 deficiency in ApoE^{-/-} mice after 0 or 3 weeks of HF diet: body weight (BW), ratio of heart weight (HW) to BW, and ratio of spleen weight (SW) to BW. Figure 2C depicts Plasma levels of cholesterol and triglycerides in ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice after 3 weeks of HF diet (HF3w).

Figure 3, comprising Figure 3A and Figure 3B, depicts experimental results showing caspase-1 (casp-1) deficiency attenuates early atherosclerotic lesion formation in aortic sinus of ApoE^{-/-}/Casp-1^{-/-} fed with a 3-week high fat (HF) diet. Figure 3A depicts representative images of atherosclerotic lesion staining of ApoE^{-/-} (n=6) and ApoE^{-/-}/Casp-1^{-/-} mice (n=9) in mouse aortic sinus, as the arrows indicated. Figure 3B depicts atherosclerotic lesion quantification. Data are expressed as mean ± SE. *P<0.05, changes with statistical significance. ApoE indicates apolipoprotein E.

Figure 4, comprising Figure 4A through Figure 4C, depicts experimental results showing caspase-1 (casp-1) deficiency attenuates monocyte infiltration into mouse aorta in ApoE^{-/-}/Casp-1^{-/-} mice fed with a 3-week high fat (HF) diet. Figure 4A depicts representative flow cytometric dot plots of live cells (Gate i) in mouse aortic single cell preparations. Monocytes were gated as CD11b⁺/F4/80⁺ and CD11b⁺/F4/80⁻. Macrophages were gated as CD11b⁻/F4/80⁺. Figure 4B depicts the percentage of macrophages (CD11b⁻/F4/80⁺), monocytes (F4/80⁺/CD11b⁺ and F4/80⁻/CD11b⁺) in total aortic cell population in ApoE^{-/-} and ApoE^{-/-}/Casp-1^{-/-} mice after 3 weeks of a HF diet (n=10 for each group). Figure 4C depicts representative flow cytometric dot plots of live cells (Gate i) in mouse peripheral blood. Mononuclear cells (MNC, Gate ii) were first gated according to the forward scatter (FSC) and side scatter (SSC). Monocytes (MC) were identified as CD11b⁺ mononuclear cells (Gate iii; n=7 for each group). Data are expressed as mean±SE. *P<0.05 and **P<0.01 indicate changes with the statistical significance. ApoE indicates apolipoprotein E.

Figure 5, comprising Figure 5A through Figure 5D, depicts experimental results showing caspase-1 (casp-1) activation regulates hyperlipidemia-induced endothelial cell (EC) activation in vivo and in vitro. Figure 5A depicts protein expression of intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin in aortic tissues from ApoE^{-/-} and ApoE^{-/-}/Casp-1^{-/-} mice after a high fat (HF) diet for 3 weeks. Representative western blots (top). Quantification of protein expression normalized to the levels of β-actin (bottom). Figure 5B depicts mRNA expressions of ICAM-1, VCAM-1, and E-selectin in mouse aortic endothelial cells (MAECs) from WT and Casp^{-/-} mice, cultured

and treated with oxidized low-density lipoprotein (oxLDL; 100 $\mu\text{g/mL}$) for 24 hours. Figure 5C depicts expression level of ICAM-1 in Casp-1 active human aortic endothelial cells (HAECs) after oxLDL treated for 6 hours. Figure 5D depicts the effect of Casp-1 inhibition on oxLDL-induced monocytic THP-1 cell static adhesion to HAECs. HAECs were cultured and treated with oxLDL (100 $\mu\text{g/mL}$) for 24 hours. Caspase-1 peptide inhibitor (10 μM , z-YVAD-FMK) and caspase-1 small molecular inhibitor (10 mmol/L) were added 1 hour before the treatment. Data are expressed as mean $\pm$ SE. * P <0.05. ApoE indicates apolipoprotein E; and WT, wild-type

Figure 6, comprising Figure 6A through Figure 6G, depicts experimental results showing caspase-1 (casp-1)-deficient aortas are less efficient in recruiting inflammatory monocytes during early atherogenesis. Figure 6A depicts a schematic representation of chimeric bone marrow (BM) enhanced green fluorescence protein (EGFP) mice generation. Casp-1^{+/+} BM cells collected from EGFP⁺ mice were injected into irradiated ApoE^{-/-} mice or ApoE^{-/-}/Casp-1^{-/-} mice to determine the effect of caspase-1 deficiency in vascular cells on monocyte migration into the aorta. After a 6-week reconstitution period, the chimeric mice were fed with a high fat (HF) diet for 3 weeks. Figure 6B depicts the reconstitution rates of EGFP⁺ nuclear cells in the peripheral blood 6 weeks after BM transplantation. Figure 6C depicts the monocyte population in mouse aorta after reconstitution with EGFP⁺ BM. Representative dot plots of CD11b⁻/EGFP⁺ cells (Gate ii), CD11b⁺/EGFP⁺ monocytes (Gate iii), and CD11b⁺/EGFP⁻ (Gate iv) monocyte in mouse aorta. Monocytes in each of the 3 gates were further divided into 3 subsets: Ly-6C^{high}, Ly-6C^{mid}, and Ly-6C^{low}. Figure 6D depicts the quantification of EGFP⁺ and CD11b⁻/EGFP⁺ cells, and CD11b⁺/EGFP⁺ and CD11b⁺/EGFP⁻ monocytes within live cells and Ly-6C^{high}, Ly-6C^{middle}, and Ly-6C^{low} monocytes within indicated gates in ApoE^{-/-} and ApoE^{-/-}/Casp-1^{-/-} mouse aortas after BM reconstitution. Number within each graph represents cells in the ApoE^{-/-}/Casp-1^{-/-} mouse group as a percentage of the ApoE^{-/-} mouse group (n=6 for each group). Figure 6E depicts the monocyte population in mouse peripheral blood after reconstitution with EGFP⁺ BM. Representative dot plots of CD11b⁺/F4/80⁺ monocytes in both EGFP⁺ and EGFP⁻ peripheral blood cells. Monocytes were further divided into 3 subsets: Ly-6C^{high}, Ly-6C^{mid}, and Ly-6C^{low}. Figure 6F depicts the quantification of CD11b⁺/F4/80⁺ monocytes in both EGFP⁺ and EGFP⁻ peripheral blood cells and Ly-6C^{high}, Ly-6C^{middle}, and Ly-6C^{low} cells in EGFP⁺ and EGFP⁻ monocytes. Number within each graph represents cells in the ApoE^{-/-}/Casp-1^{-/-} mouse group as a percentage of the ApoE^{-/-} mouse group (n=8 for each group). Figure 6G depicts the quantification of

atherosclerotic lesion area in ApoE^{-/-} and ApoE^{-/-}/Casp-1^{-/-} mouse aortas after BM reconstitution. Data are expressed as mean±SE. **P*<0.05. ApoE indicates apolipoprotein E; ECs, endothelial cells; FSC, forward scatter; and SSC, side scatter.

Figure 7, comprising Figure 7A through Figure 7D, depicts experimental results showing Oxidized low-density lipoprotein (oxLDL) and its components induce caspase-1 (casp-1) activation in human aortic endothelial cells (HAECs) via a reactive oxygen species (ROS)–mediated p-athway. Figure 7A depicts pyroptotic cell death in HAECs caused by activation of casp-1 induced by oxLDL and its components. HAECs were cultured and treated with low-density lipoprotein (LDL; 100 µg/mL), oxLDL(100 µg/mL), oxLDL-derivatives lysophosphatidic acid (LPA, 100 µM), or lysophosphatidylcholine (LPC, 15 µM) as indicated for 6 hours. Casp-1 activity was determined by a commercial kit, and 7-aminoactinomycin D (7-AAD) fluorescence dye was used to determine the cell membrane integrity. Casp-1⁺/7-AAD⁺ cells were gated as pyrototic cells (Q3), casp-1⁺ single positive cells (Q2) were gated as inflammatory cells, and 7-AAD⁺ single positive cells (Q4) were gated as necrotic cells. Figure 7B depicts ROS levels in pyroptotic cells. ROS levels were determined by dihydroethidium (DHE) fluorescence dye staining, and the mean fluorescence intensity (MFI) of DHE⁺ cell fraction was determined. Figure 7C depicts attenuation of oxLDL-induced caspase-1 activation in HAECs with ROS inhibitors Allopurinol (xanthine oxidase inhibitor) and Apocynin (NADPH oxidase inhibitor). Allopurinol (1 mmol/L) and Apocynin (100 µM) were added 1 hour before oxLDL treatment. HAECs were then treated with oxLDL (100 µg/mL) for 6 hours and stained for caspase-1 activity. Figure 7D depicts mRNA upregulation of inflammasome components, including NLRP1 (Nod-like receptor protein 1), NLRP3 (Nod-like receptor 3), PYCARD (or ASC, inflammasome adaptor apoptosis-associated speck-like protein containing a CARD), caspase-1, and IL-1β (interleukin-1β) in HAECs treated with oxLDL. Data are expressed as mean±SE. **P*<0.05, changes with statistical significance.

Figure 8, comprising Figure 8A through Figure 8C, depicts experimental results showing hyperlipidemia / dyslipidemia decreases sirtuin 1 (Sirt1) expression in ApoE^{-/-} mouse aorta and induces Sirt1 cleavage in human aortic endothelial cells (ECs) through caspase-1 (casp-1) activation. Figure 8A depicts Casp-1 deficiency results in Sirt1 accumulation in mouse aorta in ApoE^{-/-}/Casp-1^{-/-} mice. ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice were fed with a high fat (HF) diet for 3 weeks. Mouse aortic tissues were collected for uncleaved Sirt1 protein expression analysis by Western blot with the specific antibody (left panel). The quantification of Sirt1 expression in the Western blot was presented after

normalized with the expression of β -actin in the same sample (right panel). Figure 8B depicts oxidized low-density lipoprotein (OxLDL) induces Sirt1 cleavage in human aortic endothelial cells (HAECs). HAECs were cultured and treated with oxLDL (100 μ g/mL) for 24 hours. Different doses of non-caspase-1 cleavable sirt1 peptide (NC-SIRT1), superoxide scavengers PEG-SOD and PEG-CAT, and proteasome inhibitor MG-132 were added 1 hour before oxLDL treatment. The protein lysates were collected, and cleaved-Sirt1 expression was determined by Western blot with anti-Sirt1 antibody. The relative changes of Sirt1 expression normalized by β -actin (ratios) were calculated based on the ratios of Sirt1 expression levels in treated samples over that in nontreated samples. Figure 8C depicts inhibition of caspase-1 attenuates lysophosphatidylcholine (LPC)-induced AP-1 binding to the AP-1 site, revealed by AP-1 electrophoretic gel mobility shift assay (upper panel), whereas inhibition of caspase-1 does not decrease NF- κ B binding to the NF- κ B site (lower panel). Data are expressed mean $\pm$ SE. * P <0.05 changes with statistical significance. ApoE indicates apolipoprotein E. Exemplary nc-Sirt1 is set forth in SEQ ID Nos 1 and 2.

Figure 9, comprising Figure 9A through Figure 9C, depicts experimental results showing caspase-1 deficiency attenuates cytokine and chemokine expression in ApoE^{-/-}/Casp-1^{-/-} mouse aorta. Figure 9A depicts the layout of the cytokine and chemokine array (R&D system). Figure 9B depicts representative array images of the aortic lysates from ApoE^{-/-} mice or ApoE^{-/-}/Casp-1^{-/-} mice. Two aortas were pooled together for blotting each array. The signal areas of a caspase-1 substrate, IL-1 β , in two arrays were selectively highlighted with red boxes. Figure 9C depicts quantification of cytokine and chemokine expressions. The variations of the manufacture's designate positive control (PC) spots between each array were used to determine the confidence interval of non-specific variations between samples (n=4 for each group). *, p <0.05 indicates the expression changes with statistical significance

Figure 10 depicts experimental results showing no differences are found between the proliferation of macrophages/monocytes in ApoE^{-/-}/Casp-1^{-/-} mouse aortas and that of ApoE^{-/-} mice as reflected by the cell size. Cell size is determined with the scales of forward scatter by flow cytometry as an estimate of cell proliferation status.

Figure 11, comprising Figure 11A through Figure 11C, depicts experimental results showing caspase-1 promotes secretome of pro-inflammatory cytokines and chemokines in MAECs. Figure 11A depicts the of the cytokines and chemokine array purchased from R&D systems. Figure 11B depicts array images of the culture supernatant from WT MAECs or Casp-1^{-/-} MAECs cultured and primed with 50ng/ml LPS and treated

with 200 µg/ml oxLDL for 24 hours followed with ATP (5mM) spike for 20 min. The array spots of IL-1β were highlighted with the red boxes where the array spots of GM-CSF, CCL3, CCL5 and CXCL12 were indicated with the black ovals, respectively. Figure 11C depicts quantification of cytokine and chemokine expressions. The variations of the manufacture's designate positive control (PC) spots between each array were used to determine the confidence interval of non-specific variations between samples (n=2 for each group). *, p<0.05 change with significance.

Figure 12, comprising Figure 12A and Figure 12B, depicts experimental results showing generation of cell-permeable non-Casp1 cleavable Sirt1 polypeptide. Figure 12A depicts the NIH-NCBI Blast homology search between mouse SIRT1 (upper) and human SIRT1 (lower). Caspase-1 cleavage site is highlighted in the red box. Figure 12B depicts the non-cleavable Sirt1 polypeptide was generated with a single amino acid replacement in the sequence from 140-160 position of human SIRT1. Caspase-1 cleavage site D150 from human SIRT1 was mutated to A150, rendering the peptide sequence non-casp1 cleavable.

Figure 13 depicts a schematic representation of a new model for the role of caspase-1 (casp-1) activation in endothelial cells (ECs) during early atherogenesis.

Figure 14, comprising Figure 14A through Figure 14C, depicts experimental results showing proatherogenic oxidized lipids induce higher caspase-1 activation in the larger sizes of HAECs than in smaller sizes of HAECs. Figure 14A depicts experiments where HAECs were treated with different proatherogenic stimuli as follows: oxLDL (100 µM), LPA (30 µM), LPC (30 µM), and H₂O₂ (500 µM) for 6 h. Caspase-1(+) cell percentage was measured, and the results showed an increase in caspase-1 activation after proatherogenic lipid treatments. Figure 14B depicts experiments three different sizes of cell populations after caspase-1 activation were identified using FSC, which is widely used to define the cell size in flow cytometry. The gates were established as small, medium, and large according to the cell size (FSC, y axis) and caspase-1 activation (x axis) to analyze the differential caspase-1 activation percentage according to the cell size. Analysis of three gates showed an increase in caspase-1 activation percentage in larger HAECs. Figure 14C depicts the quantitation data of caspase-1 activation. *, p < 0.05.

Figure 15 depicts experimental results showing proatherogenic stimuli significantly Proatherogenic oxidized lipids induce higher caspase-1 activation in the larger sizes of HAECs than in smaller sizes of HAECs. HAECs were treated with different proatherogenic stimuli as follows: oxLDL (100 µM), LPA (30 µM), LPC (30 µM), and

H₂O₂ (500 μ M) for 6 h. Caspase-1(+) cell percentage was measured, and the results showed an increase in caspase-1 activation after proatherogenic lipid treatments. Three different sizes of cell populations after caspase-1 activation were identified using FSC, which is widely used to define the cell size in flow cytometry. The gates were established as small, medium, and large according to the cell size (FSC, y axis) and caspase-1 activation (x axis) to analyze the differential caspase-1 activation percentage according to the cell size. Analysis of three gates showed an increase in caspase-1 activation percentage in larger HAECs. C^* , $p < 0.05$. increase more pyroptosis in smaller sizes of HAECs than in larger sizes of the cells. The pyroptotic rates in LPC-treated caspase-1(+) HAECs were increased as the cell sizes became smaller. The FACS results demonstrated an increase in 7AAD⁺ pyroptotic percentage in smaller sizes of caspase-1(+) HAECs when compared with medium size and larger size caspase-1(+) cells. The bar graphs show the quantitation data of 7AAD⁺ percentages in caspase-1(+) cells. * , $p < 0.05$.

Figure 16, comprising Figure 16A and Figure 16B, depicts experimental results showing caspase-1 activation is increased after the inhibition of VEGFR-2 in LPC-treated HAECs. Figure 16A depicts VEGFR-2 depletion increases the expressions of caspase-1 and inflammasome adaptor protein ASC. The microarray data-mining analyses were performed using the National Institutes of Health NCBI-Geo-profile database. The microarray dataset IDs were indicated. Figure 16B depicts experiments where HAECs were pretreated with VEGFR-2 inhibitor (SU1498) and then treated with LPC (30 μ M) for 6 h after overnight starvation with serum-free medium. The bar graph shows the quantitation data of caspase-1 activation, which demonstrates an increase in caspase-1 activation after the inhibition of VEGFR-2 in LPC-treated HAECs. * , $p < 0.05$.

Figure 17, comprising Figure 17A through Figure 17D, depicts experimental results showing inhibition of caspase-1 activation and activation of Sirt-1 increase VEGFR-2 expression. Figure 17A depicts experiments showing caspase-1 depletion increases VEGFR-2 expression. A microarray data-mining analysis was performed by analyzing the indicated microarray dataset deposited in the National Institutes of Health NCBI-Geo-profile database. The gene expression value was determined based on the relative threshold cycle on the database. Caspase-1 expression was used as a control to show that caspase-1 expression was absent in the caspase-1 gene depletion samples. In addition, depletion of caspase-1 slightly increases the expressions of the caspase-1-cleaving substrates cytokines IL-1 β and IL-18. As the microarray data quality controls, caspase-1 depletion did not significantly change the expressions of three housekeeping genes, Gadph, Nono, and Aldoa. Figure 17B depicts

caspase-1 inhibition and Sirt-1 activation increase the expression of VEGFR-2 after LPC treatment in HAECs. HAECs pretreated with the caspase-1 inhibitor (10 μ M) and Sirt-1 activator (10 μ M) and then treated with LPC (30 μ M) for 6 h have an increased expression of VEGFR-2. Figure 17C depicts three cell size gates were established, small, medium, and large according to FSC (y axis); and VEGFR-2 expression (x axis) was measured in those gated cells to analyze differential VEGFR-2 expressions according to the cell size after treatments with LPC (30 μ M), caspase-1 inhibitor (10 μ M), and Sirt-1 activator (10 μ M) for 6 h. The analysis shows increases in VEGFR-2 expression as the cell sizes became larger. Figure 17D depicts bar graphs showing the quantitation data of VEGFR-2 expressions. *, $p < 0.05$.

Figure 18, comprising Figure 18A and Figure 18B, depicts experimental results showing tube formation, as an *in vitro* model of angiogenesis, is improved after caspase-1 inhibition in LPC-treated cells. Figure 18A depicts experiments where HAECs were treated with LPC (30 μ M) and caspase-1 inhibitor (10 μ M) for 6 h. After the treatment, the cells were incubated in the Matrigel for 16 h for the analysis of tube formation. Figure 18B depicts bar graph showing the increases of total master segment lengths after the inhibition of caspase-1 in LPC-treated HAECs. *, $p < 0.05$.

Figure 19, comprising Figure 19A through Figure 19C, depicts experimental results showing caspase-1 KO mice have an increase in blood flow after hind limb ischemia compared with wild-type mice. Figure 19A depicts experiments where hind limb ischemia model was performed in WT and caspase-1 KO mice. The blood flow was recorded with the LDSII Doppler at different time points. The data show that the caspase-1 KO mice have a trend of increased blood flow after hind limb ischemia. Figure 19B depicts linear graph shows the quantification of the ischemia/normal leg perfusion ratio. Figure 19C depicts that an absolute value (y-x) was used to create a confidence interval.

Figure 20 depicts a schematic representation of the working model. The larger HAECs have higher vascular endothelial growth factor receptor 2 (VEGFR-2) and less caspase-1(+) pyroptosis induction after dyslipidemic stimuli, which promotes angiogenesis and improves ischemia's prognosis. However, after dyslipidemic stimuli, the smaller HAECs have an increase in caspase-1(+) induction of pyroptosis and less VEGFR-2 expression, which decrease the angiogenesis and worsen ischemia's prognosis. In summary, there is a mutual inhibition between the VEGFR-2 signaling pathway and caspase-1 activation in endothelial cells.

Figure 21, comprising Figure 21A through Figure 21C, depicts experimental results showing hyperlipidemia increases caspase-1 activity in Sca-1⁺ progenitor cells. Figure 21A depicts the experiment design. Wild-type (WT) mice and ApoE^{-/-} mice were fed with either chow diet or high fat (HF) for 12 weeks (w) before their bone marrows (BM) were collected for fluorescence activated cell sorter (FACS) analysis. Figure 21B depicts experiments where after gating mononuclear cells from the BM, Sca-1⁺ stem cells were gated from the mononuclear cells. Figure 21C depicts experiments where among Sca-1⁺ stem cell populations in the BM, caspase-1 activity was measured. Gating of caspase-1 positive (Casp1⁺) cells in Sca-1⁺ population of mouse BM was shown in the left. Quantification was shown in the right.

Figure 22 depicts a flow chart of experiment design that was used for cDNA microarray analysis.

Figure 23, comprising Figure 23A through Figure 23F, depicts experimental results showing caspase-1 contributes to hyperlipidemia-induced gene changes related to vascular cell death. Figure 23A depicts volcano plots of apolipoprotein E deficient (ApoE^{-/-}) mice versus Wild type (WT) mice aorta DNA expression comparisons (blue), with the overlay of Caspase-1 (Casp1)^{-/-}/ApoE^{-/-} versus ApoE^{-/-} comparisons (red) are depicted by estimated fold change (FC)(log2 FC, x-axis) and statistical significance (-log10 P value, y-axis). Figure 23B depicts cooperation between Caspase1 and hyperlipidemia is shown by Log2 FC/Log2 FC plot comparing gene expression value for Caspase1/ApoE DKO versus ApoE KO (x-axis), and parallel ApoE KO versus WT (y-axis). Figure 23C depicts a Venn diagram showing the profile of two gene expression comparisons. Among 23,470 mapped genes, a total of 6,745 genes were significantly changed induced by hyperlipidemia and 2,541 genes were significantly changed caused by Caspase1 deletion. Among the changed genes, there are 969 genes changed in condition of hyperlipidemia and reversed by Caspase1 deletion. Figure 23D depicts heatmaps representing the z-score of the expression level of top 50 reversed genes (hyperlipidemia increased or decreased genes which are down-regulated or up-regulated by deletion of Caspase1). Figure 23E depicts core analysis with Ingenuity pathway analysis (IPA) shows that the major molecular and cellular functional pathways are cellular growth and proliferation and cell death. Figure 23F depicts the network showing the connection of the caspase-1 reserved genes associated with apoptosis and necrosis of endothelial cells.

Figure 24 depicts experimental results showing caspase-1 contributes to hyperlipidemia-induced gene changes related to heart dysfunction. Tox analysis with

Ingenuity pathway analysis (IPA) shows that the clinical pathology endpoints of these reversed genes. Heart hypertrophy and heart failure are the top endpoints associated with cardiovascular disease. Heat-maps showing the expression level of the involved genes in each endpoint are listed in the right.

5 Figure 25, comprising Figure 25A through Figure 25E, depicts experimental results showing caspase-1^{-/-} Sca-1⁺ progenitor cell therapy improves cardiac function after MI. Figure 25A depicts the myocardial infarction (MI) and cell therapy model. Schematic representation of experimental plan including high fat diet feeding, cardiac function monitoring with echocardiography, cell therapy with purified Sca-1⁺ bone marrow cells
10 followed by immunohistochemistry and flow cytometry analyses. Figure 25B depicts the CellVueR NIR780 fluorescence-labeled cells were traced to heart after intravenous injection. The CellVueR NIR780 fluorescence-labeled purified Sca-1⁺ bone marrow cells (2 × 10⁶ cells/mouse) were traced to mouse heart after cell therapy (n=4 for tracer group, n=2 for non-cell tracer group). CT: no cell therapy control; cell: cell therapy Figure 25C depicts M-mode
15 Echocardiography. Representative M-mode echocardiographs of control mice and myocardial infarcted mice. Figure 25D depicts cardiac functions measured with echocardiography. The cardiac function measurements of control mice, myocardial infarction (MI) mice, mice receiving wild-type (WT) Sca-1⁺ BM cells and mice receiving caspase-1(Casp1)^{-/-} Sca-1⁺ BM cells. The numbers shown indicate the numbers of mice in the group.
20 Figure 25 E depicts heart, Lung, Liver weight/body weight. The ratios of heart weight/body weight, lung weight/body weight and liver weight/body weight of mice receiving cell therapy and control mice.

 Figure 26, comprising Figure 26A and Figure 26B, depicts experimental results showing caspase-1^{-/-} Sca-1⁺ progenitor cell therapy increases IB4⁺ capillary density
25 and decreases TUNEL⁺ cardiomyocytes. Figure 26A depicts capillary density detected with IB4 staining for endothelial cells in neovasculture. Histochemical analysis of heart cross sections showed that cell therapy with Sca-1⁺ BM cells from casp-1^{-/-} mice increases IB4⁺ capillary density (endothelial cells) in comparison to the cell therapy with Sca-1⁺ BM cells from wild type (WT) mice. Figure 26B depicts TUNEL Assay for detecting cell death in
30 myocardial infarcted heart. Histochemical analysis of heart cross sections showed that the cell therapy with Sca-1⁺ BM cells from from casp-1^{-/-} mice decreases TUNEL⁺ cardiomyocytes in comparison to the cell therapy with Sca-1⁺ BM cells from WT mice.

 Figure 27 depicts a new working model that caspase-1 inhibition improves Sca-1⁺ stem cell therapy for myocardial infarction. Hyperlipidemia activates caspase-1

activation in Sca-1+ stem cells and vascular cells in aorta. Activation of caspase-1 upregulates proinflammatory gene expression and promotes pyroptosis and apoptosis presumably in Sca-1+ stem cells, endothelial cells and cardiomyocytes and causes cardiac dysfunction. Inhibition/depletion of caspase-1 improves survival of Sca-1+ stem
5 cells/progenitor cells, and cardiomyocytes, promotes angiogenesis, and improves cardiac function after myocardial infarction.

Figure 28 is a schematic representation of the neointimal hyperplasia (NH) development. The area enclosed by the black arrows is the intima. The black arrows show the direction of inward remodeling.

10 Figure 29 depicts experimental results showing the exposure of human aortic vascular smooth muscle cells (HAVSMCs) to uremic serum decreases the expression of contractile marker RNA transcripts, which is reversed by the inhibition of caspase-1. HAVSMCs were grown to sub-confluence and were serum starved for 24 hours and exposed to 10% pooled uremic sera from CKD patients (CKD PS) with and without Caspase-1
15 Inhibitor (Casp1 inh) for another 24 hours. The RNA was extracted, was reverse transcribed into cDNA, and the expression of smooth muscle contractile marker RNA transcripts (alpha actin and calponin) was measured by quantitative RT-PCR using the Applied Biosystems 7500, Taqman primers and probes. The relative quantification of gene RNA expression is presented after being normalized with the expression of a house-keeping gene. * *P* value <
20 0.005.

Figure 30, comprising Figure 30A and Figure 30B, depicts experimental results showing that the 5/6 nephrectomy CKD model is established in wild-type (WT) mice and caspase-1^{-/-} mice, and is followed by creation of the neointimal hyperplasia (NH) model with left common carotid ligation in CDK mice. Figure 30A depicts the experimental design
25 for the creation of CKD model and NH model in WT and caspase-1^{-/-} mice. The model was created by performing right kidney ablation at 9 weeks of age on both WT and caspase-1^{-/-} mice. After one week, left nephrectomy was performed to create a CKD state. To verify the CKD state in mice, the blood urea nitrogen (BUN) levels were measured. At week 4, after the CKD creation, a left common carotid artery (LCCA) ligation was performed in order to
30 induce neointimal hyperplasia (NH). Three weeks after the LCCA ligation, the artery was perfused and fixed with formalin at 100mm HG for 15 minutes and harvested for cross-section immunohistochemistry analysis. The Verhoeff elastic-van Gieson (VVG) staining was used on LCCA cross-sections to determine the development of neointimal hyperplasia. Figure 30B depicts the animal weight and BUN levels measured in both mouse groups. There

were no statistically significant differences in body weight and BUN levels between both groups.

Figure 31, comprising Figure 31A and Figure 31E, depicts experimental results showing the deficiency of caspase-1 reduces the CKD-induced carotid neointimal hyperplasia development in mice. Figure 31A depicts representative cross-sections of left common carotid arteries stained with VVG. At 9 weeks of age, the mice underwent CKD creation. 3 weeks later the mice underwent left common carotid artery (LCCA) ligation. At 15 weeks of age, representative cross-sections of the left common carotid arteries from WT sham, WT CKD, and caspase-1^{-/-} (Casp1^{-/-}) CKD mice were stained with the VVG. The results demonstrate that the carotid artery in caspase-1^{-/-} CKD mice has decreased neointimal hyperplasia development. Figure 31B depicts results showing the neointimal (NI) volume is significantly increased in WT CKD mice compared with that in WT sham; the NI is diminished in caspase-1^{-/-} CKD mice compared with that of WT CKD mice. Figure 31C depicts results showing the NI/Media (NI/M) ratio (%) is significantly increased in WT CKD mice compared with that in WT sham; the NI/M ratio is diminished in caspase-1^{-/-} CKD mice compared with that in WT CKD mice. Figure 31D depicts results showing vessel lumen stenosis is increased in WT CKD mice compared with WT sham; the vessel stenosis is decreased in caspase-1^{-/-} CKD mice compared with that of WT CKD mice. Figure 31E depicts results showing the media volume in WT CKD mice is not significantly different from that of caspase-1^{-/-} CKD mice. * P value < 0.05.

Figure 32 depicts experimental results showing CKD decreases the expression of vascular smooth muscle cell contractile marker RNA transcripts in carotid artery in vivo, which is reversed by the deletion of caspase-1^{-/-}. RNA was extracted from the carotid arteries of WT CKD mice and caspase-1^{-/-} CKD mice. After reverse transcription, cDNA was subjected to analysis by quantitative PCR. The expression of vascular smooth muscle contractile marker RNA transcripts such as alpha actin, calponin, SM22, and smoothelin was measured by quantitative RT-PCR using the Applied Biosystems 7500, Taqman primers and probes. The expression of smooth muscle contractile markers was increased in the carotid arteries of caspase-1^{-/-} CKD mice in comparison to that of WT CKD mice.

Figure 33, comprising Figure 33A and Figure 33B, depicts experimental results showing Integrin alpha V mRNA is higher in WT mice than caspase-1^{-/-} mice after feeding with high fat diet for 16 weeks. Figure 33A depicts microarray data analysis showing that the expression of Integrin alpha V RNA transcripts in wild-type tissue is significantly higher than that in caspase-1^{-/-} mice after feeding with high fat diet for 16 weeks. Figure 33B

depicts the mean $\pm$ 2SD of the ratio of three housekeeping genes was used as the 95% confidence interval.

Figure 34 depicts a schematic representation of a new working model about the role of caspase-1 in facilitating the development of CKD-promoted neointimal hyperplasia. The Nod-like receptors (NLRs)/inflammasomes pathway in the contractile VSMCs can sense the uremic toxic products as the metabolic danger signal-associated molecular patterns (DAMPs) in a CKD- state, which consequently activates caspase-1. The activation of caspase-1 promotes the maturation and secretion of proinflammatory cytokines IL-1b and IL-18, decreases the expression of VSMC contractile markers, and presumably makes VSMCs switch to synthetic phenotype and proliferation. The caspase-1 activation in the contractile weakened VSMCs increases the expression of Integrin α v β 3 also, which mediates the formation of neointimal hyperplasia induced by inward remodeling due to the migration of these VSMCs, which leads to the development of stenotic arterial lesion, occlusion of arterial lumen, and causes blood flow obstruction.

DETAILED DESCRIPTION

The present invention relates generally to compositions and methods for treating cardiovascular disease, inflammation, or atherosclerosis. The invention is useful, for example, in decreasing the expression of proinflammatory cytokines, atherosclerotic lesions in the early stage of atherogenesis, monocyte recruitment in the aorta, endothelial activation. The invention is also useful in increasing the anti-inflammatory protein sirt1. In certain embodiments, the invention provides compositions and methods for reducing expression of cytokines, chemokines and adhesion molecules which are expressed via an Sirt1-AP-1-mediated pathway.

In one embodiment, the present invention provides a composition for treating cardiovascular disease, inflammation, or atherosclerosis in a subject. In one embodiment, the composition comprises an inhibitor of caspase-1 expression, activity or a combination thereof. In one embodiment, the inhibitor inhibits the caspase-1 dependent cleavage of Sirt1.

In another embodiment, the present invention provides a method of treating a disease or disorder related to cardiovascular disease, inflammation, or atherosclerosis in a subject. In one embodiment, the method comprises administering to the subject an effective amount of an inhibitor of caspase-1 expression, activity or a combination thereof.

The present invention relates to a method for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including

but not limited to cardiovascular diseases and inflammatory disorders. The method comprises administering to a subject an inhibitor of caspase-1-Sirt1-AP-1 pathway. In one aspect, the method comprises administering to a subject a composition comprising a non-cleavable Sirt1 peptide inhibitor, which inhibits the activity of caspase-1.

5 In one aspect, the present invention relates to compositions and pharmaceutical compositions for inhibiting the activity of caspase-1. In one embodiment, the composition comprises a non-cleavable Sirt1 peptide inhibitor.

 In one aspect, the invention provides methods of compositions and methods for treating cardiovascular disease, inflammation, or atherosclerosis. In one embodiment, the composition comprises an inhibitor of caspase-1 activation or expression. In one
10 embodiment, the inhibitor of caspase-1 activation or expression increases VEGFR-2 expression. In another embodiment, the inhibitor of caspase-1 increases pyroptosis of large aortic endothelial cells. In another embodiment, the inhibitor of caspase-1 increases tube formation of aortic endothelial cells. In another embodiment, the inhibitor of caspase-1
15 increases ischemia and blood perfusion ratio. In yet another embodiment, the inhibitor of caspase-1 increases angiogenesis.

 In one embodiment, the method of the invention comprises, administering an inhibitor of caspase-1 activity or expression to a bone marrow-derived stem cell antigen-1 positive stem cell or progenitor cell; and transplanting the cell in a subject. In one
20 embodiment, the method the subject has experienced a myocardial infarction. In one embodiment, the transplantation improves cardiac function. In one embodiment, the transplantation decreases cardiomyocyte cell death.

 In one embodiment, the inflammation is a symptom of chronic kidney disease. In another embodiment, the inhibition of caspase-1 decreases chronic kidney disease-induced
25 neointima hyperplasia.

Definitions

 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this
30 invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.

Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and nucleic acid chemistry and hybridization are those well-known and commonly employed in the art.

Standard techniques are used for nucleic acid and peptide synthesis. The techniques and procedures are generally performed according to conventional methods in the art and various general references (e.g., Sambrook and Russell, 2012, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY, and Ausubel et al., 2002, Current Protocols in Molecular Biology, John Wiley & Sons, NY), which are provided throughout this document.

The nomenclature used herein and the laboratory procedures used in analytical chemistry and organic syntheses described below are those well-known and commonly employed in the art. Standard techniques or modifications thereof, are used for chemical syntheses and chemical analyses.

As used herein, each of the following terms has the meaning associated with it in this section.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of $\pm 20\%$ or $\pm 10\%$, more preferably $\pm 5\%$, even more preferably $\pm 1\%$, and still more preferably $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods.

“Antisense” refers particularly to the nucleic acid sequence of the non-coding strand of a double stranded DNA molecule encoding a protein, or to a sequence which is substantially homologous to the non-coding strand. As defined herein, an antisense sequence is complementary to the sequence of a double stranded DNA molecule encoding a protein. It is not necessary that the antisense sequence be complementary solely to the coding portion of the coding strand of the DNA molecule. The antisense sequence may be complementary to regulatory sequences specified on the coding strand of a DNA molecule encoding a protein, which regulatory sequences control expression of the coding sequences.

The term “cancer” as used herein is defined as disease characterized by the rapid and uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical

cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer and the like.

A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health
5 continues to deteriorate. In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.

A disease or disorder is “alleviated” if the severity or frequency of at least one
10 sign or symptom of the disease or disorder experienced by a patient is reduced.

The terms “effective amount” and “pharmaceutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease or disorder, or any other desired alteration of a biological system. An appropriate effective
15 amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

The term “expression” as used herein is defined as the transcription and/or translation of a particular nucleotide sequence driven by its promoter.

As used herein, a “peptidomimetic” is a compound containing non-peptidic
20 structural elements that is capable of mimicking the biological action of a parent peptide. A peptidomimetic may or may not comprise peptide bonds.

A “polynucleotide” means a single strand or parallel and anti-parallel strands of a nucleic acid. Thus, a polynucleotide may be either a single-stranded or a double-stranded nucleic acid. In the context of the present invention, the following abbreviations for the
25 commonly occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytidine, “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.

The term “oligonucleotide” typically refers to short polynucleotides, generally no greater than about 60 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e.,
30 A, U, G, C) in which “U” replaces “T.”

“Recombinant polynucleotide” refers to a polynucleotide having sequences that are not naturally joined together. An amplified or assembled recombinant polynucleotide may be included in a suitable vector, and the vector can be used to transform a suitable host cell.

A recombinant polynucleotide may serve a non-coding function (e.g., promoter, origin of replication, ribosome-binding site, etc.) as well.

The term “recombinant polypeptide” as used herein is defined as a polypeptide produced by using recombinant DNA methods. A host cell that comprises a recombinant polynucleotide is referred to as a “recombinant host cell.” A gene which is expressed in a recombinant host cell wherein the gene comprises a recombinant polynucleotide, produces a “recombinant polypeptide.”

As used herein, a “recombinant cell” is a host cell that comprises a recombinant polynucleotide.

By the term “specifically binds,” as used herein, is meant a molecule, such as an antibody, which recognizes and binds to another molecule or feature, but does not substantially recognize or bind other molecules or features in a sample.

As used herein, the term “transdominant negative mutant gene” refers to a gene encoding a polypeptide or protein product that prevents other copies of the same gene or gene product, which have not been mutated (i.e., which have the wild-type sequence) from functioning properly (e.g., by inhibiting wild type protein function). The product of a transdominant negative mutant gene is referred to herein as “dominant negative” or “DN” (e.g., a dominant negative protein, or a DN protein).

The phrase “inhibit,” as used herein, means to reduce a molecule, a reaction, an interaction, a gene, an mRNA, and/or a protein’s expression, stability, function or activity by a measurable amount or to prevent entirely. Inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate a protein, a gene, and an mRNA stability, expression, function and activity, e.g., antagonists.

“Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

The terms “subject” or “patient” for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a preferred

embodiment the patient is a mammal, and in a most preferred embodiment the patient is human.

The terms “treat,” “treating,” and “treatment,” refer to therapeutic or preventative measures described herein. The methods of “treatment” employ administration to a subject, in need of such treatment, a composition of the present invention, for example, a subject afflicted a disease or disorder, or a subject who ultimately may acquire such a disease or disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of the disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.

Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

Description

The present invention provides compositions and methods for treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis, including but not limited to cardiovascular diseases and inflammatory disorders.

In one embodiment, the composition comprises an inhibitor of the expression of caspase-1. For example, in one embodiment, the composition comprises an isolated nucleic acid (e.g., siRNA, ribozyme, antisense RNA, etc.) that reduces the nucleic acid or protein expression level in a cell of caspase-1.

In one embodiment, the composition comprises an inhibitor of the activity of caspase-1. For example, in one embodiment, the composition comprises a nucleic acid, peptide, antibody, small molecule, antagonist, aptamer, or peptidomimetic that reduces the activity of caspase-1.

Composition

In one embodiment, the composition of the invention comprises an inhibitor of caspase-1. An inhibitor of caspase-1 is any compound, molecule, or agent that reduces, inhibits, or prevents the function of caspase-1. In certain embodiments, the inhibitor inhibits the transcription of DNA, inhibits the translation of RNA, or inhibits the protein itself. In one embodiment, an inhibitor of caspase-1 comprises a nucleic acid, a peptide, an antibody, a small molecule, a siRNA, a ribozyme, an antisense nucleic acid, an antagonist, an aptamer, a peptidomimetic, or any combination thereof.

Small Molecule Inhibitors

In various embodiments, the inhibitor is a small molecule. When the inhibitor is a small molecule, a small molecule may be obtained using standard methods known to the skilled artisan. Such methods include chemical organic synthesis or biological means. Biological means include purification from a biological source, recombinant synthesis and in vitro translation systems, using methods well known in the art. In one embodiment, a small molecule inhibitor of the invention comprises an organic molecule, inorganic molecule, biomolecule, synthetic molecule, and the like.

Combinatorial libraries of molecularly diverse chemical compounds potentially useful in treating a variety of diseases and conditions are well known in the art as are method of making the libraries. The method may use a variety of techniques well-known to the skilled artisan including solid phase synthesis, solution methods, parallel synthesis of single compounds, synthesis of chemical mixtures, rigid core structures, flexible linear sequences, deconvolution strategies, tagging techniques, and generating unbiased molecular landscapes for lead discovery vs. biased structures for lead development.

In a general method for small library synthesis, an activated core molecule is condensed with a number of building blocks, resulting in a combinatorial library of covalently linked, core-building block ensembles. The shape and rigidity of the core determines the orientation of the building blocks in shape space. The libraries can be biased by changing the core, linkage, or building blocks to target a characterized biological structure (“focused libraries”) or synthesized with less structural bias using flexible cores.

The small molecule and small molecule compounds described herein may be present as salts even if salts are not depicted and it is understood that the invention embraces all salts and solvates of the inhibitors depicted here, as well as the non-salt and non-solvate

form of the inhibitors, as is well understood by the skilled artisan. In some embodiments, the salts of the inhibitors of the invention are pharmaceutically acceptable salts.

Where tautomeric forms may be present for any of the inhibitors described herein, each and every tautomeric form is intended to be included in the present invention, even though only one or some of the tautomeric forms may be explicitly depicted. For example, when a 2-hydroxypyridyl moiety is depicted, the corresponding 2-pyridone tautomer is also intended.

The invention also includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms of the inhibitors described. The recitation of the structure or name herein is intended to embrace all possible stereoisomers of inhibitors depicted. All forms of the inhibitors are also embraced by the invention, such as crystalline or non-crystalline forms of the inhibitors. Compositions comprising an inhibitor of the invention are also intended, such as a composition of substantially pure inhibitor, including a specific stereochemical form thereof, or a composition comprising mixtures of inhibitors of the invention in any ratio, including two or more stereochemical forms, such as in a racemic or non-racemic mixture.

In one embodiment, the small molecule inhibitor of the invention comprises an analog or derivative of an inhibitor described herein.

In one embodiment, the small molecules described herein are candidates for derivatization. As such, in certain instances, the analogs of the small molecules described herein that have modulated potency, selectivity, and solubility are included herein and provide useful leads for drug discovery and drug development. Thus, in certain instances, during optimization new analogs are designed considering issues of drug delivery, metabolism, novelty, and safety.

In some instances, small molecule inhibitors described herein are derivatized/analoged as is well known in the art of combinatorial and medicinal chemistry. The analogs or derivatives can be prepared by adding and/or substituting functional groups at various locations. As such, the small molecules described herein can be converted into derivatives/analogues using well known chemical synthesis procedures. For example, all of the hydrogen atoms or substituents can be selectively modified to generate new analogs. Also, the linking atoms or groups can be modified into longer or shorter linkers with carbon backbones or hetero atoms. Also, the ring groups can be changed so as to have a different number of atoms in the ring and/or to include hetero atoms. Moreover, aromatics can be

converted to cyclic rings, and vice versa. For example, the rings may be from 5-7 atoms, and may be homocycles or heterocycles.

As used herein, the term “analog,” “analogue,” or “derivative” is meant to refer to a chemical compound or molecule made from a parent compound or molecule by one or more chemical reactions. As such, an analog can be a structure having a structure similar to that of the small molecule inhibitors described herein or can be based on a scaffold of a small molecule inhibitor described herein, but differing from it in respect to certain components or structural makeup, which may have a similar or opposite action metabolically. An analog or derivative of any of a small molecule inhibitor in accordance with the present invention can be used to reduce skin pigmentation.

In one embodiment, the small molecule inhibitors described herein can independently be derivatized/analoged by modifying hydrogen groups independently from each other into other substituents. That is, each atom on each molecule can be independently modified with respect to the other atoms on the same molecule. Any traditional modification for producing a derivative/analog can be used. For example, the atoms and substituents can be independently comprised of hydrogen, an alkyl, aliphatic, straight chain aliphatic, aliphatic having a chain hetero atom, branched aliphatic, substituted aliphatic, cyclic aliphatic, heterocyclic aliphatic having one or more hetero atoms, aromatic, heteroaromatic, polyaromatic, polyamino acids, peptides, polypeptides, combinations thereof, halogens, halo-substituted aliphatics, and the like. Additionally, any ring group on a compound can be derivatized to increase and/or decrease ring size as well as change the backbone atoms to carbon atoms or hetero atoms.

Nucleic acid inhibitors

In other related aspects, the invention includes an isolated nucleic acid. In one embodiment, the nucleic acid comprises a promoter/regulatory sequence such that the nucleic acid is preferably capable of directing expression of the nucleic acid. Thus, the invention encompasses expression vectors and methods for the introduction of exogenous DNA into cells with concomitant expression of the exogenous DNA in the cells such as those described, for example, in Sambrook et al. (2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York) and as described elsewhere herein.

In another aspect of the invention, caspase-1, can be inhibited by way of inactivating and/or sequestering caspase-1. As such, inhibiting the activity of caspase-1 can

be accomplished by using a transdominant negative mutant.

In one embodiment, the composition comprises a nucleic acid molecule encoding a peptide inhibitor of caspase-1. In one embodiment, the nucleic acid molecule encodes a non-cleavable Sirt1 peptide, which inhibits caspase-1 activity. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a peptide inhibitor comprising an amino acid sequence of SEQ ID NO: 1. In one embodiment, the nucleic acid molecule comprises a nucleic acid sequence encoding a peptide inhibitor comprising an amino acid sequence of SEQ ID NO: 2.

In certain embodiments, the peptide inhibitor is encoded by a nucleic acid sequence that encodes the amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:1. In certain embodiments, the peptide inhibitor is encoded by a nucleic acid sequence that encodes the amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2.

In one embodiment, siRNA is used to decrease the level of caspase-1, or caspase-1 protein. RNA interference (RNAi) is a phenomenon in which the introduction of double-stranded RNA (dsRNA) into a diverse range of organisms and cell types causes degradation of the complementary mRNA. In the cell, long dsRNAs are cleaved into short 21-25 nucleotide small interfering RNAs, or siRNAs, by a ribonuclease known as Dicer. The siRNAs subsequently assemble with protein components into an RNA-induced silencing complex (RISC), unwinding in the process. Activated RISC then binds to complementary transcript by base pairing interactions between the siRNA antisense strand and the mRNA. The bound mRNA is cleaved and sequence specific degradation of mRNA results in gene silencing. See, for example, U.S. Patent No. 6,506,559; Fire et al., 1998, Nature 391(19):306-311; Timmons et al., 1998, Nature 395:854; Montgomery et al., 1998, TIG 14 (7):255-258; David R. Engelke, Ed., RNA Interference (RNAi) Nuts & Bolts of RNAi Technology, DNA Press, Eagleville, PA (2003); and Gregory J. Hannon, Ed., RNAi A Guide to Gene Silencing, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2003). Soutschek et al. (2004, Nature 432:173-178) describe a chemical modification to siRNAs that aids in intravenous systemic delivery. Optimizing siRNAs involves consideration of overall G/C content, C/T content at the termini, Tm and the nucleotide content of the 3' overhang. See, for instance, Schwartz et al., 2003, Cell, 115:199-208 and Khvorova et al., 2003, Cell

115:209-216. Therefore, the present invention also includes methods of decreasing levels of caspase-1 using RNAi technology.

In another aspect, the invention includes a vector comprising an siRNA or antisense polynucleotide. Preferably, the siRNA or antisense polynucleotide is capable of
5 inhibiting the expression of a target polypeptide. The incorporation of a desired polynucleotide into a vector and the choice of vectors is well-known in the art as described in, for example, Sambrook et al. (2012), and in Ausubel et al. (1997), and elsewhere herein.

In certain embodiments, the expression vectors described herein encode a short hairpin RNA (shRNA) inhibitor. shRNA inhibitors are well known in the art and are
10 directed against the mRNA of a target, thereby decreasing the expression of the target. In certain embodiments, the encoded shRNA is expressed by a cell, and is then processed into siRNA. For example, in certain instances, the cell possesses native enzymes (e.g., dicer) that cleaves the shRNA to form siRNA.

The siRNA, shRNA, or antisense polynucleotide can be cloned into a number
15 of types of vectors as described elsewhere herein. For expression of the siRNA or antisense polynucleotide, at least one module in each promoter functions to position the start site for RNA synthesis.

In order to assess the expression of the siRNA, shRNA, or antisense polynucleotide, the expression vector to be introduced into a cell can also contain either a
20 selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected using a viral vector. In other embodiments, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells.
25 Useful selectable markers are known in the art and include, for example, antibiotic-resistance genes, such as neomycin resistance and the like.

In one embodiment of the invention, an antisense nucleic acid sequence which is expressed by a plasmid vector is used to inhibit caspase-1, or caspase-1 protein expression. The antisense expressing vector is used to transfect a mammalian cell or the mammal itself,
30 thereby causing reduced endogenous expression of caspase-1.

Antisense molecules and their use for inhibiting gene expression are well known in the art (*see, e.g.*, Cohen, 1989, In: Oligodeoxyribonucleotides, Antisense Inhibitors of Gene Expression, CRC Press). Antisense nucleic acids are DNA or RNA molecules that are complementary, as that term is defined elsewhere herein, to at least a portion of a specific

mRNA molecule (Weintraub, 1990, Scientific American 262:40). In the cell, antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule thereby inhibiting the translation of genes.

5 The use of antisense methods to inhibit the translation of genes is known in the art, and is described, for example, in Marcus-Sakura (1988, Anal. Biochem. 172:289). Such antisense molecules may be provided to the cell via genetic expression using DNA encoding the antisense molecule as taught by Inoue, 1993, U.S. Patent No. 5,190,931.

10 Alternatively, antisense molecules of the invention may be made synthetically and then provided to the cell. Antisense oligomers of between about 10 to about 30, and more preferably about 15 nucleotides, are preferred, since they are easily synthesized and introduced into a target cell. Synthetic antisense molecules contemplated by the invention include oligonucleotide derivatives known in the art which have improved biological activity compared to unmodified oligonucleotides (*see* U.S. Patent No. 5,023,243).

15 In one embodiment of the invention, a ribozyme is used to inhibit caspase-1 expression. Ribozymes useful for inhibiting the expression of a target molecule may be designed by incorporating target sequences into the basic ribozyme structure which are complementary, for example, to the mRNA sequence encoding caspase-1. Ribozymes targeting caspase-1, may be synthesized using commercially available reagents (Applied Biosystems, Inc., Foster City, CA) or they may be genetically expressed from DNA encoding them.

20 In one embodiment, the nucleic acid inhibitor of the invention is an antagonist of caspase-1. For example, in certain embodiments, the isolated nucleic acid specifically binds to caspase-1, or a target of caspase-1, to inhibit the functional activity of caspase-1.

25 Peptide Inhibitors

In other related aspects, the invention includes an isolated peptide inhibitor that inhibits caspase-1. For example, in one embodiment, the peptide inhibitor of the invention inhibits caspase-1 directly by binding to caspase-1 thereby preventing the normal functional activity of caspase-1. In another embodiment, the peptide inhibitor of the invention 30 inhibits caspase-1 by competing with endogenous caspase-1. In yet another embodiment, the peptide inhibitor of the invention inhibits the activity of caspase-1 by acting as a transdominant negative mutant.

In one embodiment, the peptide inhibitor of the invention comprises a non-cleavable Sirt1 peptide. For example, in one embodiment, the peptide inhibitor comprises the

amino acid sequence of SEQ ID NO: 1. In one embodiment, the peptide inhibitor comprises the amino acid sequence of SEQ ID NO: 2.

In one embodiment, the peptide inhibitor comprises an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
5 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:1. In one embodiment, the peptide inhibitor comprises an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity over an entire length of the amino acid sequence set forth in SEQ ID NO:2.

10 The variants of the polypeptides according to the present invention may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, (ii) one in which there are one or more modified amino acid residues, e.g., residues that are modified by
15 the attachment of substituent groups, (iii) one in which the polypeptide is an alternative splice variant of the polypeptide of the present invention, (iv) fragments of the polypeptides and/or (v) one in which the polypeptide is fused with another polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification (for example, His-tag) or for detection (for example, Sv5 epitope tag). The fragments include polypeptides generated
20 via proteolytic cleavage (including multi-site proteolysis) of an original sequence. Variants may be post-translationally, or chemically modified. Such variants are deemed to be within the scope of those skilled in the art from the teaching herein.

A peptide inhibitor of the invention may be conjugated with other molecules, such as proteins, to prepare fusion proteins. This may be accomplished, for example, by the
25 synthesis of N-terminal or C-terminal fusion proteins provided that the resulting fusion protein retains the functionality of the peptide inhibitor.

Cyclic derivatives of the peptides or chimeric proteins of the invention are also part of the present invention. Cyclization may allow the peptide or chimeric protein to assume a more favorable conformation for association with other molecules. Cyclization may
30 be achieved using techniques known in the art. For example, disulfide bonds may be formed between two appropriately spaced components having free sulfhydryl groups, or an amide bond may be formed between an amino group of one component and a carboxyl group of another component. Cyclization may also be achieved using an azobenzene-containing amino acid as described by Ulysse, L., et al., J. Am. Chem. Soc. 1995, 117, 8466-8467. The

components that form the bonds may be side chains of amino acids, non-amino acid components or a combination of the two. In an embodiment of the invention, cyclic peptides may comprise a beta-turn in the right position. Beta-turns may be introduced into the peptides of the invention by adding the amino acids Pro-Gly at the right position.

5 It may be desirable to produce a cyclic peptide which is more flexible than the cyclic peptides containing peptide bond linkages as described above. A more flexible peptide may be prepared by introducing cysteines at the right and left position of the peptide and forming a disulphide bridge between the two cysteines. The two cysteines are arranged so as not to deform the beta-sheet and turn. The peptide is more flexible as a result of the length of
10 the disulfide linkage and the smaller number of hydrogen bonds in the beta-sheet portion. The relative flexibility of a cyclic peptide can be determined by molecular dynamics simulations.

(a) Tags

 In one embodiment, the composition comprises a peptidomimetic inhibitor of at least one of caspase-1. Peptidomimetics are compounds based on, or derived from,
15 peptides and proteins. The peptidomimetics of the present invention typically can be obtained by structural modification of known caspase-1 sequences or sequences that interact with caspase-1, using unnatural amino acids, conformational restraints, isosteric replacement, and the like. The peptidomimetics constitute the continuum of structural space between peptides and non-peptide synthetic structures.

20 Such peptidomimetics can have such attributes as being non-hydrolyzable (e.g., increased stability against proteases or other physiological conditions which degrade the corresponding peptide), increased specificity and/or potency, and increased cell permeability for intracellular localization of the peptidomimetic. For illustrative purposes, peptide analogs of the present invention can be generated using, for example, benzodiazepines (e.g., see
25 Freidinger et al. in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, p123), C-7 mimics (Huffman et al. in *Peptides: Chemistry and Biology*, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, p. 105), keto-methylene pseudopeptides
30 (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, Ill., 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans 1*:1231), β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys*

Res Commun 134:71), diaminoketones (Natarajan et al. (1984) Biochem Biophys Res Commun 124:141), and methyleneamino-modified (Roark et al. in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, p134). Also, see generally, Session III: Analytic and synthetic methods, in in Peptides: Chemistry and
5 Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988)

In addition to a variety of side chain replacements which can be carried out to generate peptidomimetics, the present invention contemplates the use of conformationally restrained mimics of peptide secondary structure. Numerous surrogates have been developed for the amide bond of peptides. Frequently exploited surrogates for the amide bond include
10 the following groups (i) trans-olefins, (ii) fluoroalkene, (iii) methyleneamino, (iv) phosphonamides, and (v) sulfonamides.

A peptide or peptidomimetic inhibitor of the invention may be synthesized by conventional techniques. For example, the peptide or peptidomimetic inhibitor may be synthesized by chemical synthesis using solid phase peptide synthesis. These methods
15 employ either solid or solution phase synthesis methods (see for example, J. M. Stewart, and J. D. Young, Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford Ill. (1984) and G. Barany and R. B. Merrifield, The Peptides: Analysis Synthesis, Biology editors E. Gross and J. Meienhofer Vol. 2 Academic Press, New York, 1980, pp. 3-254 for solid phase synthesis techniques; and M Bodansky, Principles of Peptide Synthesis, Springer-
20 Verlag, Berlin 1984, and E. Gross and J. Meienhofer, Eds., The Peptides: Analysis, Synthesis, Biology, supra, Vol 1, for classical solution synthesis.)

Antibody Inhibitors

The invention also contemplates an inhibitor of caspase-1 comprising an
25 antibody, or antibody fragment, specific for caspase-1. That is, the antibody can inhibit caspase-1 to provide a beneficial effect.

The antibodies may be intact monoclonal or polyclonal antibodies, and immunologically active fragments (e.g., a Fab or (Fab)₂ fragment), an antibody heavy chain, an antibody light chain, humanized antibodies, a genetically engineered single chain Fv
30 molecule (Ladner et al, U.S. Pat. No. 4,946,778), or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are of human origin. Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art.

However, the invention should not be construed as being limited solely to methods and compositions including these antibodies or to these portions of the antigens. Rather, the invention should be construed to include other antibodies, as that term is defined elsewhere herein, to antigens, or portions thereof. Further, the present invention should be construed to encompass antibodies, *inter alia*, bind to the specific antigens of interest, and they are able to bind the antigen present on Western blots, in solution in enzyme linked immunoassays, in fluorescence activated cells sorting (FACS) assays, in magnetic-activated cell sorting (MACS) assays, and in immunofluorescence microscopy of a cell transiently transfected with a nucleic acid encoding at least a portion of the antigenic protein, for example.

One skilled in the art would appreciate, based upon the disclosure provided herein, that the antibody can specifically bind with any portion of the antigen and the full-length protein can be used to generate antibodies specific therefor. However, the present invention is not limited to using the full-length protein as an immunogen. Rather, the present invention includes using an immunogenic portion of the protein to produce an antibody that specifically binds with a specific antigen. That is, the invention includes immunizing an animal using an immunogenic portion, or antigenic determinant, of the antigen.

The invention also includes functional equivalents of the antibodies described herein. Functional equivalents have binding characteristics comparable to those of the antibodies, and include, for example, hybridized and single chain antibodies, as well as fragments thereof.

Single chain antibodies (scFv) or Fv fragments are polypeptides that consist of the variable region of the heavy chain of the antibody linked to the variable region of the light chain, with or without an interconnecting linker. Thus, the Fv comprises an antibody combining site.

Functional equivalents of the antibodies of the invention further include fragments of antibodies that have the same, or substantially the same, binding characteristics to those of the whole antibody. Such fragments may contain one or both Fab fragments or the F(ab')₂ fragment. The antibody fragments contain all six complement determining regions of the whole antibody, although fragments containing fewer than all of such regions, such as three, four or five complement determining regions, are also functional. The functional equivalents are members of the IgG immunoglobulin class and subclasses thereof, but may be or may combine with any one of the following immunoglobulin classes: IgM, IgA, IgD, or IgE, and subclasses thereof. Heavy chains of various subclasses, such as the IgG subclasses,

are responsible for different effector functions and thus, by choosing the desired heavy chain constant region, hybrid antibodies with desired effector function are produced. Exemplary constant regions are gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3), and gamma 4 (IgG4). The light chain constant region can be of the kappa or lambda type.

5 The immunoglobulins of the present invention can be monovalent, divalent or polyvalent. Monovalent immunoglobulins are dimers (HL) formed of a hybrid heavy chain associated through disulfide bridges with a hybrid light chain. Divalent immunoglobulins are tetramers (H₂L₂) formed of two dimers associated through at least one disulfide bridge.

10 Cells

 In certain embodiments, the composition comprises a cell genetically modified to express one or more isolated nucleic acids and/or proteins described herein. For example, the cell may be transfected or transformed with one or more vectors comprising a nucleic acid encoding a caspase-1 inhibitor. The cell can be the subject's cells or they can be
15 haplotype matched. In specific embodiments, the cell is a stem cell. In some embodiments the stem cell is a bone marrow-derived Scd1⁺ stem cell.

Scaffolds

 The present invention provides a scaffold or substrate composition comprising
20 an inhibitor of the invention, a peptide of the invention, a cell of the invention or any combination thereof.

 For example in one embodiment, the scaffold or substrate composition comprising an inhibitor of caspase-1, a nucleic acid molecule encoding a caspase-1 inhibitor, a cell comprising a caspase-1 inhibitor, a cell comprising a nucleic acid molecule encoding a
25 caspase-1 inhibitor, or a combination thereof.

 For example, in one embodiment, an inhibitor of caspase-1, a nucleic acid molecule encoding a caspase-1 inhibitor, a cell comprising a caspase-1 inhibitor, a cell comprising a nucleic acid molecule encoding a caspase-1 inhibitor, or a combination thereof is within a scaffold.

30 In one embodiment, an inhibitor of caspase-1, a nucleic acid molecule encoding a caspase-1 inhibitor, a cell comprising a caspase-1 inhibitor, a cell comprising a nucleic acid molecule encoding a caspase-1 inhibitor, or a combination thereof is applied to the surface of a scaffold.

The scaffold of the invention may be of any type known in the art. Non-limiting examples of such a scaffold includes a, hydrogel, electrospun scaffold, foam, mesh, sheet, patch, and sponge.

5 Treatment Methods

The present invention provides methods of treating or preventing a disease or disorder associated with endothelial activation, inflammation or atherogenesis. In one embodiment, the method comprises administering an effective amount of a composition of the invention.

10 Administration of a caspase-1 inhibitor comprising for example one or more peptides, a small molecule, an antisense nucleic acid, a soluble receptor, an antibody, a cell, or a scaffold in a method of treatment can be achieved in a number of different ways, using methods known in the art.

It will be appreciated that an inhibitor of the invention may be administered to
15 a subject either alone, or in conjunction with another therapeutic agent.

In one embodiment, an exogenous caspase inhibitor of the invention is administered to a subject. The exogenous peptide may also be a hybrid or fusion protein to facilitate, for instance, delivery to target cells or efficacy. In one embodiment, a hybrid protein may comprise a tissue-specific targeting sequence.

20 The therapeutic and prophylactic methods of the invention thus encompass the use of pharmaceutical compositions comprising a caspase inhibitory peptide, fusion protein, small molecule, soluble receptor, or antibody of the invention and/or an isolated nucleic acid encoding a caspase inhibitory peptide, fusion protein small molecule, soluble receptor, or antibody of the invention to practice the methods of the invention. The pharmaceutical
25 compositions useful for practicing the invention may be administered to deliver a dose of from ng/kg/day and 100 mg/kg/day. In one embodiment, the invention envisions administration of a dose which results in a concentration of the compound of the present invention from 1 μ M and 10 μ M in a mammal.

Typically, dosages which may be administered in a method of the invention to
30 a mammal, preferably a human, range in amount from 0.5 μ g to about 50 mg per kilogram of body weight of the mammal. While the precise dosage administered will vary depending upon any number of factors, including but not limited to, the type of mammal and type of disease state being treated, the age of the mammal and the route of administration. Preferably,

the dosage of the compound will vary from about 1 µg to about 10 mg per kilogram of body weight of the mammal. More preferably, the dosage will vary from about 3 µg to about 1 mg per kilogram of body weight of the mammal.

The compound may be administered to a mammal as frequently as several
5 times daily, or it may be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less. The frequency of the dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disease being treated, the type and age of the mammal, etc.

10 The administration of the inhibitor of the invention to the subject may be accomplished using gene therapy. Gene therapy, which is based on inserting a therapeutic gene into a cell by means of an ex vivo or an in vivo technique. Suitable vectors and methods have been described for genetic therapy in vitro or in vivo, and are known as expert on the matter; see, for example, Giordano, *Nature Medicine* 2 (1996), 534-539; Schaper, *Circ. Res*
15 79 (1996), 911-919; Anderson, *Science* 256 (1992), 808-813; Isner, *Lancet* 348 (1996), 370-374; Muhlhauser, *Circ. Res* 77 (1995), 1077-1086; Wang, *Nature Medicine* 2 (1996), 714-716; WO94/29469; WO97/00957 or Schaper, *Current Opinion in Biotechnology* 7 (1996), 635-640 and the references quoted therein. The polynucleotide codifying the polypeptide of the invention can be designed for direct insertion or by insertion through liposomes or viral
20 vectors (for example, adenoviral or retroviral vectors) in the cell. Preferably the cell is a cell of the germinal line, an embryonic cell or egg cell or derived from the same, more preferably the cell is a core cell. Suitable gene distribution systems that can be used according to the invention may include liposomes, distribution systems mediated by receptor, naked DNA and viral vectors such as the herpes virus, the retrovirus, the adenovirus and adeno-associated
25 viruses, among others. The distribution of nucleic acids to a specific site in the body for genetic therapy can also be achieved by using a biolistic distribution system, such as that described by Williams (*Proc. Natl. Acad. Sci. USA*, 88 (1991), 2726-2729). The standard methods for transfecting cells with recombining DNA are well known by an expert on the subject of molecular biology, see, for example, WO94/29469; see also supra. Genetic therapy
30 can be carried out by directly administering the recombining DNA molecule or the vector of the invention to a patient or transfecting the cells with the polynucleotide or the vector of the invention ex vivo and administering the transfected cells to the patient.

Pharmaceutical Compositions

The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.

Although the description of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as non-human primates, cattle, pigs, horses, sheep, cats, and dogs.

Pharmaceutical compositions that are useful in the methods of the invention may be prepared, packaged, or sold in formulations suitable for ophthalmic, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.

In addition to the active ingredient, a pharmaceutical composition of the invention may further comprise one or more additional pharmaceutically active agents. Other active agents useful in the treatment of fibrosis include anti-inflammatories, including corticosteroids, and immunosuppressants.

5 Controlled- or sustained-release formulations of a pharmaceutical composition of the invention may be made using conventional technology.

As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the
10 tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, intraocular, intravitreal, subcutaneous,
15 intraperitoneal, intramuscular, intrasternal injection, intratumoral, and kidney dialytic infusion techniques.

Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations may be prepared,
20 packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations.
25 Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (i.e. powder or granular) form for reconstitution with a suitable vehicle (e.g. sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition.

30 The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared

using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations which are useful include those which
5 comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

10 A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for
15 administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the active ingredient dissolved or suspended in a low-boiling propellant in a sealed container. Preferably, such powders comprise particles wherein at least 98% of the particles by weight have a diameter
20 greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

25 Low boiling propellants generally include liquid propellants having a boiling point of below 65°F at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic or solid anionic surfactant or a solid diluent (preferably having a particle size
30 of the same order as particles comprising the active ingredient).

Pharmaceutical compositions of the invention formulated for pulmonary delivery may also provide the active ingredient in the form of droplets of a solution or suspension. Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, comprising the active ingredient, and

may conveniently be administered using any nebulization or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate. The droplets provided
5 by this route of administration preferably have an average diameter in the range from about 0.1 to about 200 nanometers.

The formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of a pharmaceutical composition of the invention.

Another formulation suitable for intranasal administration is a coarse powder
10 comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.

Formulations suitable for nasal administration may, for example, comprise
15 from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may further comprise one or more of the additional ingredients described herein.

A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets or lozenges made using conventional methods, and may, for
20 example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder or an aerosolized or atomized solution or suspension comprising the active ingredient. Such powdered, aerosolized, or aerosolized formulations, when dispersed, preferably have an
25 average particle or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.

As used herein, "additional ingredients" include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents;
30 flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials. Other

“additional ingredients” which may be included in the pharmaceutical compositions of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (1985, Genaro, ed., Mack Publishing Co., Easton, PA), which is incorporated herein by reference.

5 These methods described herein are by no means all-inclusive, and further
methods to suit the specific application will be apparent to the ordinary skilled artisan.
Moreover, the effective amount of the compositions can be further approximated through
analogy to compounds known to exert the desired effect.

10 EXPERIMENTAL EXAMPLES

The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

Example 1: Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway

25 This study examined a novel hypothesis that caspase-1 in ECs can sense hyperlipidemia in mice fed a HF diet for 3 weeks and that caspase-1 activation in ECs, potentially via the caspase-1–Sirt1 pathway, can promote endothelial activation, monocyte recruitment, and atherogenesis. Double gene knockout (KO) mice were generated that are deficient of caspase-1 and ApoE (ApoE^{-/-}/caspase-1^{-/-}) by crossing caspase-1^{-/-} mice into
30 ApoE^{-/-} mouse background. Our results demonstrate that caspase-1 activation significantly contributes to endothelial activation, monocyte recruitment, and atherogenesis via the caspase-1–Sirt1–activator protein-1 (AP-1) pathway. Therefore, these results indicate a role for caspase-1 activation in sensing hyperlipidemia as a DAMP and promoting endothelial activation.

The results demonstrate for the first time that early hyperlipidemia promotes EC activation before monocyte recruitment via a caspase-1-sirtuin 1-activator protein-1 pathway, which provides an important insight into the development of novel therapeutics for blocking caspase-1 activation as early intervention of metabolic cardiovascular diseases and inflammations.

The material and methods employed in these experiments are now described.

Reagents

Dulbecco's modified Eagle's medium, M199, penicillin, streptomycin, L-glutamate, and heparin were purchased from Invitrogen (Carlsbad, CA). Dihydroethidium (DHE) was purchased from Molecular Probes (Eugene, OR). Caspase-1 peptide inhibitor (Ac-YVAD-CHO) was from ALEXIS Biochemicals (San Diego, CA), and caspase-1 small molecular inhibitor was generously provided by Dr. Craig Thomas of the NIH Chemical Genomics Center. Antibodies against β -actin were purchased from Sigma-Aldrich (St. Louis, MO). Caspase-1 antibody (Cat #14-9832-80) was purchased from eBioscience (San Diego, CA). Low-density lipoprotein (LDL), oxidized LDL (oxLDL), and acetylated LDL labeled with 1,1'-dioctadecyl-3,3',3'-tetramethyl-indocarbocyanine perchlorate (Dil-Ac-LDL) were purchased from Biomedical Technologies (Stoughton, MA). Lysophosphatidylcholine (LysoPC, 1-hexadecanoyl-sn-glycerol-3-phosphorylcholine) and lysophosphatidic acid (LysoPA; mono-acylsn-glycerol-3-phosphate) were purchased from Avanti Polar Lipids (Alabaster, AL). Antibodies to intercellular adhesion molecule-1 (ICAM-1) (sc-18853), vascular cell adhesion molecule-1 (VCAM-1) (sc-8304), and E-selectin [CD62 antigen-like family member E (CD62E)] (sc-14011) were purchased from Santa Cruz (Santa Cruz, CA). All other reagents were purchased from Sigma-Aldrich, unless indicated otherwise.

Mice and Diets

C57BL/6J mice, chicken β -actin promoter possessing cytomegalovirus (CMV) enhancer driven enhanced green fluorescence protein (EGFP)-transgenic mice, and apolipoprotein E gene deficient (ApoE^{-/-}) mice in a C57BL/6J background were obtained from the Jackson Laboratory (Bar Harbor, Me). Caspase-1^{-/-} (Casp-1^{-/-}) mice in a C57BL/6J background were generously provided by Dr. Richard Flavell's laboratory (Yale University School of Medicine, CT). ApoE^{-/-} mice and Casp-1^{-/-} mice were crossed to establish ApoE^{-/-}/Casp-1^{-/-} mice. All mice were kept under specific pathogen-free conditions in a temperature

controlled environment. Age-matched male mice were used for all experiments. At the age of 8 weeks, mice were maintained on a normal chow diet (5% fat, Labdiet 5001) or fed a diet supplemented with 0.2% (w/w) cholesterol and 21.2% (w/w) fat (HF diet) (TD. 88137, Harlan Teklad, WI) for designated periods. For tissue collection, mouse heart, aorta, and spleen were collected under a dissecting microscope and weighed from euthanized mice. All procedures in animals were performed in accordance with the approvals of Temple University Institutional Animal Care and Use Committee (IACUC).

Genotyping

Murine genomic deoxyribonucleic acid (DNA) was collected using the following method. Briefly, a small piece of mouse tail tissue was collected from the mouse and digested with 500 μ l lysate buffer [100 mM Tris-HCl (pH 8.5), 5 mM EDTA, 0.2% SDS, 200 mM NaCl] supplemented with 200 mg/mL proteinase K (EMD Millipore, Billerica, MA) overnight at 55°C with shaking in a Thermomixer. The DNA was separated from the wrapping protein by occasional gentle taps of the digestion tube during the digestion process. The tissue debris was separated by centrifugation. The digestion supernatant (450 μ L) was transferred into a new tube and mixed with 700 μ L of isopropanol. The DNA was then precipitated and transferred into a new tube containing 200 μ L of H₂O, and dissolved by overnight incubation at 55°C. The genomic DNA was used for polymerase chain reaction (PCR) and the PCR product was separated on an agarose gel. Specific primers were used to determine the genotype of the mice. For ApoE, primer 180 (5'-GCCTAGCCGAGGGAGAGCCG-3' (SEQ ID NO: 3)), 181 (5'-TGTGACTTGGGAGCTCTGCAGC-3' (SEQ ID NO: 4)), and 182 (5'-GCCGCCCCGACTGCATCT-3' (SEQ ID NO: 5)) were used. The PCR cycle was 94°C for 30 seconds (sec), 68°C for 40 sec, 72°C for 1 minute (min), and repeated for 35 cycles. The DNA fragment for ApoE^{-/-} mice was 245 base pairs (bp), and the DNA fragment for WT mice was 150bp in length. For detection of caspase-1 KO mice, primer ICE 3 (5'-ATGGCACACCACAGATATCGG-3' (SEQ ID NO: 6)), ICEKO (5'-TGCTAAAGCGCATGCTCCAGACTG-3' (SEQ ID NO: 7)), and ICE5 (5'-GAGACATATAAGG GAGAAGGG-3' (SEQ ID NO: 8)) were used. The PCR cycle was 94°C for 30 sec, 60°C for 1 min, 72°C for 1 min, and repeat for 40 cycles. The DNA fragment for Casp-1^{-/-} mice was 300bp and the DNA fragment for WT mice was 500bp in length.

Lipid and Lipoprotein Analysis

Blood was collected in 5% EDTA coated tubes from the inferior vena cava of anesthetized animals. Plasma was separated by low speed centrifugation for 20 min at 4°C. Plasma concentrations of total cholesterol (TC) and triglyceride (TG) in each sample were measured at the National Mouse Metabolic Phenotyping Center in Vanderbilt University (Nashville, TN).

Aortic Sinus Cross-section and Atherosclerotic Lesion Characterization

Mouse hearts were harvested, weighed, and fixed overnight with 4% paraformaldehyde (PFA). Fixed tissues were then impregnated with 20% (v/v) sucrose in PBS [1mM Na₂HPO₄, 137mM NaCl, 1.5mM KH₂PO₄, 2.7mM KCl at pH 7.4] embedded with optimal cutting temperature compound (OCT) (Tissue Tek, Sakura Finetek, DK), and quickly frozen on dry ice. Serial cross sections of the aortic root were collected on slides; 10µm cryostat sections were taken from the level where the 3 aortic valves first appeared to the level where the aortic valves disappeared. A total of 80 sections were collected on 10 slides. Sections of the aortic sinus were stained with Oil Red O and alum hematoxylin. Briefly, fixed sections were rinsed with 60% isopropanol and stained with freshly prepared Oil Red O working solution (0.3% Oil Red O in 60% isopropanol) for 18 min. Followed with another rinse with 60% isopropanol, the sections were then stained with alum hematoxylin and washed with distilled water. The stained sections were then mounted in aqueous mounting medium and stored in room temperature until imaging. Images were captured with a Zeiss Axioscope microscope (Carl Zeiss Inc., Thornwood, NY). Atherosclerotic lesion area was defined as the red area staining with Oil red O and measured with ImageJ (NIH, Bethesda, MD). The percentage of lesion area was calculated by dividing lesion area by the total sinus area, and the average value of eight sections on each slide was presented.

Mouse Peripheral Blood Cell Isolation

Peripheral blood was drawn from the inferior vena cava or by tail bleeding from anesthetized animals. Red blood cells were lysed with Ammonium-Chloride-Potassium (ACK) lysing buffer [0.15M ammonium chloride (NH₄Cl), 10mM potassium bicarbonate (KHCO₃), 0.1mM EDTA] for 8 min at room temperature. The remaining cells were washed with PBS supplemented with 2% (v/v) fetal bovine serum (FBS) (GIBCO Laboratory, Grand Island, NY) and stained as described below for flow cytometry analysis.

Aortic Cell Isolation and Staining

ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice were fed with a HF diet for 3 weeks and sacrificed at the end of the feeding period. Their vasculatures were perfused by cardiac puncture with PBS containing 20U/mL of heparin to remove blood cells from all vessels. The
5 aortas were collected and digested as previously described with slight modification. Briefly, the entire mouse thoracic and abdominal aortas were isolated from the surrounding fat, minced with scissors, and digested with 125U/mL collagenase type XI, 60U/mL hyaluronidase type I, 60U/ml DNaseI, and 450U/mL collagenase type I in PBS containing 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (GIBCO Laboratory,
10 Grand Island, NY) at 37°C for 45 min. Aortic cell suspensions were then washed with Hank's balanced salt solution (HBSS) (Cellgro Mediatech, Washington, DC) supplemented with 2% FBS and filtered through a 70µM cell strainer (BD Falcon, San Jose, CA). The passed fluid containing the suspended cells was then ready for antibody staining.

Both cells from blood samples and from aortic tissues were first stained with
15 LIVE/DEAD® Fixable Violet dye (Invitrogen, USA) for 20 min at 4°C to exclude dead cells, washed, and were co-incubated with three monoclonal antibodies, CD11b-phycoerythrin (PE) (BD Biosciences, monocyte marker), Ly-6C-fluorescein isothiocyanate (FITC) (BD Biosciences, an inflammatory monocyte marker) and F4/80-phycoerythrin-cyanine (PE-Cy7) (eBioscience, macrophage marker) for 30 min at 4 °C. The stained cells were then fixed with
20 2% PFA for at least 1 hour at 4°C and analyzed on the LSR II flow cytometer (BD Biosciences, San Jose, CA).

Bone Marrow Transplantation

Eight week-old ApoE^{-/-} mice and ApoE^{-/-}/Casp-1^{-/-} mice were irradiated with a
25 single dose of nine Gy using the model 30-1 Irradiator (J.L. Shepherd & Associates, San Fernando, CA). The donor bone marrow (BM) cells were harvested from 8 week-old enhanced green fluorescent protein (EGFP)-transgenic mice. Briefly, BM cells were flushed out from tibia and femur with HBSS supplemented with 2% FBS and filtered through a 70µM cell strainer. The un-fractionated EGFP⁺ BM cells (5 x 10⁶ cells) were administered by
30 retro-orbital injection into the irradiated mice 2 hours after irradiation. To assess the irradiation efficiency, a group of mice without receiving BM transplantation after irradiation was used as controls. More than 80% of the non-BM recipient control mice died after irradiation while all BM transplanted mice survived. To assess hematopoietic chimerism, peripheral blood cells were collected from the recipient mice 6 weeks after BM

transplantation, and the frequency of EGFP⁺ cells among peripheral nucleated blood cells was determined by flow cytometry after hemolysis with ACK lysis buffer. The chimeric mice were then fed a HF diet for 3 weeks, and the rates of EGFP⁺ monocyte migration into the aorta were accessed by the single cell suspension method as described previously.

5

Human Aortic Endothelial Cell Culture

Human aortic endothelial cells (HAECs) (Clonetics Corporation, San Diego, CA) were cultured as we previously described. The cells were maintained on a 0.2% gelatin-coated 75-cm² flask in M199 (Hyclone Labs., Logan, UT) supplemented with 20% FBS, 1% Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 3ng/mL EC growth supplement (ECGS) (BD Biosciences, San Jose, CA), and 5U/ml heparin at 37°C under 5% CO₂, 95% air until passage 8. For our experiments, HAECs (≤ passage 9) were used and treated with desired stimuli for indicated time.

15

Mouse Endothelial Cell Isolation and Primary Culture

Mouse aorta ECs (MAECs) were isolated and cultured as previous described with modifications. Briefly, the entire mouse thoracic aorta was exposed, perfused with PBS containing 1,000U/mL heparin, and filled with Dulbecco's modified eagle medium (DMEM) (Hyclone Labs., Logan, UT) plus 300U/mL collagenase type 2 (Worthington Biochemical Corp., Freehold, NJ) with ligation at both ends. The aorta was then isolated and incubated in 20% FBS/DMEM at 37°C for 1 hour. The fluid inside the aorta was flushed out with 20% FBS/DMEM and drained into a 15-mL tube containing 10 mL of endothelial growth medium (EGM) [50% DMEM; 40% F-12 (Invitrogen, Carlsbad, CA), 10% FBS; 0.3% ECGS; 10U/mL Heparin; 1% Penicillin/Streptomycin]. After centrifugation, all cells were collected and re-suspended with fresh EGM. The cells were then transferred into collagen-coated 35-mm dishes (2 aortas/dish) and incubated for 1 hr. The non-adhered cells were then washed away with sterile Dulbecco's phosphate-buffered saline (DPBS) (Hyclone Labs., Logan, UT), and the MAECs were cultured with EGM until 80% confluence was achieved.

The specificity of ECs was determined by Dil-Ac-LDL uptake and CD31 staining. Briefly, Dil-Ac-LDL was added to the culture medium at the final concentration of 10μg/mL. MAECs were incubated with the dye-labeled lipoprotein for 4 hours at 37°C. The cells were then washed twice with PBS, fixed with 4% PFA for 20 min, and stained with 4', 6-diamidino-2-phenylindole (DAPI) (1μg/mL) for 5 min. For CD31 (platelet endothelial cell adhesion molecule-1, EC marker) staining, MAECs were cultured on a sterile cover slip and

fixed with 4% PFA for 20 min before staining. Rat anti-mouse CD31 antibody (BD Pharmingen, San Diego, CA) and FITC conjugated rabbit anti-rat secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) were used. All images were captured with a Zeiss Axioscope microscope.

5

Caspase-1 Activity Assay

Active caspase-1 level was determined with APO LOGIX kit (Cell Tech., Mountain View, CA). The kit contains a carboxyfluorescein (FAM) [Excitation/Emission (nm):490/520]-labeled peptide fluoromethyl ketone (FMK) caspase-1 inhibitor (FAM-YVAD-FMK), which irreversibly binds to active caspase-1. All procedures were performed according to the manufacturer's instruction. Briefly, HAECs ($\leq$ passage 9) were cultured in 6-well plates and serum starved overnight to quiescent the cells before treatment. Next day, HAECs were treated with indicated stimuli for 6 hr. Cells were then digested by trypsin-EDTA and suspended at 1×10^6 cells/ml. 150 μ l of cell suspension were incubated at 37°C with 1 x FAM-YVAD-FMK for 1 hour then washed with 1x washing buffer. Unfixed caspase-1 stained cells were then incubated with 7-aminoactinomycin D (7-AAD; cell membrane integrity marker) (BD Pharmingen, San Diego, CA) for no more than 10 min before analysis. The Calibur flow cytometer (BD Biosciences, San Jose, CA) was used to determine caspase-1 active (Caspase-1⁺) and 7-AAD⁺ cells. Data were analyzed with the FlowJo software (Tree Star, Ashland, OR).

20

Reactive Oxygen Species Level Detection

Dihydroethidium (DHE) was applied to detect reactive oxygen species (ROS) levels in HAECs. DHE can be oxidized by superoxide anion, which then bind with the cell's DNA and stain its nucleus a bright red fluorescent [Excitation/Emission (nm):518/605]. For staining, suspended HAECs were incubated in 150 μ L culture medium containing 3 μ M DHE for 40 min at 37°C in the dark. The samples were washed with flow cytometry washing buffer (PBS/2% FBS) and immediately analyzed by flow cytometry.

25

30

Data Analysis using the FlowJo Software

All flow cytometric data were analyzed with the FlowJo software. The uncompensated data was collected from the flow cytometer (either Calibur flow cytometer or LSRII flow cytometer). Forward and side scatter gates were used to select live cell population

from clumps and debris. The positive gate was determined by its matched IgG control, and single staining was used to determine the compensation parameter.

Protein Extraction and Western Blot Analysis

5 Cell pellets from HAECs were collected and lysed with protein lysing buffer [0.75% SDS, 0.03M Tris-HCl stock (pH 6.8), 5.6% glycerol, 1mM EDTA, 0.04mg/ml phenylmethanesulfonylfluoride (PMSF), 1 x protease inhibitor tablet (Roche Applied Science, Indianapolis, IN)]. For aorta, the fat-free aortic tissues were collected and dissected with scissors before lysing. The cells/tissues were further lysed by sonication, and the debris
10 was centrifuged down. The supernatant was transferred into a new tube and the protein concentration was determined by the bicinchoninic acid assay (Pierce/Thermo, Rockford, IL). Forty µg to 100µg protein was loaded into a 10% sodium dodecyl sulfate polyacrylamide gels and transferred onto nitrocellulose membranes (Whatman, Clifton, NJ), and the membranes were then stained with 1% Ponceau S for loading controls. Then the blots were
15 blocked with 5% non-fat milk in PBST (PBS + 0.1% Tween 20) for 1 hr at room temperature and probed with diluted primary antibodies overnight at 4°C. Blots were then washed 4 times with PBST and incubated with horseradish peroxidase (HRP) conjugated anti-mouse, anti-rabbit, or anti-goat secondary antibodies (Santa Cruz) for 1 hr at room temperature. After another 4 washes with PBST, the blots were then incubated with enhanced
20 chemiluminescence (ECL) substrate for horseradish peroxidase (Pierce/Thermo, Rockford, IL), and the ECL intensity was detected by X-ray film exposure in a dark room. The X-ray films were developed by the SRX-101A medical film processor. The expression levels of proteins as indicated by the ECL intensity were measured with ImageJ (NIH, Bethesda, MD, USA)

RNA Extraction and Real-Time PCR

Messenger RNA (mRNA) was extracted from cultured cells or tissues using TRIzol® Reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instruction. Briefly, the cells or tissue samples were lysed with enough TRIzol® Reagent for 5 min at
30 room temperature and then phase separated with chloroform. After high speed centrifugation, the upper aqueous phase was collected and transferred into a new tube with an equal volume of isopropanol. The mRNA was centrifuged down at high speed for 15 min, washed twice with 70% ethanol in RNAase free water (Qiagen, Valencia, CA), and dissolved in RNAase free water. The mRNA concentration was determined on a Nanodrop 2000 (Thermo Fisher

Scientific, San Jose, CA). Two μ g of mRNA was then reverse transcribed into complementary DNA (cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). For real-time PCR (RT-PCR), a SYBR-green PCR system (SABiosciences, Frederick, MD) was used, and the real-time PCR was performed on the StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA).

The primers used for the real-time PCR are listed below. Human NLRP1-Forward: 5'-AAGTGACTGCTCCATTCGGAA-3' (SEQ ID NO: 9); Human NLRP-Reverse: 5'-CTCCGAGAACAGCTGGTCTTCT-3' (SEQ ID NO: 10); Human NLRP3-Forward: 5'-TGAAGA GGAGTGGATGGGTT-3' (SEQ ID NO: 11); Human NLRP3-Reverse: 5'-TTCAATGCACTGGAA TCTGC-3' (SEQ ID NO: 12); Human PYCARD-Forward: 5'-ATGGACGCCTTGACCTACCG-3' (SEQ ID NO: 13); Human PYCARD-Reverse: 5'-TGGCTTGGCTGCCGACTGAGGA-3' (SEQ ID NO: 14); Human CASPASE-1-Forward: 5'-AGCTCCTCAGGCAGTGCAGGA-3' (SEQ ID NO: 15); Human CASPASE-1-Reverse: 5'-AGAGCAAGACGTGTGCGGCT-3' (SEQ ID NO: 16); Human IL1 β -Forward: 5'-ACAGATGAAGTGCTCCTTCCA-3' (SEQ ID NO: 17); Human IL1 β -Reverse: 5'-GTCGGAGATTCGTAGCT GGAT-3' (SEQ ID NO: 18); Human β -actin-Forward: 5'-ACCTTCTACAAT GAGCTGCG-3' (SEQ ID NO: 19); Human β -actin-Reverse: 5'-CCTGGATAGCAAGTACATGG-3' (SEQ ID NO: 20); Mouse Caspase-1-Forward: 5'-CCCTCAAGTTTTGCCCTTTAGA-3' (SEQ ID NO: 21); Mouse Caspase-1-Reverse: 5'-CCCTCGGAG AAAGATGTTGAAA -3' (SEQ ID NO: 22); Mouse ICAM-1-Forward: 5'-GTTCTCTAATGTCTCCGAG GC-3' (SEQ ID NO: 23); Mouse ICAM-1-Reverse: 5'-CTTCAGAGGCAGGAAACAGG-3' (SEQ ID NO: 24); Mouse VCAM-1-Forward: 5'-GCAAAGGACACTGGAAAAGAG-3' (SEQ ID NO: 25); Mouse VCAM-1-Reverse: 5'-TCAAAGGGATACACATTAGGGAC-3' (SEQ ID NO: 26); Mouse E-selectin-Forward: 5'-GCTGGAGAACTTGCGTTTAAG-3' (SEQ ID NO: 27); Mouse E-selectin-Reverse: 5'-AGATAAGGCTT CACACTGGAC-3' (SEQ ID NO: 28); Mouse GAPDH-Forward: 5'-GAGGCCGGTGCTGAGTATGTCG TGGA-3' (SEQ ID NO: 29); Mouse GAPDH-Reverse: 5'-CACACCCATCACAACTGGGGGCAT-3' (SEQ ID NO: 30).

Cytokine Array

A mouse cytokine array (R&D Systems, Minneapolis, MN) was used to determine the cytokine and chemokine expression in mouse aorta as well as in stimulated MAECs following the manufacturer's instruction. Briefly, the nitrocellulose membranes pre-spotted with 40 cytokine and chemokine antibodies were first blocked with 1 $\times$ blocking

buffer for 1 hr. Meanwhile, protein lysates or supernatant were incubated with the detection antibody cocktail for 1 hr. The blocked membranes were incubated with the premixed protein/antibody solutions overnight at 4°C. Then membranes were washed with 1x wash buffer three times and incubated with HRP-conjugated Streptavidin for 30 min at room temperature, and followed with another three washes with 1x wash buffer. The membranes were then incubated with the chemiluminescent reagents and exposed to X-ray films for 1-10 min. The expression levels of the cytokines and chemokines were determined by the intensity of the spots measured with ImageJ software. The variations of the manufacture's designate positive control (PC) spots between each array were used to determine the confidence interval of non-specific variations between samples

Static Adhesion Assay

HAECs were cultured and seeded on 24-well plates. THP-1 human monocytic cells were maintained in RPMI 1640 with 10% FBS and 2mM L-Glutamine (GIBCO Laboratory, Grand Island, NY). THP-1 cells were stained with 2 µM calcein green AM for 30 min at 37°C. Then 1×10^6 /mL THP-1 cells were suspended in 1 mL of 1640 and M199 medium (1:1) and added to HAEC monolayer. After 1 hr incubation at 37°C, unattached cells were removed by PBS washes and then the plates were read in a fluorescence microplate reader.

Preparation of Nuclear Extracts

HAECs cultured in 100-mm dishes were collected and homogenized in a low-salt buffer [10mM HEPES (pH 7.9), 1.5mM magnesium chloride (MgCl_2), 10mM KCl, 0.2mM phenylmethylsulfonyl fluoride (PMSF), 0.5M dithiothreitol (DTT)]. The cytoplasmic fraction was removed, and the isolated nuclei were resuspended in a high-salt buffer [20mM HEPES (pH 7.9), 25% glycerol, 1.5mM MgCl_2 , 420mM NaCl, 0.2mM EDTA, 0.2mM PMSF, 0.5M DTT] to release soluble proteins. The nuclear protein preparation was then collected and stored at -80°C. Protein concentration was determined by the bovine serum albumin (BCA) assay (Pierce) using BSA as a standard.

Generation of Cell Permeable Human Non-Casp1 Cleavable Sirt1 Polypeptide

The specific cleavage site of Human Sirt1 by Casp1 was identified by running NIH-NCBI Blast homology search between mouse Sirt1 (NIH-NCBI protein ID: NP_062786) and human Sirt1 protein sequence (NIH-NCBI protein ID: NP_036370) (Figure

12A). After matching mouse Casp1 cleavage site of Sirt1 (D142, Asp at the amino acid 142) identified previously (Libby et al., 2011, Nature 473:317-25), human Casp1 cleavage site of Sirt1 (D150) was predicted and confirmed using our previously published method (Mestas and Ley, 2008, Trends Cardiovasc Med 18:228-32). Human Non-Casp1 cleavable Sirt1 (NC-Sirt1) was then generated by connecting a cell membrane permeable protein transduction sequence in the N-terminal (Jiang et al., 2005, Arterioscler Thromb Vasc Biol 24:2515-21), as shown for other cell permeable peptides in the InvivoGen, Inc., to the single site mutated sequence (D150A, replacing the caspase-1 cleavage essential amino acid Asp with the amino acid Ala) of human Sirt1 140-160 position, rendering the sequence non-Casp1 cleavable (Figure 12B). Of note, the Sirt1 amino acids 140-149 (N-terminal to the D150 cleavage site) and Sirt1 amino acids 151-160 (C-terminal to the D150 cleavage site) were designed to secure the caspase-1 specific binding to Sirt1, as we reported (Mestas and Ley, 2008, Trends Cardiovasc Med 18:228-32). Exemplary nc-Sirt1 is set forth in SEQ ID NOs 1 and 2.

Electrophoretic Mobility Shift Assay

Transcription factor interactions with DNA response elements were assessed using electrophoretic mobility shift assay (EMSA). Activator protein-1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) consensus oligonucleotides end-labeled with IR700 were purchased from LI-COR (Lincoln, Nebraska). The sequences of the probes are as follows: AP-1, 5'-CGCTTGATGACTCAGCCGGAA-3' (SEQ ID NO: 31); and NF- κ B, 5'-AGTTGAGGGGACTTTCCCAGGC-3' (SEQ ID NO: 32). Unlabeled probes were purchased from Santa Cruz and were used at a 30-fold excess of labeled probe. EMSA were carried out using an Odyssey Infrared EMSA kit (LI-COR) according to the manufacturer's instructions. Three μ g of nuclear extracts were added to each binding reaction. The probe and nuclear proteins were incubated for 30 min at room temperature and DNA-protein complexes were resolved on a 5% non-denaturing polyacrylamide gels afterwards. Images of gel were then obtained in an Odyssey scanner (LI-COR).

Data Analysis

All experiments were performed at least three times, and results were expressed as the mean $\pm$ standard error (S.E.). Statistical comparison of single parameters between 2 groups was performed by paired Student *t* test. The Kruskal-Wallis 1-way ANOVA was used to compare the means of multiple groups and were followed by Dunn's test. Data were considered statistically significant if *p* was <0.05 .

The results of the experiments are now described.

Hyperlipidemia Induces the Upregulation of Caspase-1 Expression and Caspase-1 Activation in ApoE^{-/-} Aorta

To examine our hypothesis that early hyperlipidemia activates the caspase-1 (Yin et al., 2013, Front Biosci 18:638-49) in the aortic tissue, we performed Western blot analysis with caspase-1 antibodies on mouse aortic protein lysates collected from wild-type (WT) mice and ApoE^{-/-} mice fed a HF diet for 0, 3, and 6 weeks. Plasma lipid profiling data (Figure 1A) showed that 3-week HF diet feeding significantly increased plasma cholesterol levels and triglyceride levels in ApoE^{-/-} mice, reaching hyperlipidemic conditions (>200 mg/dL). More importantly, pro-caspase-1 expression levels (Figure 1B) were significantly upregulated in ApoE^{-/-} mouse aorta after feeding a HF diet for 3 (122%) and 6 weeks (160%), respectively. Because catalytic activation of procaspase-1 (45 kDa) into 2 smaller subunits, p20 and p10, in a protein complex termed inflammasome is required for its protease activity, we also examined the expression of activated caspase-1 p20 subunit. The results (Figure 1B) showed that activated caspase-1 was increased in ApoE^{-/-} mouse aorta fed with a HF diet for 3 weeks (604%) and 6 weeks (818%), respectively. Of note, upregulation of pro-caspase-1 induced by 6 weeks of HF diet feeding in ApoE^{-/-} mouse aorta was ≈2-folds higher than that of WT mouse aorta. In contrast, activated caspase-1 p20 expression in HF diet-fed ApoE^{-/-} mouse aorta was >8 folds higher than that of WT mouse aorta. With the lipid profiling data, we performed regression analysis of the lipid data against expression data of p20-activated caspase-1 detected by Western blot in Figure 1B. We found that activated caspase-1 p20 expression in ApoE^{-/-} mouse aorta was correlated well with increased plasma cholesterol levels ($R^2=0.8096$; $P=0.0004<0.01$) and increased triglyceride levels ($R^2=0.7469$; $P=0.0013<0.01$; Figure 1C), suggesting that caspase-1 activation is tightly associated with elevated cholesterol and triglycerides levels, as early as 3 weeks of hyperlipidemia. Of note, the expression of pro-caspase-1 in non-HF diet fed ApoE^{-/-} mouse aorta was not significantly higher than that in non-HF diet fed WT mouse aorta, suggesting that upregulation of procaspase-1 in HF diet-fed ApoE^{-/-} mouse aorta was not because of deficiency of the ApoE gene. The results showed that hyperlipidemia also upregulated the expression of caspase-1 mRNA ≈2-folds (Figure 1D), which was similar to the upregulation of pro-caspase-1 detected by Western blots. These results suggest that upregulation of pro-caspase-1 induced by hyperlipidemia in HF diet-fed ApoE^{-/-} mouse aorta results from the

hyperlipidemia-induced transcriptional mechanism and the posttranslational mechanism. As the substrate of activated caspase-1, cleaved and activated IL-1 β was induced after 3 weeks of HF diet in the aortas of WT and ApoE^{-/-} mice. In addition, the expression of pro-IL-1 β was also induced (Figure 1E). Taken together, the results demonstrated that early

hyperlipidemia induces the upregulation of caspase-1/IL-1 β expression and caspase-1/IL-1 β activation in mouse aorta. Because significant monocyte recruitment into ApoE^{-/-} mouse aorta does not happen until 6 weeks after HF diet feeding, these results suggest that caspase-1 is activated in aortic residential cells at the early stage of atherosclerosis.

Deficiency of Caspase-1 in ApoE^{-/-} Background Results in Decreased Atherosclerotic Lesion in the Early Stage of Atherogenesis

To examine the hypothesis that caspase-1 plays an important role in early atherogenesis, ApoE^{-/-}/caspase-1^{-/-} double gene KO mice were generated. The protein expression of pro-caspase-1 in mouse aorta (Figure 2A) was absent in the double KO mice, which were verified with the mouse tail genomic DNA analysis (Figure 2A). General health, body weight, heart and spleen weights (Figure 2B), and plasma cholesterol and triglyceride levels (Figure 2C) of ApoE^{-/-}/caspase-1^{-/-} mice were not significantly different from those of ApoE^{-/-} mice. More importantly, after 3 weeks of HF diet, the atherosclerotic lesions in the aortic sinus area, the most sensitive atherogenic area in the aorta, of the double KO mice were significantly decreased by 44% (lesion area mean $\pm$ 2SD=3.92% $\pm$ 1.42%) compared with that of ApoE^{-/-} mice (6.98% $\pm$ 2.67%; $P=0.0147$; Figure 3A and 3B). The results demonstrated that caspase-1 plays a critical role in promoting early atherogenesis.

Deficiency of Caspase-1 in ApoE^{-/-} Background Results in Decreased Expression of Proinflammatory Cytokines and Chemokines in the Aorta

Because proinflammatory cytokines and chemokines play essential roles in recruiting inflammatory cells into the aorta during atherogenesis (Hansson et al., 2011, Nat Immunol 2:204-12), to determine the molecular mechanism underlying the reduction in atherosclerotic lesion formation in ApoE^{-/-}/caspase-1^{-/-} mice, we examined the hypothesis that the decrease in atherosclerotic lesion may be a result of the decreased generation of proinflammatory cytokines and chemokines in mouse aorta. We used an antibody array to compare simultaneously the expressions of 40 cytokines and chemokines in ApoE^{-/-}/caspase-1^{-/-} mouse aorta and ApoE^{-/-} mouse aorta (Figure 9). The results showed that the expressions of 17 cytokines and chemokines out of 40 examined in ApoE^{-/-} mouse aorta were higher than

those in caspase-1^{-/-}/ApoE^{-/-} mouse aorta. These 17 upregulated cytokines and chemokines included soluble intercellular adhesion molecule-1 (ICAM-1), chemokine (C-C motif) ligand-17 (CCL17), granulocyte-macrophage colony stimulation factor (CSF2), tissue inhibitor of metalloproteinases-1, IL-27, IL-2, CCL1, IL-23, IL-7, IL-10, IL-16, IL-1 α , CCL11, CCL2, CCL4, IL-1 receptor antagonist (IL-1ra), and CCL12. Most of these cytokines and chemokines are proinflammatory except tissue inhibitor of metalloproteinases-1, IL-10, and IL-1ra, suggesting that early hyperlipidemia promotes the generation of proinflammatory cytokines and chemokines more than anti-inflammatory cytokines/chemokines, whereas caspase-1 deficiency attenuates the generation of these proinflammatory cytokines and chemokines. It has been reported previously that besides being the converting enzyme for IL-1 β and IL-18 maturation, caspase-1 also serves as a regulator for the expression of IL-1 α , TNF- α , and IL-6 (Kuida et al., 1995, Science 267:2000-3) and for the secretion of unconventional proteins (Keller et al., 2008, Cell 132:818-31). Of note, IL-1 β was not detected in ApoE^{-/-} mouse aorta after 3 weeks of HF feeding, suggesting that the cytokine array used here is not sensitive enough to detect the IL-1 β differences between the groups. Several proinflammatory cytokines, including IL-4, IL-5, IL-6, and IL-12, were reported to express in mouse plasma samples collected from 10-week-old HF diet fed ApoE^{-/-} mice (Tabibiazar et al., 2006, Physiol Genomics 25:194-202), which was not evident in our results. This discrepancy may be because our experiments were designed to examine early hyperlipidemia (3 weeks of HF diet feeding)-induced cytokine expression. Taken together, our results suggest that deficiency of caspase-1 results in decreased expression of proinflammatory cytokines and chemokines in the aorta.

Deficiency of Caspase-1 in ApoE^{-/-} Background Results in Decreased Recruitment of Monocytes into the Aorta

Because recruitment of monocytes and other inflammatory cells into the mouse aorta and other arteries is essential for atherogenesis (Libby et al., 2011, Nature 473:317-25), based on the above results of decreased expression of inflammatory cytokines and chemokines in double KO aorta, we hypothesized that caspase-1 deficiency may result in reduced monocyte recruitment into the mouse aorta. We performed single cell analysis of mouse aortic cells with fluorescence-conjugated antibody staining for F4/80 and CD11b followed by flow cytometric analysis as reported previously (Kim et al., 2011, Immunity 34:769-80; Goncalves et al., 2011, J Exp Med 208:1253-65). The results (Figure 4A and 4B) showed that caspase-1 deficiency in ApoE^{-/-} background decreased

F4/80⁺/CD11b⁻ macrophage recruitment into the aorta, but the reduction did not have statistical significance ($P=0.0621$). In contrast, the results also showed that caspase-1 deficiency significantly decreased F4/80⁺CD11b⁺ monocyte recruitment into the aorta ($P=0.0045$) and F4/80⁻CD11b⁺ monocyte recruitment into the aorta ($P=0.0194$), respectively.

In addition, we further determined whether aortic monocyte composition changes resulted from the changes in the peripheral blood. The results in Figure 4C showed that total mononuclear cells and CD11b⁺ monocytes in ApoE^{-/-}/Caspase-1^{-/-} mouse blood had no statistical differences to that of ApoE^{-/-} mice. Moreover, we determined whether aortic monocyte composition changes as a result of alterations in the proliferation of recruited monocytes in mouse aorta. Because cell size of cell populations detected by the forward scatter with flow cytometry could be an estimate of cell proliferation status (Böhmer et al., 2011, Cytometry A 79:646-52), the results in Figure 10 showed that the 3 cell size fractions (large, middle, and small) in 3 cell subsets, including F4/80⁺CD11b⁻ macrophages, F4/80⁺CD11b⁺ monocytes, and F4/80⁻CD11b⁺ monocytes, in ApoE^{-/-}/Caspase-1^{-/-} mouse aortas had no statistical differences in comparison to that of ApoE^{-/-} mouse aortas. Taken together, our results demonstrated that first, caspase-1 deficiency in ApoE^{-/-} background decreased the recruitment of monocytes into the mouse aorta in early atherosclerosis; second, caspase-1 deficiency in ApoE^{-/-} background did not significantly decrease F4/80⁺CD11b⁻ macrophage recruitment into the aorta in early atherosclerosis, suggesting that caspase-1 deficiency did not result in a defect of monocyte-to-macrophage differentiation in the early atherosclerosis; and third, the aortic data of caspase-1 deficiency in ApoE^{-/-} background was a result of aortic recruitment of monocytes but not as a result of the percentage changes of mononuclear cell and CD11b⁺ monocyte populations in the peripheral blood in early atherosclerosis.

Deficiency of Caspase-1 in ApoE^{-/-} Background Results in Decreased Endothelial Activation, Including Reduced Cell Adhesion Molecule Expression and Attenuated Cytokine and Chemokine Secretion

A significant decrease in the recruitment of monocytes into the mouse aorta without changes in the peripheral blood monocyte compositions leads to our hypothesis that caspase-1 deficiency in early atherosclerosis decreases endothelial activation rather than reducing the potency of monocyte infiltration into the mouse aorta. Endothelial activation can be examined from 2 perspectives. First, we reasoned that decreased endothelial activation would result in decreased secretion of cytokines and chemokines. To examine this possibility,

mouse aortic ECs (MAECs) from WT mice and caspase-1^{-/-} mice were cultured and primed with 50 ng/mL lipopolysaccharide and treated with 200 µg/mL of oxidized low-density lipoprotein (oxLDL; first signals for the inflammasome activation) (Yin et al., 2009, Int J Immunopathol Pharmacol 22:311-22) for 24 hours followed with adenosine-5'-triphosphate (5 mmol/L) spike (second signal for the inflammasome activation) (Yin et al., 2013, Front Biosci 18:638-49) for 20 minutes. The antibody array results (Figure 11) showed that caspase-1 deficiency significantly attenuated the secretion of C-X-C motif chemokine 10 (CXCL10), CCL3, CXCL2 (MIP-2) and granulocyte-macrophage colony stimulation factor levels from MAECs.

Second, we further reasoned that decreased endothelial activation in caspase-1-deficient mice would result in decreased upregulation of endothelial adhesion molecules, including ICAM-1, vascular cell adhesion molecule (VCAM)-1, and E-selectin. To examine this possibility, we first examined the adhesion molecule expression in aortas from ApoE^{-/-} mice and ApoE^{-/-}/caspase-1^{-/-} mice. The results (Figure 5A) showed that 3 weeks of HF feeding induced upregulation of ICAM-1 (17.8-folds) and VCAM-1 (3.5-fold) protein expressions in ApoE^{-/-} mouse aorta, respectively. On the contrary, HF diet feeding upregulated ICAM-1 and VCAM-1 expressions only by 2-folds and 1.5-folds, respectively, in the ApoE^{-/-}/caspase-1^{-/-} aorta. Of note, we did not find a difference in E-selectin expression between ApoE^{-/-} and ApoE^{-/-}/caspase-1^{-/-} aortas. We then used RT-polymerase chain reaction to further examine the mRNA transcripts of ICAM-1, VCAM-1, and E-selectin in MAECs from WT mice and caspase-1^{-/-} mice stimulated with oxLDL (100 µg/mL). The results (Figure 5B) showed that oxLDL stimulation induced mRNA upregulation of ICAM-1, VCAM-1, and E-selectin in WT MAECs by 10-, 8-, and 17-folds, respectively. In contrast, oxLDL stimulation induced no mRNA upregulation of ICAM-1, VCAM-1, and E-selectin in caspase-1^{-/-} MAECs. The differences between the protein expression of adhesion molecules in mouse aortas and their mRNA expressions in MAECs may be because in addition to ECs, some adhesion molecules are also expressed in other vascular cells, including smooth muscle cells in mouse aorta (Braun et al., 1999, Cardiovasc Res 41:395-401). Regardless of the differences between the 2 experimental systems, caspase-1 deficiency resulted in decreased induction of EC adhesion molecules ICAM-1 and VCAM-1 in mouse aorta and MAECs in response to hyperlipidemic stimulations. Because attenuation of hyperlipidemia-induced ICAM-1 upregulation by caspase-1 deficiency was most dramatic among adhesion molecules examined, we looked into the possibility that caspase-1 activity-positive ECs may have higher ICAM-1 expression than caspase-1-inactive ECs. The results (Figure 5C) showed that

ECs with active caspase-1 have higher ICAM-1 expression than caspase-1-inactive ECs, suggesting that caspase-1 activation promotes ICAM-1 upregulation and endothelial activation. Furthermore, we wanted to determine whether caspase-1 activation functionally promotes human aortic ECs (HAECs) to be more adhesive to unstimulated monocytes.

5 Indeed, we found that oxLDL increased adhesiveness of ECs to monocytes (Figure 5D), which were inhibited by caspase-1 inhibitors, suggesting that caspase-1 activation increases upregulation of adhesion molecules, promotes endothelial activation, and makes ECs more adhesive to monocytes.

10 Deficiency of Caspase-1 in the Aorta of ApoE^{-/-} Mice Results in Decreased Recruitment of Transplanted Caspase-1^{+/+} Bone Marrow-Derived Inflammatory Ly6C^{middle/high} Monocytes into the Aorta

To further consolidate our finding on the role of caspase-1 in promoting aortic endothelial activation and monocyte recruitment into the aorta, we performed chimeric bone marrow (BM) transplantation with enhanced green fluorescence protein transgenic mouse
15 BM as the donor group and ApoE^{-/-} mice and ApoE^{-/-}/caspase-1^{-/-} mice as the 2 recipient groups (Figure 6A and 6B). We reasoned that if caspase-1 activation promotes endothelial activation and monocyte recruitment, then more caspase-1 activity⁺ enhanced green fluorescence protein⁺BM-derived Ly6C^{middle/high} inflammatory monocytes should migrate into
20 the ApoE^{-/-} aorta than the ApoE^{-/-}/caspase-1^{-/-} aorta. Indeed, we found that significantly more GFP⁺CD11b⁻Ly6C^{middle} cells and GFP⁺CD11b⁺Ly6C^{high} BM-derived monocytes migrated into the ApoE^{-/-} aorta than the ApoE^{-/-}/caspase-1^{-/-} aorta (Figure 6C and 6D; $P < 0.05$). As control experiments, we examined the peripheral blood monocyte subsets in the 2 recipient mouse groups. In contrast, we did not find any significant difference
25 in peripheral blood monocyte subsets between the 2 recipient groups (Figure 6E and 6F). In addition, after caspase-1^{+/+}(WT) GFP transgenic BM cell transplantation into either ApoE^{-/-} recipient mice or caspase-1^{-/-}/ApoE^{-/-} double gene KO recipient mice, caspase-1^{-/-}/ApoE^{-/-} double gene KO recipient mice had significantly less atherosclerotic lesions than ApoE^{-/-} recipient mice (Figure 6G). Although that ECs are not the only vascular residential
30 cells that have caspase-1 activation in response to inflammatory stimuli (Young et al., 2000, J Exp Med 191:1535-44) and that EC-specific role of caspase-1 may ultimately require the model of EC-specific deficient mice of caspase-1, the results correlated well with our previous findings and suggested that caspase-1 activation in aortic ECs promotes monocyte recruitment into the aorta.

Atherogenic Lipid Products Induce Caspase-1 Activation and Endothelial Inflammation via a Reactive Oxygen Species–Dependent Pathway

Our data demonstrated that caspase-1 plays a critical role in promoting EC
 5 activation and monocyte recruitment into the mouse aorta exposed to hyperlipidemia. To
 further determine whether atherogenic lipid products induce caspase-1 activation in ECs and
 whether reactive oxygen species (ROS) plays any role in caspase-1 activation in ECs, we
 used oxLDL and 2 oxLDL derivatives, lysophosphatidic acid (lysoPA), and
 lysophosphatidylcholine (lysoPC) (Zhou et al., 2011, Cell Metab 13:592-600) to stimulate
 10 HAECs. Because plasma membrane rupture and caspase-1 activation are 2 key features of the
 newly characterized inflammatory cell death (pyroptosis) (Miao et al., 2010, Nat Immunol
 11:1136-42), in addition to using a flow cytometry–based fluorescence-labeled caspase-1
 enzymatic activity assay to detect caspase-1 activation, we also used fluorescence dye 7-
 AAD to measure plasma membrane integrity. We classified caspase-1 enzymatically active
 15 (caspase-1⁺) and 7AAD[−] (caspase-1⁺/7-AAD[−]) cells as inflammatory ECs, caspase-1⁺/7-
 AAD⁺ cells as pyroptotic cells, and caspase-1[−]/7-AAD⁺ cells as necrotic cells. We found that
 oxLDL, lysoPA, and lysoPC induced inflammation, inflammatory cell death (pyroptosis), and
 necrosis after 6-hour stimulation in HAECs (Figure 7A). We then examined whether ROS
 plays any role in oxidized lipids–induced caspase-1 activation by costaining inflammatory,
 20 pyroptotic, and necrotic ECs with ROS probe dihydroethidium. Our results showed that the
 mean fluorescence intensities of dihydroethidium stain in ruptured cells (either pyroptotic
 cells or necrotic cells) were higher than that of the inflammatory cells (Figure 7B), suggesting
 that oxidized lipids increased ROS-mediated caspase-1 activation and that cell death requires
 higher ROS levels to trigger than inflammation. We further verified the results with ROS
 25 inhibitors allopurinol (xanthine oxidase inhibitor) and apocynin (NADPH oxidase inhibitor)
 for inhibition of caspase-1 activation (Figure 7C). Finally, we examined whether oxLDL
 induces upregulated caspase-1 and inflammasome component transcripts in ECs. The RT-
 polymerase chain reaction results (Figure 7D) showed that treatment of oxLDL for 24 hours
 upregulated significantly NLRP1, NLRP3, caspase-1, PYCARD, and IL-1 β transcripts.
 30 Because inflammasome assembly for caspase-1 activation requires NLRP, PYCARD, and
 procaspase-1, and effective upregulation of transcription of inflammasome and caspase-1
 occurs $\approx$ 24 hours after stimulation, these results suggest that post-translational caspase-1
 activation is much earlier than upregulation of caspase-1 and inflammasome transcription in
 ECs.

Caspase-1 Activation in the Mouse Aorta and Human Aortic Endothelial Cells Decreases the Expression of Anti-Inflammatory Protein/Histone Deacetylase Sirt1 by Cleaving Sirt1

As we detected only weak active IL-1 β expression in the mouse aorta (Figure 1E) in ApoE^{-/-} mice after 3 weeks of HF diet, we hypothesized that the effect of caspase-1 activation on endothelial activation is probably contributed more by other pathways rather than the IL-1 β pathway. Thus, we attempted to search for novel substrate of caspase-1 that could modulate inflammation and endothelial activation. Among 24 experimentally verified caspase-1 substrates that we found in a literature search (Shen et al., 2010, Atherosclerosis 201:422-9), Sirt1 has recently been suggested to be cleaved by caspase-1 (Chalkiadaki and Guarente, 2012, Cell Metab 16:180-8). Because Sirt1 has previously been reported to regulate endothelial activation and has antiatherogenic function (Zhang et al., 2008, Cardiovasc Res 80:191-9), we then hypothesized that caspase-1-deficient mouse aorta has accumulation of noncleaved Sirt1. To test this hypothesis, we examined Sirt1 expression by Western blot with Sirt1 antibody in the following 4 groups of mice (2 mice/group): (1) ApoE^{-/-} mice fed a normal chow diet; (2) ApoE^{-/-} mice fed a HF diet; (3) ApoE^{-/-}/caspase-1^{-/-} mice fed a normal chow diet; and (4) ApoE^{-/-}/caspase-1^{-/-} mice fed a HF diet. Our results showed that compared with ApoE^{-/-} aorta fed a normal chow diet, ApoE^{-/-}/caspase-1^{-/-} aorta expressed significantly higher amount of Sirt1 (Figure 8A). HF-fed ApoE^{-/-}/caspase-1^{-/-} aorta had decreased Sirt1 accumulation to 1/3 of the level of ApoE^{-/-}/caspase-1^{-/-} mice fed a normal chow diet. These results suggest that a HF diet induces other proteinase(s) activities, which participate in Sirt1 cleavage in the absence of caspase-1. Of note, plasma cholesterol levels in ApoE^{-/-} mice and ApoE^{-/-}/caspase-1^{-/-} mice (Figure 2C) were in the range of 220 to 320 mg/dL, which were a few folds higher than those in WT mice (average 109 mg/dL; Figure 1A). Our results suggest that caspase-1 activation induced by moderate hyperlipidemia is responsible for cleaving Sirt1 and hyperlipidemia induced by HF feeding further triggers additional uncharacterized proteinase(s) to cleave/degrade Sirt1. Then, we examined whether oxLDL decreases Sirt1 expression in HAECs by caspase-1 cleavage mechanism. The results (Figure 8B) showed that oxLDL induced the expression of cleaved-Sirt1 by 2.4-folds in HAECs. To examine whether the induced cleavage form of Sirt1 was the result from the specific enzyme activity of Casp1, we designed a new cell permeable noncleavable Sirt1 (NC-Sirt1) by replacing the aspartate (D) in the amino acid position 150 of human Sirt1 with alanine (A), the specific cleavage site of Sirt1 recognized by Casp1 (Chalkiadaki and Guarente, 2012, Cell Metab 16:180-8) (Figure

12). Our results showed that NC-Sirt1 dose-dependently decreases the cleavage of Sirt1 induced by oxLDL. In addition, 2 different ROS scavengers (PEG-SOD and PEG-catalase) independently and synergistically inhibit oxLDL-induced, Casp1-mediated Sirt1 cleavage. Furthermore, the proteasome inhibitor MG-132 inhibited oxLDL-induced Sirt1 cleavage, suggesting that the cleaved Sirt1 may be further subjected to a putative proteolysis by an uncharacterized proteasome-controlled proteinase. Thus, when MG-132 inhibits proteasome, the expression of this uncharacterized proteasome-controlled proteinase is increased, which leads to decreased expression of caspase-1 cleaved Sirt1. These results suggest that oxLDL first increases ROS, which promotes caspase-1 activation for cleaving Sirt1. We then used the PeptideCutter database of the Swiss Institute of Bioinformatics to analyze the potential enzymes that can cleave the human Sirt1 protein sequence. The results (Table 1) showed that caspase-1 and caspase-3 are among the enzymes that can cleave Sirt1 and are regulated by ROS, although the predicted cleavage site on Sirt1 for caspase-1 is not the same one as experimentally determined (Chalkiadaki and Guarente, 2012, Cell Metab 16:180-8). Taken together, our results suggest that caspase-1 in the mouse aorta and HAECs cleaves Sirt1 protein in response to hyperlipidemic stimuli.

Table 1. Predicted proteinases for human Sirt1 protein cleavage.				
Name of Enzyme	Predicted No. of cleavages	Predicted positions of cleavage sites	Regulated by Apocynin	PMID
Caspase-1	1	528	Yes	N/A
Caspase-3	1	242	Yes	19592621
Caspase-7	1	242	Not Tested	N/A
Thrombin	1	202	Not Tested	N/A
Caspase-10	0			N/A
Caspase-2	0			N/A
Caspase-4	0			N/A
Caspase-5	0			N/A
Caspase-6	0			N/A
Caspase-8	0			N/A
Caspase-9	0			N/A
Enterokinase	0			N/A
Factor Xa	0			N/A
Granzyme B	0			N/A

Caspase-1 Activation Induces Expression of Cytokines, Chemokines, and Adhesion Molecules via an Sirt1-AP-1-Mediated Pathway

Our data showed that caspase-1 activation induces the upregulation of several EC activation-associated cytokines, chemokines, and endothelial adhesion molecules. To further explore the mechanism underlying this caspase-1 function, we hypothesized that

caspase-1 activation leads to a Sirt1-controlled transcription factor pathway to regulate these genes. Among the transcription factors that are modulated by Sirt1 are AP-1 (Zhang et al., 2010, J Biol Chem 285:7097-10) and NF- κ B (Yang et al., 2012, PLoS One 7:e46364). We examined whether lysoPC-activated AP-1 activity and NF- κ B activity can be inhibited by caspase-1 inhibitors by performing electrophoretic mobility shift assay. The results (Figure 8C) showed that lysoPC-induced AP-1 binding to AP-1 consensus nucleotides were inhibited by caspase-1 inhibitor, whereas lysoPC-activated NF- κ B binding to NF- κ B consensus probe was not significantly affected by caspase-1 inhibitors. We then searched for published experimental evidence that caspase-1-induced cytokines, chemokines, and adhesion molecules (Figures 6, 9 and 11)) are AP-1 targeted genes. The results (Table 2) showed that 11 out of 14 caspase-1-induced genes are experimentally verified AP-1 pathway-induced genes.

In addition, analysis from the microarray experimental results of Sirt1 gene-deficient mice in comparison to WT mice showed that the expression of these AP-1-targeted genes are increased in Sirt1-deficient mice (Table 2), suggesting that Sirt1 inhibits the expression of AP-1 targets. Moreover, the data-mining results (Table 3) showed that the expressions of AP-1 genes themselves, including Jun and Fos, are increased in Sirt1-deficient mice. Taken together, the results suggest that caspase-1-cleavable Sirt1 inhibits the expression of caspase-1-induced cytokines, chemokines, and adhesion molecules by suppressing AP-1 gene transcription and AP-1-targeted gene transcription, which further suggest that caspase-1 induces the expression of cytokines, chemokines, and adhesion molecules in ECs by cleavage and inhibition of Sirt1.

Table 2.

Gene ID	PMID (Ap1 Target genes)	Microarray data obtained via mining			
		Fold Change	p	Comparison	PMID
CCL11*	22311973	1.456	0.0084	Sirt1 (-/-) vs. WT	22715468
CCL2*	8630731	2.364	0.0155	Sirt1 (-/-) vs. WT With HFD	
CCL3*	14747532	8.623	0.0000	Sirt1 (-/-) vs. WT With HFD	22883230
CCL4*	18789903	2.736	0.0000	Sirt1 (-/-) vs. WT With HFD	
CCL17*	14747532	1.591	0.0010	Sirt1 (-/-) vs. WT With LFD	
GM-CSF**	9190901	2.265	0.0084	Sirt1(-/+) vs. Sirt1(+/-)	22006157
CXCL12*	17393416	1.813	0.0172	Sirt1 (-/-) vs. WT	22169038
IL2*	1737937	1.184	0.0469	Sirt1 (-/-) vs. WT With LFD	22883230
		1.339	0.0258	Sirt1 (-/-) vs. WT	
		1.372	0.0024	Sirt1 (-/-) vs. WT	22715468
EBI3 (IL27)*	15728491	1.484	0.0032	Sirt1 (-/-) vs. WT With HFD	
		2.014	0.0004	Sirt1 (-/-) vs. WT With LFD	
		3.018	0.0021	Sirt1 (-/-) vs. WT With HFD	22883230
TIMP1*	10051488	1.435	0.0068	Sirt1 (-/-) vs. WT With LFD	
		1.638	0.0003	Sirt1 (-/-) vs. WT With HFD	
		1.169	0.0445	Sirt1 (-/-) vs. WT With LFD	
VCAM1†	1379595	1.824	0.0285	Sirt1 (-/-) vs. WT	22169038
		1.433	0.0213	Sirt1 (-/-) vs. WT	
		1.306	0.0055	Sirt1 (-/-) vs. WT With LFD	
CCL12*	Not found	3.764	0.0054	Sirt1 (-/-) vs. WT With LFD	22883230
IL7*	Not found	1.317	0.0248	Sirt1 (-/-) vs. WT With LFD	
		2.262	0.0115	Sirt1(-/+) vs. Sirt1(+/-)	22006157

Table 3.

Gene	Fold Change	p	Compares	PMID
Jun	1.778	0.000495	Sirt1 KO vs. WT with LFD	22883230
Fos	3.523	0.017899	Sirt1 KO vs. WT with LFD	22883230
Fos1	3.022	0.000628	Sirt1 KO vs. WT with HFD	22883230

5

Hyperlipidemia induces endothelial activation

Although the role of caspase-1 in atherogenesis remains controversial (Menu et al., 2011, Cell Death Dis 2:e137), the prevailing concept is that caspase-1 plays a proatherogenic role, which is supported by results collected from ApoE^{-/-}/caspase-1^{-/-} mice

10

(Gage et al., 2012, Can J Cardiol 28:222-9; Usi et al., 2012, Biochem Biophys Res Commun 425:162-8), inflammasome sensor NLRP3 KO BM cells in LDL receptor (LDLR)^{-/-} mice (Duewell et al., 2010, Nature 464:1357-61), ApoE^{-/-}/IL-1β^{-/-} mice (Kirii et al., 2003, Arterioscler Thromb Vasc Biol 23:656-60), and ApoE^{-/-}/IL-18^{-/-} mice (Elhage et al., 2003, Cardiovasc res 59:234-40). Of note, Gage et al (Gage et al., 2012, Can J Cardiol 28:222-9) and Usui et al (Usi et al., 2012, Biochem Biophys Res Commun 425:162-8) studied the role of caspase-1 deficiency in full-blown atherosclerosis in ApoE^{-/-} mice after HF feeding for 8 weeks (Gage et al., 2012, Can J Cardiol 28:222-9) and 12 weeks (Usi et al., 2012, Biochem Biophys Res Commun 425:162-8). In addition, it has been reported that NLRP3 mediates hemodynamic-induced EC activation (Xiao et al., 2013, Circulation 128:632-42) and that the IL-1β mRNA/protein as well as NLRP3 mRNA are upregulated in 30 week HF feeding-induced atherosclerotic lesion and endothelium of diabetic pigs (Li et al., 2013, PLoS One 8:e67532). Along the line, we further asked whether in the early atherogenesis associated with early hyperlipidemia induced by only 3 week HF feeding, caspase-1 activation, as metabolic stress-related danger signal-associated molecular pattern-sensing pathway (Yin et al., 2013, Front Biosci 18:638-49), could be involved in endothelial activation. Using biochemical, immunologic, and pathological approaches and our newly generated ApoE^{-/-}/caspase-1^{-/-} mice, we addressed this question and have the following results: (1) early hyperlipidemia induces the upregulation of caspase-1 expression and caspase-1 activation in ApoE^{-/-} aorta, which supports our previously proposed 3-tier/inflammation privilege model for determining tissue readiness to caspase-1 activation and inflammation initiation (Yin et al., 2009, Int J Immunopathol Pharmacol 22:311-22); (2) caspase-1 deficiency in ApoE^{-/-} background results in decreased early atherosclerotic lesion formation, suggesting that caspase-1 activation in ECs promotes early atherogenesis; and (3) caspase-1 deficiency in ApoE^{-/-} background results in decreased expression of proinflammatory cytokines and chemokines in the aorta. Of note, the expression of 2 anti-inflammatory cytokines IL-10 and IL-1ra were also decreased in caspase-1-deficient aorta. However, the decreased expressions of as many as 15 proinflammatory cytokines in caspase-1-deficient aorta outweigh concomitant reduction of 2 anti-inflammatory cytokines, suggesting that caspase-1 activation promotes an inflammatory environment and a chemokine gradient more than anti-inflammatory environment for the recruitment of monocytes and other inflammatory cells into the aorta; (4) caspase-1 deficiency in ApoE^{-/-} background results in decreased recruitment of monocytes into the aorta but has no significant role in monocyte composition in the peripheral blood in the early stage of atherosclerosis, suggesting

that caspase-1 activation promotes monocyte recruitment into the aorta presumably via promoting endothelial activation and not via increasing monocyte compositions in the peripheral blood; (5) caspase-1 deficiency in ApoE^{-/-} background results in decreased endothelial activation, including reduced cell adhesion molecule expression and attenuated cytokine and chemokine secretion, suggesting that increased caspase-1 activities promote endothelial activation; (6) caspase-1 deficiency in ApoE^{-/-} mice results in decreased recruitment of transplanted caspase-1⁺ BM-derived inflammatory Ly6C^{middle/high} monocytes into the caspase-1^{-/-} aorta, suggesting that caspase-1 activation can lead to endothelial activation, which subsequently recruits more monocyte into the aorta. Decreased recruitment of caspase-1⁺ BM-derived inflammatory Ly6C^{middle/high} monocytes into the caspase-1^{-/-} aorta results in less atherosclerosis than caspase-1^{+/+} aorta. To further determine the underlying molecular signaling mechanisms, we found (7) atherogenic lipid products induce caspase-1 activation and endothelial inflammation via a ROS-dependent pathway; (8) caspase-1 deficiency in ApoE^{-/-}/caspase-1^{-/-} aorta and inhibition of caspase-1 in ECs result in accumulation of anti-inflammatory protein/histone deacetylase Sirt1, which is a substrate of caspase-1, suggesting that caspase-1 activation in early atherogenesis promotes endothelial activation via a Sirt1 pathway; and (9) caspase-1 activation induces the upregulation of cytokines, chemokines, and adhesion molecules in ECs via a Sirt1-AP-1-mediated pathway.

Although our previous report showed that caspase-1 can cleave numerous protein substrates (Shen et al., 2010, *Atherosclerosis* 201:422-9), it is generally considered that caspase-1 fulfills its proinflammatory functions predominately by cleaving pro-IL-1 β and pro-IL-18 into mature IL-1 β and IL-18, respectively. Although the role of proinflammatory cytokines IL-1 β (Kirii et al., 2003, *Arterioscler Thromb Vasc Biol* 23:656-60) and IL-18 (Elhage et al., 2003, *Cardiovasc res* 59:234-40), as the classical substrates of caspase-1, in the promotion of atherosclerosis has been reported, the role of caspase-1, IL-1 β , and IL-18 in promoting EC activation in the early stage of atherogenesis remained unknown. As defined by Ross' laboratory in ApoE^{-/-} mice (Nakashima et al., 1994, *Arterioscler Thromb* 14:133-40), early atherosclerosis is the initiative stage precedent the occurrence of a large number of monocyte recruitment before 6 weeks of HF feeding in ApoE^{-/-} mice. Our results were well correlated with a previous report that IL-1 β secretion from human ECs are 70.6-folds lower than that secreted from human monocytes (Wilson et al., 2007, *Br J Pharmacol* 151:115-27), suggesting that IL-1 β role in ECs may not be as significant as that in monocytes. These results indicate that caspase-1 may not only act through an IL-1 β - or IL-18-dependent pathway to promote endothelial activation. Instead, we found that caspase-1 activation in

mouse aorta in early atherogenesis and in human aortic ECs stimulated by oxLDL promotes endothelial activation via a Sirt1-inhibitable pathway. It was reported that Sirt1 reduces endothelial activation (Stein et al., 2010 *Aging* 2:353-60), and overexpression of Sirt1 in ECs inhibits atherosclerosis (Zhang et al., 2008, *Cardiovasc Res* 80:191-9). Mechanistically, adenovirus-mediated overexpression of Sirt1 significantly inhibits PMA (phorbol 12-myristate 13-acetate)/ionomycin-induced ICAM-1 expression in human umbilical vein ECs, whereas knockdown of Sirt1 by RNA interference results in increased expression of ICAM-1 and increases NF- κ B p65 binding ability to the ICAM-1 promoter by ChIP assays in human umbilical vein endothelial cells (Jia et al., 2013, *Sci China Life Sci* 56:19-25). However, the issue of whether caspase-1 in aortic ECs senses hyperlipidemia to initiate vascular inflammation via inhibiting Sirt1 was not examined until this report. Taken together, our results demonstrate a novel mechanism in early atherosclerosis: caspase-1 promotes EC activation and monocyte recruitment via decreasing Sirt1 expression and activating AP-1 pathway. The novel caspase-1-Sirt1-AP-1 pathway and the classical caspase-1-IL-1 β -IL-18 are not mutually exclusive. HF diet feeding for >6 weeks promoted monocyte recruitment into the aorta (Nakashima et al., 1994, *Arterioscler Thromb* 14:133-40), thus, the classical caspase-1-IL-1 β and IL-18 pathway in recruited monocytes and macrophages may interplay with caspase-1-Sirt1-AP-1 pathway in ECs during later stages of atherosclerosis.

Endothelial activation is the first and essential step for atherogenesis, which includes 2 molecular events—upregulation of cell surface adhesion molecules to make ECs more adhesive and increased secretion of proinflammatory cytokines and chemokines to attract monocytes and other inflammatory cells for transendothelial recruitment (Yang et al., 2008, *Drug Discov Today Ther Strateg* 5:125-420). Monocytes and macrophages play an essential role in promoting atherogenesis; however, we reason that if ECs are not activated during the initiation of atherogenesis, then no monocytes in the peripheral blood can be recruited into the aorta. Our results showed that caspase-1 deficiency did not alter the composition of peripheral blood monocytes and macrophages in early hyperlipidemia but instead significantly decreased aortic monocyte recruitment, suggesting that caspase-1-deficient ECs are less activated for recruitment of monocytes into the aorta. These findings were further supported by our BM transplantation results, as well as the decreased ICAM-1 and VCAM-1 and proinflammatory cytokine and chemokine expressions/secretion in HAECs and in caspase-1-deficient mouse aorta. A recent report showed that suppression of monocyte recruitment results in removal of macrophage from atherosclerotic plaques of ApoE^{-/-} mice (Potteaux et al., 2011, *J Clin Invest* 121:2025-36), which echoes the importance of our

finding. It has been reported that chemokine CXCL16 and its receptor CXCR6 play a critical role in mediating T cell migration into aorta during atherogenesis (Sheikine and Sirsjö, 2008, Atherosclerosis, 197:487-95). To determine whether CXCL16 and CXCR6 expressions are regulated by caspase-1 pathway, we searched extensively the National Institute of Health-
5 GeoProfile microarray database and found that both CXCL16 and its receptor CXCR6 expressions are downregulated in caspase-1 KO mice microarray in comparison to that in WT control microarray (Geo-data set GDS3925), suggesting that caspase-1 activation promotes CXCL16 and CXCR6 expression and presumably T cell migration into aorta during atherogenesis. Thus, T cell migration into caspase-1^{-/-}/ApoE^{-/-} mouse aortas may be
10 decreased.

In our newly proposed working model, we summarize our findings and highlight current understanding (Figure 13): (1) hyperlipidemia induces elevation of ROS via NADPH oxidase-dependent pathway; (2) increased ROS levels induce caspase-1 activation, EC inflammation, and endothelial pyroptosis (inflammatory cell death); (3) activated
15 caspase-1 decreases anti-inflammatory protein/histone deacetylase Sirt1 expression by cleaving Sirt1; (4) Sirt1 is a high hierarchy gene that can deacetylate and inhibit proinflammatory transcription factors, including AP-1; and (5) the caspase-1-Sirt1-AP-1 pathway can promote endothelial activation, inflammation, and atherogenesis. Our results have demonstrated for the first time how hyperlipidemia, one of the most important metabolic
20 risk factors, induces endothelial activation, which provides an important insight for future development of novel therapeutics for early intervention of cardiovascular diseases and other inflammatory diseases.

Example 2: Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis

25 Deficient angiogenesis may contribute to worsen the prognosis of myocardial ischemia, peripheral arterial disease, ischemic stroke, etc. Dyslipidemic and inflammatory environments attenuate endothelial cell (EC) proliferation and angiogenesis, worsening the prognosis of ischemia. Under these dyslipidemic and inflammatory environments, EC-caspase-1 becomes activated and induces inflammatory cell death that is defined as
30 pyroptosis. However, the underlying mechanism that correlates caspase-1 activation with angiogenic impairment and the prognosis of ischemia remains poorly defined. By using flow cytometric analysis, enzyme and receptor inhibitors, and hind limb ischemia model in caspase-1 knock-out (KO) mice, we examined our novel hypothesis, i.e. inhibition of caspase-1 in ECs under dyslipidemic and inflammatory environments attenuates EC

pyroptosis, improves EC survival mediated by vascular endothelial growth factor receptor 2 (VEGFR-2), angiogenesis, and the prognosis of ischemia. We have made the following findings. Proatherogenic lipids induce higher caspase-1 activation in larger sizes of human aortic endothelial cells (HAECs) than in smaller sizes of HAECs. Proatherogenic lipids increase pyroptosis significantly more in smaller sizes of HAECs than in larger sizes of the cells. VEGFR-2 inhibition increases caspase-1 activation in HAECs induced by lysophosphatidylcholine treatment. Caspase-1 activation inhibits VEGFR-2 expression. Caspase-1 inhibition improves the tube formation of lysophosphatidylcholine-treated HAECs. Finally, caspase-1 depletion improves angiogenesis and blood flow in mouse hind limb ischemic tissues. Our results have demonstrated for the first time that inhibition of proatherogenic caspase-1 activation in ECs improves angiogenesis and the prognosis of ischemia.

Our novel hypothesis in this study is that the inhibition of caspase-1 attenuates pyroptosis (inflammatory cell death) in ECs, improves EC survival mediated by VEGFR-2 signaling, angiogenesis, and ischemia's prognosis under dyslipidemic and inflammatory environments. To examine this hypothesis, we used the hind limb ischemia model in caspase-1 KO mice and stimulated HAECs with proatherogenic lipids, oxidized low density lipoprotein (oxLDL), carbamylated LDL, oxLDL-derived lipids, lysophosphatidylcholine (LPC), and lysophosphatidic acid (LPA) (Limbouurg et al., 2009 Nat. Protoc. 4, 1737–1746). Our results showed that caspase-1 inhibition improves the tube formation of LPC-treated HAECs and that caspase-1 depletion improves angiogenesis and blood flow in mouse hind limb ischemic tissues. Our results have demonstrated for the first time that inhibition of proatherogenic caspase-1 activation in ECs improves angiogenesis and the prognosis of ischemia.

The materials and methods employed in this example are now described.

Reagents

The oxLDL and carbamylated LDL were purchased from Biomedical Technologies (Stoughton, MA). LPC and LPA were purchased from Avanti Polar Lipids (Alabaster, AL). Hydrogen peroxide (H₂O₂) was purchased from Sigma. Vascular endothelial growth factor receptor II inhibitor (SU1498) was purchased from EMD Millipore (Billerica, MA).

Human Aortic Endothelial Cell Culture

Human aortic endothelial cells (HAECs) were purchased at Clonetics Corp. (San Diego). The cells were cultured in a 2% gelatin-coated 75-cm² flask in M199 (Hyclone Labs., Logan, UT) with 20% fetal bovine serum (FBS), 1% penicillin/streptomycin
5 (Invitrogen), 3 ng/ml EC growth supplement (BD Biosciences), and 5 units/ml heparin (Sigma) at 37 °C under 5% CO₂, 95% air until passage 8. For experiments, HAECs (≤ passage 9) were used and treated with the desired stimuli for the indicated time.

Caspase-1 Activity Assay

10 Active caspase-1 levels were determined with an APO LOGIX kit (Cell Technology, Mountain View, CA). The kit contained a carboxyfluorescein (FAM) (excitation/emission (nm): 490/520)-labeled peptide fluoromethyl ketone (FMK) caspase-1 inhibitor (FAM-YVAD-FMK), which irreversibly binds to active caspase-1. The procedures were performed according to the manufacturer's instructions. HAECs were cultured in 6-well
15 dishes and serum-starved overnight to ensure quiescence of the cells before treatment. The next day, HAECs were treated with the indicated stimuli for 6 h. Cells were harvested and suspended at 1×10^6 cells/ml. The cell suspension (150 µl) was incubated in 37 °C with $1 \times$ FAM-YVAD-FMK for 1 h. After being washed with $1 \times$ washing buffer, the cells were fixed with fixative buffer and stored in 4 °C for up to 24 h. To determine the cell membrane
20 integrity, the unfixed cells were stained with 7-AAD (Pharmingen) (0.25 µg/test) and incubated for no more than 10 min before analysis.

Flow Cytometer

The FACSCalibur flow cytometer (BD Biosciences) was used to determine
25 FAM⁺ staining (caspase-1 activity marker, FL-1 channel), 7-AAD⁺ staining (cell membrane integrity marker, FL-4 channel), and ICAM-1 staining (adhesion molecule marker, FL-4 channel).

Data Analysis Using FlowJo Software

30 All flow cytometric data were analyzed by using the FlowJo software (Tree Star, Ashland, OR). The uncompensated data were collected from the flow cytometer (either FACSCalibur flow cytometer or LSRII flow cytometer; BD Biosciences). Forward and side scatter gates were used to select live cell populations from clumps and debris. The positive gating was determined by its matched IgG control, and single staining was used to determine

the compensation parameter. Different gates were established to analyze the data according to cell size as described in our figures.

Mice

5 Wild-type mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Caspase-1^{-/-} (Casp-1^{-/-}) mice in a C57BL/6J background were obtained. Mice were housed in a specific pathogen-free environment. Mice were maintained on a normal chow diet (5% fat, Lab diet 5001).

Murine Hind Limb Ischemia Model

10 Age-matched 8-week-old male mice were used to create the mouse model of hind limb ischemia as reported previously (Limbouurg et al., 2009 Nat. Protoc. 4, 1737–1746). An incision was made in the skin at the mid-portion of the right hind limb. The femoral artery and vein were then dissected free from nerve. Proximal and distal portions of the femoral
15 artery were ligated followed by complete excision from the hind limb.

Laser Doppler Perfusion Imaging

Blood perfusion in the hind limb was monitored by using laser Doppler perfusion imaging (Lisca, North Brunswick, NJ). The mice were anesthetized before
20 initiating the image scanning. For each time point, the laser Doppler image obtained was analyzed by averaging the perfusion and expressed as the relative unit of flux, as determined by Moor Instruments, over the surface of the ischemic and nonischemic foot.

Tube Formation Assay

25 The Matrigel matrix (Bedford, MA) was used to coat the 96-well plates. Human aortic endothelial cells were cultured. The cells were treated with caspase-1 inhibitor (Anaspec, Fremont, CA) and proatherogenic stimulus LPC for 24 h. HAECs were harvested and suspended. Cell concentration was determined and added to each Matrigel-coated well and incubated for 16–18 h. Images were collected using the inverted microscope.

Data Analysis

30 The experiments were performed at least three times, and results were expressed as the means ± S.E. Statistical comparison of single parameters between two groups was performed by paired Student's *t* test, and multiple group comparisons were

performed by one-way analysis of variance. Data were considered statistically significant if p was <0.05 .

The results of the experiments are now described.

5

Proatherogenic Oxidized Lipids Induce Higher Caspase-1 Activation in the Larger Sizes of HAECs than in Smaller Sizes of HAECs

To examine our hypothesis that the size and growth status of endothelial cells regulate caspase-1 activation induced by proatherogenic lipids, we performed the stimulation of HAECs followed by flow cytometric analysis, and we determined the caspase-1 activation in the five groups of HAECs, including untreated control, oxLDL-treated, LPA-treated, LPC-treated, and H₂O₂-treated control. The results showed that proatherogenic lipids significantly activate caspase-1 (Fig. 14A). To determine whether caspase-1 is activated differently in various cell sizes of HAECs in response to proatherogenic lipid stimulation, we used the forward scatter (FSC) function in the y axis to establish the cell size and caspase-1 activation in the x axis to determine the activation of HAECs during the analysis of the FACS data using the FlowJo software. The results in the dot plot (Fig. 14B, *upper panel*) showed that caspase-1-positive population spreads in a slightly diagonal manner along the forward scatter (y axis) and caspase-1 activity (x axis), suggesting a possibility that larger sizes of cells have higher caspase-1 activity than smaller sizes of HAECs. After gating out HAECs into three populations, large, medium, and small using FSC in the y axis, we examined caspase-1 activation in the x axis in these three cell size populations as we described previously. The results showed that oxLDL, LPA, and LPC induce caspase-1 activation in a larger size of HAECs by 63.6, 54.4, and 52.8%, respectively, higher than that in the smaller size of HAECs (14.4, 25.2, and 38.2%) (Fig. 14, *B and C*), suggesting that caspase-1 activation is associated with high cell growth status in larger cell sizes and that various lipid stimuli show no significant differences in activating caspase-1 in various sizes of HAECs. Here, we found the new results on the effects of other proatherogenic lipids in promoting caspase-1 activation. Taken together, the results demonstrated that proatherogenic lipids induce caspase-1 activation in HAECs, which may promote EC activation in a larger size of cells and inflammatory cell death in a smaller size of cells.

Proatherogenic Lipids Significantly Increase Pyroptosis in Smaller Sizes of Human Aortic Endothelial Cells than in Larger Sizes of the Cells

Inflammatory cell death (pyroptosis) is a newly characterized form of cell death with the features of caspase-1 activation, plasma membrane rupture, and release of inflammatory factors (Miao et al., 2010 Nat. Immunol. 11, 1136–1142). In Fig. 14, *B* and *C*, we noticed that caspase-1 activities in LPC-treated HAECs and H₂O₂-treated positive control

5 HAECs are lower in the medium sizes of HAECs than in the smaller sizes of cells, suggesting that increased caspase-1 activities in the smaller sizes of cells result in poorer survival and decreased sizes of cells. To examine the hypothesis that proatherogenic lipids promote caspase-1 activation and promote higher EC pyroptosis in the smaller size of HAECs compared with the larger size of HAECs, we stimulated HAECs with LPC and co-stained

10 them with the caspase-1 fluorescence probe to analyze the activation of caspase-1 and the viable fluorescence dye 7-AAD to determine the plasma membrane integrity, viability, and pyroptosis. We first analyzed the activation of caspase-1 in HAECs, and we established the *y* axis as FSC, which evaluates the cell size, and the *x* axis to measure the activation of caspase-1. Using these parameters, we analyzed caspase-1 activation in three sizes of cell

15 populations. After that, we analyzed the 7-AAD staining that determines HAEC pyroptosis in different sizes of caspase-1(+) HAECs. The results showed that in LPC-treated HAECs, the smaller size of caspase-1(+) cells has an increase in pyroptosis (38.77%) compared with that in medium size (20.17%) and that in the large size of caspase-1(+) HAECs (9.93%). The bar graphs results in Fig. 15 showed that LPC stimulation significantly induced 7-

20 AAD⁺ pyroptosis from 22.50 to 38.77% in smaller size of caspase-1(+) HAECs ($p < 0.01$). However, LPC stimulation did not induce significant pyroptosis in the medium and larger size of caspase-1(+) HAECs from 10 to 12% ($p > 0.05$). It should be noted that in unstimulated cells, the percentage of 7-AAD⁺ cells in the smaller sizes of HAECs (22.50%) was much higher than that in both the medium size (10.71%) and larger size of HAECs

25 (10.49%), suggesting that the membrane integrity in the medium and larger sizes of caspase-1(+) HAECs is significantly better preserved than that of the smaller sizes of caspase-1(+) HAECs. The results demonstrated that caspase-1 activation induced by LPC in the larger sizes of HAECs may promote EC activation but not significant pyroptosis and that as HAECs become smaller in size, LPC-induced caspase-1 activation promotes measurable pyroptosis.

VEGFR-2 Inhibition Increases Caspase-1 Activation in HAECs Induced with LPC Treatment

Our data suggest that as cell growth status improves, endothelial cell size becomes larger and less pyroptotic than smaller cell sizes. These results lead us to hypothesize that vascular endothelial growth factor signaling may inhibit caspase-1 activation

and pyroptosis. To examine this possibility, we searched for supporting evidence with unpublished microarray data deposited in the National Institutes of Health NCBI-Geo-Profile database. The experimental data of a microarray analysis with *vegfr2* gene knockdown (KD) samples, compared with wild-type control samples in two different time courses (84 and 95 h after gene knockdown), showed that the expressions of caspase-1 and inflammasome component apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) were increased at a ratio of 1.48 and 2.45, respectively ($p = 0.00014-0.06443$) (Fig. 16A). The expression of two caspase-1 substrates, such as IL-1 β and IL-18, and two housekeeping genes was not significantly changed. To further consolidate the conclusion, we then stimulated HAECs with LPC in the presence or absence of the VEGFR-2 inhibitor SU1498, followed by co-stained HAECs with a caspase-1 activity probe. The results showed that VEGFR-2 inhibition increases caspase-1 activation in HAECs (Fig. 16B). These results suggest that VEGFR-2 cell growth signaling inhibits caspase-1 activation and cell death.

Caspase-1 Activation Inhibits VEGFR-2 Expression

As indicated above, our results give rise to the following question. How can caspase-1 promote HAEC activation in larger cell sizes and simultaneously enhance pyroptosis in the smaller size of HAECs? One possibility is that caspase-1 activation and VEGFR-2 signaling interplay each other in their functions. To examine this possibility, we analyzed the National Institutes of Health NCBI-Geo-Profile database. The experimental data of a microarray analysis showed that the ratio of VEGFR-2 expression levels in the wild-type control samples *versus* caspase-1 gene-deficient (KO) samples was 0.62 (Fig. 17A), suggesting that VEGFR-2 expression is increased in caspase-1 gene depletion samples and that caspase-1 activation inhibits VEGFR-2 signaling. The caspase-1 expression level was 22.23-fold higher in wild-type samples than in caspase-1 KO samples, justifying the *bona fide* comparison of wild-type samples and caspase-1 KO samples.

In addition, the expression levels of three housekeeping genes were within the range of 1.04 to 0.99, suggesting the high quality of the microarray experimental datasets. To gain further support for our conclusion, we then stimulated HAECs with LPC in the presence or absence of caspase-1 inhibitor followed by the analysis of the FACS data, which showed that after the inhibition of caspase-1 in LPC-treated HAECs, VEGFR-2 expression was increased (Fig. 17B). We further determined the expression of VEGFR-2 after caspase-1 inhibition in LPC-treated HAECs in different cell sizes. Three gates were established according to the cell size using FSC in the y axis to analyze the cell sizes and VEGFR-2

expression in the x axis. The results showed that pretreatment with caspase-1 inhibitor in LPC-treated HAECs increased the expression of VEGFR-2 when compared with LPC-treated HAECs from 11.3 to 22.1% in the smaller size of HAECs, from 22.1 to 50.0% in the medium size of HAECs, and from 34.3 to 64.4% in the larger size of HAECs (Fig. 17, C and D). It has been demonstrated in our recent report that caspase-1 deficiency in apolipoprotein E (apoE)^{-/-}/caspase-1^{-/-} mouse aorta and the inhibition of caspase-1 in ECs result in accumulation of anti-inflammatory protein/histone deacetylase sirtuin 1 (Sirt1), which is a proteolytic substrate of caspase-1, suggesting that caspase-1 activation in early atherogenesis promotes endothelial activation via a Sirt1 degradation pathway. To determine whether activation of Sirt1 has the same effect as inhibition of caspase-1 in promoting VEGFR-2 expression, we performed the same experiment as previous ones using Sirt1 activator pretreatment in LPC-treated HAECs. We used the same method to analyze the data according to cell sizes and VEGFR-2 expression. The VEGFR-2 expression was increased in LPC-treated HAECs pretreated with Sirt-1 activator compared with LPC-treated HAECs. The VEGFR-2 expression in the above-mentioned groups increased from 11.3 to 21.0% in the smaller size of HAECs, from 22.1 to 52.5% in the medium size of HAECs, and from 34.3 to 70.2% in the larger size of HAECs. Taken together, the results suggest that LPC-induced caspase-1 activation decreases VEGFR-2 expression levels in HAECs, whereas the inhibition of caspase-1 and activation of Sirt-1 rescue VEGFR-2 expression levels in LPC-treated HAECs.

Caspase-1 Inhibition Improves Tube Formation of LPC-treated Human Aortic Endothelial Cells

Because EC tube formation assay has been widely used in determining VEGFR-2-mediated angiogenesis (27), we used the EC tube formation assay in the Matrigel to test the hypothesis that caspase-1 inhibition improves VEGFR-2-mediated HAEC tube formation. To test this hypothesis, we performed tube formation assays with untreated HAECs, LPC-treated HAECs, and LPC plus caspase-1 inhibitor co-treated HAECs. The results showed that the lengths of the total master segment length (in micrometers) of tube formation in LPC-treated HAECs were significantly lower (317 μ m) than in untreated HAEC controls (718 μ m). In addition, LPC plus caspase-1 inhibitor co-treated HAECs have restored the EC tube formation (827 μ m) (Fig. 18). The results suggest that caspase-1 inhibition not only increases VEGFR-2 expression levels but also functionally improves VEGFR-2-mediated EC tube formation.

Caspase-1 Depletion Improves Angiogenesis and Ischemia/Normal Blood Perfusion Ratio in Hind Limb Ischemic Mouse Tissues

Because the mouse model of hind limb ischemia has been widely used in determining the gene effect on hind limb ischemia-triggered angiogenesis (25), we performed the hind limb ischemia model on wild-type mice and caspase-1 KO mice followed by the blood flow measurement with the LDSII Doppler at days 0–3, 7, 10, and 21. The results showed that caspase-1 depletion increased the ischemia/normal leg blood perfusion ratios from 25.5 to 32.7% on day 1, from 37.8 to 44.1% on day 3, and from 57.62 to 66.49% on day 7, respectively, in hind limb ischemia-affected tissues in caspase-1 KO mice in comparison with that in wild-type mice at the same time points ($p > X \pm 2SD$) (Fig. 19). The results suggest that caspase-1 depletion improves angiogenesis and blood supply in hind limb ischemic mouse tissues.

A novel therapeutic for ischemia

Our results have addressed the issue about the mechanism in the interplay between inflammatory environment, initiation of EC activation, inflammatory cell death (pyroptosis) in ECs, angiogenesis impairment in ECs, and ischemia in animal tissue. We examined caspase-1 activation in ECs, EC pyroptosis, the microarray data, EC tube formation, and hind limb ischemia mouse model, and we investigated our novel hypothesis that the inhibition of caspase-1 in ECs attenuates EC pyroptosis, improves VEGFR-2-mediated ECs survival, angiogenesis, and ischemia's prognosis under inflammatory and dyslipidemic environment. We have made the important finding that dyslipidemic environment induces higher caspase-1 activation in the larger sizes of HAECs than in smaller sizes of HAECs. Moreover, the smaller HAECs have higher pyroptosis rates than larger HAECs after stimulation with proatherogenic lipids. The activation of caspase-1 after stimulation with proatherogenic lipids promotes ECs activation as judged by increased intercellular adhesion molecule-1 expression in HAECs as demonstrated elsewhere herein. Our results show that the inhibition of VEGFR-2 increases caspase-1 activation in HAECs induced by LPC treatment and that the activation of caspase-1 inhibits VEGFR-2 expression in HAECs. The molecular data were further consolidated with the evidence in functional angiogenesis models that caspase-1 inhibition improves tube formation of LPC-treated HAECs and the depletion of caspase-1 improves angiogenesis and blood supply in the hind limb of ischemic mouse tissues.

Although microvascular endothelial cells are often involved in angiogenesis, aortic endothelial cells are also used as experimental models for angiogenesis such as the aortic ring angiogenesis model (Blacher et al., 2001 *Angiogenesis* 4, 133–142). In addition, neovessel formation was recently found in the human thoracic aneurysm of the ascending
5 aorta (Kessler et al., 2014 *Cardiovasc. Res.* 104, 147–159) and revascularization in atherosclerotic aorta (Luttun et al., 2002 *Nat. Med.* 8, 831–840). The use of aortic endothelial cells in the commonly used experimental angiogenesis model and the involvement of aortic endothelial cells in pathological angiogenesis and atherosclerosis justified our use of aortic endothelial cells in this study.

10 Our recent review summarized that there are 11 endogenous metabolic stress-related danger signals, including oxLDL and cholesterol crystals that induce caspase-1 activation (Yin et al., 2013 *Front. Biosci.* 18, 638–649). However, the issue of whether several oxLDL-derived lipids, such as LPC and LPA (Zhou et al., 2011 *Cell Metab.* 13, 592–600), can induce caspase-1 activation was not clear. Our results reported here have
15 demonstrated for the first time that LPC and LPA, small non-crystal lipids, can induce caspase-1 activation, presumably not via particle-lysosome pathway (Yin et al., 2013 *Front. Biosci.* 18, 638–649). Because LPA acts on the LPC receptors, including LPA1-6 G protein-coupled receptors (Haas et al., 1997 *Microvasc. Res.* 53, 113–120), and LPC acts on the LPC receptor, GPCR-G2A (Schmitz et al., 2010 *Atherosclerosis* 208, 10–18), the signals from
20 these receptors to activate caspase-1 have been intensely studied in our investigation.

It was reported that lipopolysaccharide induces a caspase-3/caspase-1-dependent EC apoptosis, which can be inhibited by VEGF (Munshi et al., 2002 *J. Immunol.* 168, 5860–5866). However, we showed for the first time that VEGFR-2 signaling inhibits caspase-1-dependent pyroptosis, which is demonstrated by positive 7-AAD staining. Of note,
25 7-AAD staining is not a feature of apoptosis (Miao et al., 2010 *Nat. Immunol.* 11, 1136–1142). In addition, the detailed molecular mechanisms underlying caspase-1 inhibition of VEGFR-2 transcript expression remain unknown. It was reported that caspase-1 generated proatherogenic cytokine IL-1 β , which counteracts mechanical signals that induced VEGFR-2 signaling and inhibits EC proliferation (Liu et al., 2010 *J. Immunol.* 185, 1215–1221). Our
30 results showed that caspase-1 has an IL-1 β , IL-18, and sirtuin 1-independent transcription regulatory effect.

In our newly proposed working model (Fig. 20), we summarize our findings and highlight the current understanding that the larger size of HAECs has higher VEGFR-2 expression and less caspase-1(+) induction of pyroptosis than the smaller cells under the

dyslipidemic and inflammatory environment, which promotes cell survival and angiogenesis and improves the prognosis of the ischemia. In contrast, under dyslipidemic and inflammatory environments, the smaller size of HAECs has an increase in caspase-1(+) induction of pyroptosis and less VEGFR-2 expression than the larger cells that decrease the angiogenesis and cell survival and worsen ischemia's prognosis. In summary, there is a mutual inhibition between the VEGFR-2 signaling pathway and caspase-1 activation in endothelial cells. Our novel results provide important insight on the future development of a novel therapeutic approach, based on the inhibition of caspase-1 for suppression of vascular inflammation and improvement of angiogenesis and ischemia prognosis under inflammatory environments (Annex et al., 2013 Nat. Rev. Cardiol. 10, 387–396).

Example 3: Caspase-1 mediates hyperlipidemia-weakened progenitor cell vessel repair

Caspase-1 activation senses metabolic danger-associated molecular patterns (DAMPs) and mediates the initiation of inflammation in endothelial cells. Here, we examined whether the caspase-1 pathway is responsible for sensing hyperlipidemia as a DAMP in bone marrow (BM)-derived Stem cell antigen-1 positive (Sca-1⁺) stem/progenitor cells and weakening their angiogenic ability. Using biochemical methods, gene knockout, cell therapy and myocardial infarction (MI) models, we had the following findings: 1) Hyperlipidemia induces caspase-1 activity in mouse Sca-1⁺ progenitor cells in vivo; 2) Caspase-1 contributes to hyperlipidemia-induced modulation of vascular cell death-related gene expression in vivo; 3) Injection of Sca-1⁺ progenitor cells from caspase-1^{-/-} mice improves endothelial capillary density in heart and decreases cardiomyocyte death in a mouse model of MI; and 4) Caspase-1^{-/-} Sca-1⁺ progenitor cell therapy improves mouse cardiac function after MI. Our results provide insight on how hyperlipidemia activates caspase-1 in Sca-1⁺ progenitor cells, which subsequently weakens Sca-1⁺ progenitor cell repair of vasculature injury. These results demonstrate the therapeutic potential of caspase-1 inhibition in improving progenitor cell therapy for MI.

In this study, we examined the hypothesis that the caspase-1 pathway in BM-derived Sca-1⁺ progenitor cells can sense dyslipidemia and that caspase-1 activation in Sca-1⁺ progenitor cell impairs their angiogenic ability during ischemic injury. To examine this hypothesis, we examined caspase-1 activity in mouse Sca-1⁺ progenitor cells in atherogenic apolipoprotein E deficient (ApoE^{-/-}) mice after high fat (HF) diet feeding in vivo. We also performed cDNA microarray analysis to determine the downstream effects of hyperlipidemia-induced caspase-1 activation in vivo. In addition, we utilized a mouse model

of myocardial infarction (MI) to determine whether caspase-1 gene depletion could enhance the therapeutic efficacy of progenitor cell therapy in ischemic myocardium. Our results demonstrate that caspase-1 activation is responsible for hyperlipidemia-induced vascular dysfunction by impairing vessel repair of Sca-1⁺ progenitor cells.

5

The material and methods employed in these experiments are now described.

Reagents

EGM-2 Medium was purchased from Lonza corporation (CC-3202).

- 10 Histopaque®-1083 was from Sigma-Aldrich (10831). FAM-YVAD-FMK caspase-1 detection kit was from Cell Technology (FAM600-2). Anti-APC MultiSort kit and MicroBeads were from MACS (130-091-255/130-048-801). Rat IgG2a K Isotype control APC was from eBioscience (17-4321-81). Biotinylated Griffonia simplicifolia lectin I (isolectin B4) from Vector (B-1205), Biotin-XX conjugate was from Invitrogen (I21414).
- 15 APC anti-mouse Ly-6A/E (Sca-1) antibody were from Biolegend (121906/108112). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Mice and diets

- 20 All mice were in a C57B/L6 strain background. Wild-type (WT) and ApoE^{-/-} mice were purchased from the Jackson Laboratories (Bar Harbor, Maine). Caspase 1^{-/-} mice were obtained (17). ApoE/caspase-1 double gene deficient (ApoE^{-/-}/caspase-1^{-/-}) mice were generated by crossing caspase-1^{-/-} mice into ApoE^{-/-} mice as we reported (4). Male mice were fed either standard rodent chow diet (catalog #8640; Harlan Teklad, Madison, WI) or HF diet (catalog #88137, Harlan Teklad) starting from 8 weeks to induce dietary
- 25 dyslipidemia as we reported (4).

Transcriptome microarray analysis

- Total RNA was extracted from the aortas of mice using the RNeasy Kit (Qiagen, Valencia, CA). RNA quantity was determined by the NanoDrop ND-2000 (Thermo
- 30 Scientific, Wilmington, DE). The RNA integrity was determined by the RNA 28S/18S ratio using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Then samples were labeled and hybridized to the Affymetrix Genechip Mouse Gene 2.0.ST Arrays (Santa Clara, CA) following the manufacturer's instructions. Scanned microarray images were

analyzed using the Affymetrix Gene Expression Console with Robust Multiarray Average normalization algorithm.

Microarray data analysis

5 Our affymetrix data analysis was done in the R statistical environment using “oligo” and “limma” packages. Venn diagram analysis was performed in the R statistical environment using the package “VennDiagram”. Heat map and scatter plot were performed using the statistical tools provided by the R and Bioconductor projects.

Ingenuity pathway analysis

10 In order to categorize clinical functions and molecular and cellular functions related to the identified genes in our microarray analysis, the Ingenuity Pathway Analysis (IPA, Ingenuity Systems) was used. The differentially expressed genes were identified and uploaded into IPA for analysis. The IPA Tox analysis was used for clinical pathology
15 functions and the Core analysis was used for molecular and cellular pathways.

Flow cytometry analysis of Sca-1+ cells

20 After mouse BM was harvested from the femurs and tibiae, the collected cells were added with ACK buffer to lysis red blood cells and homogenized into a single cell suspension afterwards by mixing and filtering through a 70 micron filter. After centrifugation, cells were washed and resuspended in EGM-2 medium. Active caspase-1 levels were determined with APO LOGIX kit (Cell Tech., Mountain View, CA). The kit contains a carboxyfluorescein (FAM)(Excitation/Emission (nm):490/520)-labeled peptide
25 fluoromethyl ketone (FMK) caspase-1 inhibitor (FAMYVADFMK), which enters the cell and irreversibly binds to activated caspase-1 but not pro-caspase-1. All procedures were performed according to the manufacturer's instruction. Briefly, cell suspension were incubated at 37°C with 1 x FAM-YVAD-FMK for 1 hour and then washed with 1x washing buffer. For the cell surface marker Sca-1 staining, cells were incubated for 30 minutes with
30 monoclonal antibody against mouse Sca-1 or isotype control. Cells were washed afterwards and fixed in 2% paraformaldehyde before flow cytometry analysis. The data were analyzed by LSR II flow cytometer (BD Biosciences, San Jose, CA) and the FlowJo software (Tree Star, Ashland, OR).

Magnetic cell sorting and cell trace of Sca-1+ cells

BM-derived mononuclear cells were isolated from the BM of WT mice or caspase-1^{-/-} mice by density gradient using Histopaque-1083. Sca-1⁺ cells were purified by an autoMACS separator (Miltenyi Biotec), using magnetic beads-coated mouse APC anti-
5 mouse Ly-6A/E (Sca-1) antibody and an Anti-APC MultiSort Kit according to the manufacturer's instructions. To evaluate the homing of injected cells to infarcted heart, purified Sca-1⁺ cells were labeled with CellVueR NIR (near infrared) 780 (Excitation max: 745nm/Emission max: 776nm, Mol. Targeting Tech. Inc. West Chester, PA) and injected peri-orbitally into C57/B6 mice, 6 hours before MI procedure. Images for tracing CellVueR
10 NIR-labelled Sca-1⁺ cells were performed using the Multispectral FX Pro (Fixed Lens) Image Station (Carestream Health, Woodbridge, CT) for near-infrared fluorescence (NIRF) signals both prior to and at 0, 21, 24 and 45 hours post-CellVueR and post-PSVue injection.

Experimental MI and cell therapy

15 Experiments were performed in 14-16 weeks old male WT mice fed a HF diet for 6 weeks. Acute MI was induced by permanent left anterior descending coronary artery ligation as previously described (Gao et al., 2010, *Circ Res*, 107(12), 1445-53). Briefly, mice were anesthetized with 2% isoflurane. A skin incision was made over the left thorax, and the pectoral muscles were retracted to expose the ribs. At the level of the fourth intercostal space,
20 the heart was exposed and pumped out through an expanded space between ribs. After a permanent knot was made around the left anterior descending coronary artery (LAD) at 2–3 mm from its origin with 6-0 silk suture, the heart was immediately placed back into the intrathoracic space, followed by manual evacuation of pneumothoraces and closure of the incision. Sham-operated animals were subjected to the same surgical procedures except that
25 the suture was passed under the LAD but was not tied. After full recovery from cardiac surgery (four hours after MI), animals were randomized into two cell therapy groups. Purified Sca-1⁺ cells were injected peri-orbitally into those mice.

Measurement of cardiac function

30 Mouse cardiac function was measured with echocardiography (ECHO). ECHO was performed with VisualSonics Velvo 770 high-resolution in vivo microimaging system (FUJIFILM VisualSonics, Toronto, Canada). Mice were anesthetized with 2% isoflurane initially and then 1% during the ECHO procedure. Hearts were examined in the short-axis between the two papillary muscles of the left ventricle (LV) and analyzed in M-

mode. The parameters of cardiac function were measured offline with the Velvo 770 software including LV end diastolic diameter (EDD), end-systolic diameter (ESD), posterior wall thickness (PWT), and septal wall thickness (SWT) to determine cardiac morphological changes and ejection fraction (EF), heart rate and fractional shortening (FS). The EF and FS were calculated as reported (Rottman et al., 2007, Echocardiography, 24(1), 83-9).

TUNEL assay

Apoptotic cells were detected by terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) using the APO-BrdU TUNEL Assay Kit (Millipore) as per the manufacturer's protocol. Briefly, Hearts were embedded in OCT media (Sakura Finetechnical Co., Ltd. Japan). Frozen ventricular sections (5 μ m) were fixed in 4% (w/v) paraformaldehyde for 15 min on ice, permeabilized with 70% ethanol for 30 min on ice, and incubated with 50 μ L DNA-labeling solution containing TdT enzyme and Br-dUTP at 37°C for 60 min. After the labeling reaction, the sections were washed and stained with fluorescein-labeled anti-BrdU antibody for 30 min. Before mounting, the cells were stained with 4', 6-diamidino-2-phenylindole (DAPI) and Alexa Fluor 594-labeled phalloidin (Invitrogen). Images were captured using a Zeiss 710 confocal microscope, 63 x oil objective, 1.4. x digital zoom with excitations at 405, 488, and 594 for nuclei, TUNEL, and phalloidin, respectively. The percentage of TUNEL positive cells was quantitated using Image J (NIH) from 4–5 regions per heart, and an area of at least 100 cardiac myocytes.

Capillary density assay

Mouse hearts were removed at two weeks after MI and kept at -80°C until histological analysis. Frozen heart tissues were cut into 5 μ m thick slices. Adjacent sections (taken at the midpoint between LAD ligation site and apex) were stained with Biotinylated Griffonia simplicifolia lectin I (isolectin B4) to stain endothelial cells in neovasculature from the mouse myocardial infarcted heart section (Chavakis et al., 2005, J Exp Med, 201(1), 63-72). Images were captured using a Zeiss 710 confocal microscope using a 63 x oil objective and 1.4. x digital zoom with excitations at 405 and 594 for nuclei and IB4, respectively. Capillary density was expressed as IB4+ endothelial cells per field.

Data analysis

All the experiments were performed at least twice, and results were expressed as the mean $\pm$ standard error (S.E.). Statistical comparison of single parameters between two

groups was performed by paired Student t test. One-way ANOVA was used to compare the means of multiple groups. Data were considered statistically significant if p was <0.05.

The results of the experiments are now described.

5

Hyperlipidemia increases caspase-1 activity in Sca-1+ progenitor cells

We and the others have shown previously that caspase-1 activation is responsible for hyperlipidemia-induced endothelial cell activation and macrophage inflammation (Yin et al., 2015, *Arterioscler Thromb Vasc Biol* ; Duewell et al., 2010, *Nature*, 10 464(7293), 1357-61; Rajamaki et al, 2010, *PLoS One*, 5(7), e11765). However, the question of whether caspase-1 is activated in Sca-1+ progenitor cells in response to hyperlipidemia remained unknown. We hypothesized that Sca-1+ progenitor cells also had a functional inflammasome pathway, which could sense hyperlipidemia and activate caspase-1. To test this hypothesis, we measured caspase-1 activity in BM-derived Sca-1+ progenitor cells after 15 hyperlipidemia challenge. We collected BM cells from WT mice and ApoE^{-/-} mice fed with either chow diet or HF diet for 12 weeks and prepared single cell suspensions for flow cytometry analysis (Figure 21A). Within the mononuclear cell populations of BM, we gated Sca-1+ progenitor cells to measure their caspase-1 activity (Figure 21B). We found that when compared with either ApoE^{-/-} mice or WT mice fed with chow diet, HF diet feeding 20 significantly increased caspase-1 activity in mouse Sca-1+ progenitor cells (p<0.05) (Figure 21C), suggesting that at least one type of NLR inflammasomes and caspase-1 are fully expressed/functional in progenitor cells and could be post-translationally activated by hyperlipidemia stimuli.

25 Caspase-1 contributes to hyperlipidemia-induced modulation of vascular cell death gene expression

A recent report showed that stem cells/endothelial progenitor cells were present at low levels in mouse organs with the highest levels in adipose and aorta (Russell and Brown, 2014, *Mol Cancer*, 13, 177). To determine the functional effects of 30 hyperlipidemia-induced caspase-1 activation in Sca-1+ progenitor cells in mouse aortic context related to hyperlipidemia diseases, we performed cDNA microarray analysis in WT mice, ApoE^{-/-} mice, and ApoE^{-/-}-Caspase-1^{-/-} mice fed with 3 weeks of HF diet. Since we have found that caspase-1 serves as a hyperlipidemia sensor during early hyperlipidemia (Yin et al., 2015, *Arterioscler Thromb Vasc Biol*, 35(4), 804-16), use of three-week HF diet

feeding is justified. Of note, at this age of mice, plasma cholesterol triples in both ApoE^{-/-} and ApoE^{-/-}Caspase-1^{-/-} mice when compared with that in WT mice (Yin et al., 2015, *Arterioscler Thromb Vasc Biol*, 35(4), 804-16; Plump et al., 1992, *Cell*, 71(2), 343-53; Nakashima et al., 1994, *Arterioscler Thromb*, 14(1), 133-40). This allows us to identify genes whose RNA expressions are changed in response to hyperlipidemia (ApoE^{-/-} mice compared with WT mice) and identify how many genes whose RNA expressions are changed in response to hyperlipidemia can be reversed by caspase-1 gene deletion (ApoE^{-/-}Caspase-1^{-/-} mice compared with ApoE^{-/-} mice) (Figure 22). We found that among 23,470 genes that could be detected by the microarray analysis, 6,745 genes were significantly changed in response to hyperlipidemia, while 2,541 genes were significantly changed in response to caspase-1 gene deletion (Figure 23A and Figure 23C). More importantly, most of the genes that were induced by hyperlipidemia could be significantly down-regulated by caspase-1 deficiency (Figure 23B). Moreover, among 6,745 differentially expressed genes induced by hyperlipidemia, 969 genes could be reversed by caspase-1 deficiency (Figure 23C).

Interestingly, IL-1 β , the proteolytic substrate of caspase-1, was among the most significantly decreased genes besides caspase-1 after caspase-1 deficiency (Figure 23D). This result suggested that caspase-1 could also transcriptionally up-regulate IL-1 β gene expression independent from its well-characterized enzymatic cleavage activity. In addition, we found that apoptosis-related gene caspase-4 was among the genes that decreased the most after caspase-1 deficiency, suggesting that caspase-1 also promotes apoptosis (programmed cell death) besides its ability to induce pyroptosis (inflammatory cell death). Moreover, a group of different microRNAs (Mir) such as Mir 145 and Mir 143 were among the most significantly increased genes after caspase-1 gene deficiency instead, which suggested that caspase-1 could negatively affect regulatory noncoding RNA gene expressions, thereby contributing to epigenetic regulation of gene expression changes.

To identify the functional pathways of the pathological effects of Caspase 1 in hyperlipidemia, we analyzed the signatures of the 969 genes regulated by caspase-1 deficiency using IPA software. When we examined top molecular pathways that were regulated by caspase-1 in hyperlipidemia condition, “Cellular Growth and Proliferation”, “Cell Death and Survival” were the top two pathways identified, suggesting that hyperlipidemia-induced caspase-1 regulates vascular cell death (Figure 23E). In addition, we identified 13 genes associated with apoptosis and necrosis of endothelial cells that are regulated by hyperlipidemia-induced caspase-1 activation, such as tumor necrosis factor (TNF) super family members including tumor necrosis factor (ligand) superfamily member

10 (TNFSF10) and Fas ligand (FASLG), matrix degradation enzyme metalloproteinase 9 (MMP9), and mitogen-activated protein kinase (MAPK) family member MAP3K5 (Figure 23F). When we chose clinical endpoints as the readouts in our IPA analysis, we found that “Cardiac Hypertrophy” and “Increase Heart Failure” were among the top pathways that are regulated by hyperlipidemia-induced caspase-1 activation (Figure 24). Although mouse aortas instead of heart were used in our analysis, caspase-1 might mediate hyperlipidemia-induced cardiac dysfunction and hypoxia-triggered damage by inducing vascular cell death in these tissues.

10 Caspase-1^{-/-} Sca-1⁺ progenitor cell therapy improves cardiac function after MI

Based on our results above that that dyslipidemia increases caspase-1 activity in Sca-1⁺ progenitor cells; and that caspase-1 contributes to the regulation of hyperlipidemia-induced vascular cell death, we hypothesized hyperlipidemia-induced caspase-1 activation in Sca-1⁺ progenitor cells leads to vascular cell damage by impairing their vessel repair capacity. To test this hypothesis, we compared the angiogenesis capacity of purified Sca-1⁺ cells from WT mice and those purified from caspase-1 deficient mice in a mouse model of MI (Iwasaki et al., 2006, Circulation, 113(10), 1311-25). We used four groups of mice, (i) the mock-MI control group (n=13), (ii) the MI with no cell therapy control group (n=4), (iii) the MI with WT Sca-1⁺ progenitor cell therapy group (n=5), and (iv) the MI with caspase-1^{-/-} Sca-1⁺ progenitor cell therapy group (n=5). As shown in Figure 25A, we first pre-conditioned the mice with a six week HF diet feeding (from day -42 to day 0). Sca-1⁺ progenitor cells were purified using a magnetic Sca-1⁺ cell purification column, and Sca-1⁺ cells were enriched from 35.5.% to as high as 85.4.% after the purification (Figure 25A). Then, we performed experimental acute MI procedures at the day 0 (18), to the three groups of the recipient mice, followed by Sca-1⁺ progenitor cell therapy (2×10^6 cells/mouse). The numbers of transferred Sca-1⁺ progenitor cells were similar to 1×10^6 BM-derived cells per mouse in a previous report (Chen et al., 2009, Am J Pathol, 174(2), 701-11). After MI, the control mice received purified WT Sca-1⁺ progenitor cells and the experimental mice received caspase-1^{-/-} Sca-1⁺ purified progenitor cells. To ensure that Sca-1⁺ progenitor cells migrate to the acute MI lesion site, we used CellVue® NIR780-labelled Sca-1⁺ progenitor cells (2×10^6 cells/mouse, n=4) to perform adoptive transfer to trace the Sca-1⁺ progenitor cell migration. 45 hours after the injection, we found that the CellVue® NIR780 near-infrared labeled Sca-1⁺ progenitor cells mostly migrated to the infarcted heart (Figure 25B). To examine whether caspase-1^{-/-} Sca-1⁺ progenitor cell therapy has an enhanced therapeutic

effects, we performed cardiac function analysis one day before MI and 14 days after MI using the M-mode echocardiography. The M-mode tracings presented in Figure 25C were obtained from WT mice without MI (control) and with MI using a 13 MHz transducer with the depth from 0 to -1 cm for 500 milliseconds as reported (Scherrer-Crosbie and Thibault, 2008, J Am Soc Echocardiogr, 21(10), 1083-92). The ejection fraction (EF) and fractional shortening (FS) are two commonly examined cardiac functions assayed by the M-mode echocardiography. As shown in Figure 25D left panel, the ejection fraction in the mouse group receiving caspase-1^{-/-} Sca-1⁺ progenitor cell therapy was increased to 39.9.% from 23% in the mouse group receiving WT Sca-1⁺ progenitor cell therapy control ($p < 0.0.5$). Similarly, the faction shorten index (Figure 25D right panel) in the mouse group receiving caspase-1^{-/-} Sca-1⁺ progenitor cell therapy was also increased to 19.5% from 10.4.% in the mouse group receiving WT Sca-1⁺ progenitor cell therapy control ($p < 0.0.5$). These results suggest that caspase-1^{-/-} Sca-1⁺ progenitor cell therapy significantly improves cardiac function compared to WT Sca-1⁺ progenitor cell therapy. In addition, we also examined weight ratios and liver weight/body weight ratios in the three MI groups. As shown in Figure 25E, the heart weight/body weight ratios and liver weight/body weight ratios were not significantly changed among three MI groups. In contrast, the lung weight/body weight ratios in the caspase-1^{-/-} Sca-1⁺ progenitor cell therapy group were significantly decreased to 0.0.075 from 0.0.119 (WT Sca-1⁺ cell therapy) and 0.0.094 (no cell therapy control)($p < 0.0.5$). The results suggest that the improved cardiac function in caspase-1^{-/-} Sca-1⁺ progenitor cell therapy group may have relieved lung congestion and edema. Taken together, our results suggest that caspase-1^{-/-} Sca-1⁺ progenitor cell therapy significantly improves cardiac function.

Caspase-1^{-/-} Sca-1⁺ progenitor cell therapy improves endothelial capillary density and decreases cardiomyocyte cell death in the infarcted heart zone after MI

To determine the mechanisms underlying the beneficial effects of caspase-1^{-/-} Sca-1⁺ progenitor cell therapy, we then hypothesized that the enhanced regenerative capacity of caspase-1^{-/-} Sca-1⁺ progenitor cell therapy resulted from improved neovasculature formation and reduced cardiac myocyte cell death in comparison to the mice receiving WT Sca-1⁺ progenitor cells. To test this hypothesis, we examined whether mouse hearts receiving caspase-1^{-/-} progenitor cell therapy have higher endothelial capillary density after MI than mouse hearts receiving WT Sca-1⁺ cell therapy using IB4 to stain endothelial cells in neovasculature from the infarcted heart sections (Chavakis et al., 2005, J Exp Med, 201(1),

63-72). The immunohistochemistry results in Figure 26A showed that the infarcted heart section from the mice receiving caspase-1^{-/-} Sca-1⁺ progenitor cell therapy have higher numbers of IB4⁺ endothelial cells than that of untreated MI hearts and that of the MI mice receiving WT Sca-1⁺ progenitor cell therapy. The fold change of IB4⁺ endothelial cell numbers in caspase-1^{-/-} Sca-1⁺ progenitor cell therapy group over no treatment MI group is 1.3.1 ($p < 0.05$). Then, we examined whether the enhanced angiogenesis in the MI lesion area of mice receiving caspase-1^{-/-} Sca-1⁺ progenitor cell therapy leads to the reduction of cardiomyocyte cell death using TUNEL assay. The results in Figure 26B showed that the infarcted heart sections from the mice receiving caspase-1^{-/-} Sca-1⁺ progenitor cell therapy have lower numbers of TUNEL⁺ cardiomyocytes (14.9.%) than that of untreated MI hearts (30.8.%) and that of the MI mouse hearts receiving WT Sca-1⁺ progenitor cell therapy (25.1.%) ($p < 0.05$). Taken together, our results suggest that caspase-1^{-/-} Sca-1⁺ progenitor cell therapy improves cardiac function from enhanced angiogenesis and reduction of cardiomyocyte cell death after MI.

Caspase-1 inhibitory progenitor cell therapy

Stem cell based therapies for the prevention and treatment of CVDs such as myocardial infarction have attracted considerable interest since it was reported in 2001 that BM-derived stem cells could repair myocardial infarcts in mice (Orlic et al., 2001, Ann N Y Acad Sci, 938, 221- 9; discussion 229-30). Originally it was considered that stem cell therapies reverses myocardial remodeling by directly incorporate into the myocardium for de novo myocardiogenesis, it is believed today that the beneficial effects of stem cell therapy on ischemic myocardium are mainly due to neovascularization and paracrine effects (Kinnaird et al., 2004, Circulation, 109(12), 1543-9). The results from clinical trials suggest that stem cell therapy for the prevention and treatment of cardiac dysfunction is safe and potentially efficacious, but the therapeutic efficacy of stem cell therapy is greatly hampered by poor survival, proliferation, engraftment, and differentiation of the grafted stem cells due to the hostile microenvironment of ischemic tissue such as hyperlipidemia, hypoxia, and inflammation (Penn and Mangi, 2008, Circ Res, 102(12), 1471-82; Yang, 2007, Cell Mol Immunol, 4(3), 161-71). To overcome these limitations, a number of studies utilized genetic engineering and pharmacological approaches to empower stem cells for myocardial regeneration (Mohsin et al., 2011, Circ Res, 109(12), 1415-28). However, three important questions remained poorly determined: first, whether progenitor cells have a functional caspase-1 pathway in sensing dyslipidemia/hyperlipidemia; second, whether caspase-1

induced cell death pathways including pyroptosis, apoptosis, and necrosis weaken angiogenesis and vascular repair function of progenitor cells after hyperlipidemia stimulation; and third, whether inhibition of caspase-1 in progenitor cells improves their angiogenesis capacity after MI. In this report, by using various techniques including immunological, biochemical, microarray analysis followed by bioinformatics analysis, gene deficient mice, cell therapy, experimental MI model, and mouse cardiac function assessment, we have made the following important findings: 1) Dyslipidemia increases caspase-1 activity in Sca-1+ progenitor cells; 2) Caspase-1 gene deficiency significantly reversed hyperlipidemia-induced gene changes in mouse aortas including progenitor cells, some of which are involved in vascular cell death; 3) Caspase-1^{-/-} Sca-1+ progenitor cell therapy significantly improves mouse cardiac functions after MI compared to the Sca-1+ progenitor cell treatment; and 4) Caspase-1^{-/-} Sca-1+ progenitor cell therapy improves capillary endothelial cell density and decrease cardiomyocyte cell death after MI. Taken together, our novel findings have provided the first insight on the role of dyslipidemia as DAMP in promoting caspase-1 dependent impairment of progenitor cell repairing capacity after MI.

As we pointed out in our recent review, several types of inflammasomes involved in activating caspase-1 have been characterized including NLRP1, NLRP3, NLRC4 (IPAF), NLRP6 and NLRP12 (Yin et al., 2013, Front Biosci (Landmark Ed), 18, 638-49). Among these, the NLRP3 inflammasome is the only one found to activate caspase-1 in response to endogenous metabolic danger signals (DAMPs) including lipid metabolites. Nevertheless, future work is needed to verify the role of NLRP3 inflammasome in activating caspase-1 in Sca-1+ progenitor cells. A previous report showed that inhibition of caspase-1 in BM-derived progenitor cells from patients and mice with systemic lupus erythematosus improves their differentiation ability (Kahlenberg et al., 2011, J Immunol, 187(11), 6143-56). However, the questions related to caspase-1 activation in progenitor cells in response to dyslipidemia and its effects on angiogenesis and vascular repair after MI have not been examined until this study.

In addition to the phenotypic characterization of caspase-1^{-/-} Sca-1+ progenitor cell therapy for MI, we have also made the findings that after MI, caspase-1^{-/-} Sca-1+ progenitor cells improved capillary density and enhanced cardiomyocyte survival after MI, which are the mechanisms underlying the better efficiencies of caspase-1^{-/-} Sca-1+ progenitor cell therapy and better cardiac function in comparison to that of WT Sca-1+ progenitor cells. Since that caspase-1 is the converting enzyme responsible for the maturation of pro-interleukin-1 β (pro-IL-1 β) and pro-IL-18 into IL-1 β and IL-18, respectively (Shen et

al., 2010, *Atherosclerosis*, 210(2), 422-9); and that caspase-1 deficiency results in deficiency of functional IL-1 β and IL-18 and decreased secretion of tumor necrosis factor- α (TNF- α) (Yin et al., 2013, *Front Biosci (Landmark Ed)*, 18, 638-49), there might be less proinflammatory cytokines IL-1 β , IL-18 and TNF- α in the downstream of caspase-1 activation, resulting in improved vessel repair ability in the caspase-1 $^{-/-}$ Sca-1 $^{+}$ progenitor cells. Finally, we and others have reported previously that Sirtuin 1 (Sirt1), an inhibitory NAD $^{+}$ -dependent histone deacetylase, is cleaved by caspase-1 after hyperlipidemia stimulation (Yin et al., 2015, *Arterioscler Thromb Vasc Biol*, 35(4), 804-16; Chalkiadaki and Guarente, 2012, *Cell Metab*, 16(2), 180-8). Disruption of Sirt1 gene results in defective blood vessel formation and inhibits ischemia-induced neovascularization (Potente et al., 2007, *Genes Dev*, 21(20), 2644-58). Thus, caspase-1 $^{-/-}$ Sca-1 $^{+}$ progenitor cells might retain the Sirt1 function, which may also benefit ischemia-induced neovascularization during MI. Based on these analyses, we have proposed a new working model to integrate our findings (Figure 27). In summary, our results hold a promise for the future development of caspase-1 inhibitory progenitor cell therapy for inflammatory diseases, ischemic diseases, and cancers.

Example 4: Caspase-1 plays a critical role in accelerating chronic kidney disease-promoted neointimal hyperplasia

Chronic kidney disease (CKD) affects over 15% of the adult population (Levey et al., 2003, *Ann Intern Med* 139:137-47; Basnakian et al., 2010, *Adv Clin Chem* 51:25-52) and is a significant contributor to morbidity and mortality in the general population. CKD results from a progressive loss in renal function and is identified by pathological high levels of plasma creatinine, which results from a lower glomerular filtration rate (GFR, <60ml/min/1.73 sq. meters) (Foundation, 2002, *Am J Kidney Dis* 39:S1-266). Thus, due to a decrease in kidney function, CKD results in an accumulation of metabolic wastes such as urea and other uremic toxins (Moradi et al., 2013, *Am J Nephrol* 38:136-48). When the kidney function drops to 10-15 % of normal kidney function, the hemodialysis procedure is indicated for the patient survival (Feldman et al., 1996, *J Am Soc Nephrol* 7:523-35). Moreover, it has been demonstrated that the CKD patients have a significantly increased incidence in the development of cardiovascular disease (CVD) and patient's mortality (Go et al., 2004, *N Engl J Med* 351:1296-305). Several vascular disorders in CKD patients, such as atherosclerosis, arteriovenous fistula (AVF) stenosis in CKD-dialysis patients and allograft vasculopathy, are associated with the development of neointima hyperplasia (NH) and stenosis of the vessel lumen. Recent reports have shown that the

uremic's state in CKD accelerates the development of NH in CKD patients with AVF (Langer et al., 2010, *Kidney Int* 78:1312-21; Kokubo et al., 2009, *J Am Soc Nephrol* 20:1236-45). In addition, previous data also suggested that NH is present prior the AVF creation in CKD patients (Wasse et al., 2012, *J Vasc Access* 13:168-74). Moreover, other studies demonstrated that humans and pigs fed with high fat diet develop atherosclerosis at site of preexisting NH (Kim et al., 1987, *Atherosclerosis* 64:321-42; Schwartz et al., 1995, *Circ Res* 77:445-65; Stary et al., 1992, *Arterioscler Thromb* 12:120-34; Virmani et al., 2000, *Arterioscler Thromb Vasc Biol* 20:1262-75). Therefore, it is urgent to identify novel therapies to inhibit the initiation and progression of NH in CKD patients.

The Neointimal Hyperplasia refers to inward proliferation and migration of vascular smooth muscle cells (VSMC) primarily in the tunica intima, resulting in the thickening of arterial walls and decreased arterial lumen space. Fully differentiated VSMC are associated with high expression of several specific contractile proteins that include smooth muscle α -actin, smooth muscle myosin heavy chain, SM22 and calponin (Alexander and Owens, 2012, *Annu Rev Physiol* 74:13-40) in a healthy kidney-controlled plasmic and artery environment. In contrast, VSMC exhibit a "contractile" to a "synthetic" phenotypic change by the downregulation of VSMC contractile gene expression in response to vascular injury induced by CKD, uremia and mechanic stress as we recently reported (Monroy et al., 2014, *Front Biosci (Landmark Ed)* 20:784-95). This "synthetic" phenotype is characterized by the loss of contractility, abnormal proliferation, as well as migration and matrix secretion that is an important step in the formation of NH. The VSMC "synthetic" phenotype can induce inward remodeling, significantly narrow the vessel lumen, and accelerate the development of various vascular pathologies such as atherosclerosis, hypertension and post-angioplasty restenosis (Regan et al., 2000, *J Clin Invest* 106:1139-47; Owens et al., 2004, *Physiol Rev* 84:767-801). However, the sensing molecular mechanism which bridges elevated metabolic wastes and uremic toxins in plasma and increases the mechanic stress on the initiation and development of NH in CKD patients remains unknown.

The Toll-like receptors (TLR) are located in the plasma membrane and recognize a variety of conserved microbial pathogen-associated molecular patterns (PAMP) and danger signal-associated molecular patterns (DAMP) as well as promote proinflammatory gene transcription. As we described previously (Yin et al., 2009, *Int J Immunopathol Pharmacol* 22:311-22), for tissues in which receptors for DAMP are not constitutively expressed, TLR also work in synergy with cytosolic sensing receptor families, which include NLR [NOD (nucleotide binding and oligomerization domain)-like receptors],

to recognize endogenous DAMP and mediate the upregulation and activation of a range of inflammatory genes (Yin et al., 2013, Front Biosci 18:638-49). Caspase-1 is a member of the cysteine protease family of caspases that requires the posttranslational cleavage and assembly of a NLR family member-containing protein complex called “inflammasome” for activation and is present in the cell cytosol as an inactive zymogen pro-caspase-1. Activated caspase-1 is required for the cleaving and processing of pro-interleukin-1 β (pro-IL-1 β) and pro-IL-18 into functional mature pro-inflammatory cytokines IL-1 β and IL-18, respectively, as well as the activation of other inflammatory pathways. Although caspase-1 inflammasome activation has been reported in the pathogenesis of kidney disease (Anders and Muruve, 2011, J Am Soc Nephrol 22:1007-18), an important issue of whether caspase-1 plays any role in CKD-accelerated NH and VSMC phenotypic change from a “contractile” to a “synthetic” phenotype remains unknown.

In this study, we examined a novel hypothesis that caspase-1 promotes the CKD-induced VSMC switch from a “contractile” to “synthetic” phenotype and the NH development. We applied a carotid artery ligation mouse model reported previously (Kumar et al., 1997, Circulation 96:4333-42) on the CKD model we developed (Kokubo et al., 2009, J Am Soc Nephrol 20:1236-45) for the development of neointimal hyperplasia in wild-type (WT) and caspase-1 gene deficient (caspase-1 $^{-/-}$) mice (Kuida et al., 1995, Science 267:2000-3). Our data has demonstrated that caspase-1 plays a critical role in the downregulation of VSMC contractile marker gene expression and promotion of neointimal hyperplasia formation in CKD mouse models.

The materials and methods employed in this example are now described.

Human Vascular Smooth Muscle Cell Culture and Uremic Serum Collection

Blood samples were obtained from 6 healthy donors with normal kidney function and 20 patients with end stage renal disease who were on hemodialysis. In HD, blood was collected prior to the routine HD session as we reported (Lee et al., 2010, Nephrol Dial Transplant 27:4166-72). Blood samples were centrifuged at 3,000 revolutions per minute (rpm), and the serum was aliquoted and incubated at -80°C. Human aortic smooth muscle cells (HAVSMC) were obtained from Lonza (CC-2571, Allendale, NJ) and cultured in smooth muscle basal media (SmBM) supplemented with growth factors and 5% fetal bovine serum (FBS) (CC-3182, Lonza), according to the manufacturer's guidelines. Cells from passage 4-8 were used in the described studies. For experimental conditions, growth medium was supplemented with 10% vol./vol. normal or uremic serum. We used pooled

serum from (3-5) maintenance hemodialysis patients in each experiment. Experiments were repeated using serum from different hemodialysis patients. Normal serum pooled from healthy donors was used for comparison in the different assays. The human aortic vascular smooth muscles cells were serum starved for 48-72 hours followed by serum treatment for 24 hours. The cells were then treated with serum, patient CKD serum and caspase-1 inhibitor (Z-YVAD-FMK, BioVision, Inc., Milpitas, CA) and CKD serum. Untreated serum starved cells were used as a control.

RNA Extraction and Quantitative Real-Time PCR

Total RNA from cultured cells was extracted using the RNeasy kit (Qiagen, Valencia, CA), and cDNA was synthesized with the VILO first-strand synthesis system (Invitrogen, Grand Island, NY). In real time PCR, cDNA was amplified with inventoried gene assay products containing two human gene specific primers (ACTA2 (SMA), Hs00909449_m1; CNN1 (calponin), Hs00923894_m1; Applied Biosystems, Grand Island, NY), four mouse gene specific primers (Acta2, Mm725412_s1; Cnn1, Mm00487032_m1; Sm22 (Tagln), Mm00441661_g1; and Smtn, Mm00449973_m1; Applied Biosystems) and one FAM dye labeled Taq Man MGB probe all using the 7500 Real Time PCR System (Applied Biosystems). Relative gene expression levels were calculated after normalization with the internal control eukaryotic 18S gene using the $2^{-\Delta\Delta C_t}$ method, where C_t is the threshold value.

Mouse carotid arteries from five WT and five Caspase -/- mice were collected and frozen. Total RNA was later extracted using Trizol (Invitrogen). For arrays, 1 µg of RNA was reversed transcribed using the RT Kit Qiagen. A genomic DNA elimination step is employed before the reverse transcription step. cDNAs were then used for gene expression analysis using the mouse inflammasome array (Qiagen). For vascular smooth muscle cell gene expression, cDNA was assayed using gene specific Taq Man probes as described above.

Mice

All animal studies were conducted in accordance with the principles and procedures outlined in the National Institute of Health Guide for the Care and Use of Animals. Mice were housed in veterinarian-supervised AALAC-accredited facilities. The proposed experiments were approved by the Animal Care and Use Committee Institutional Review Board of Temple University School of Medicine. We purchased WT (C57BL/6) mice from the Jackson Laboratory (Bar Harbor, Maine). Caspase-1 -/- (background, C57BL/6)

mice animals were generously provided by Dr. Richard Flavell from Yale University (Kuida et al., 1995, Science 267:2000-3). For CKD experiments, we used 9- to 16-week-old male mice in the study. The mice were housed in polycarbonate cages in a pathogen-free, temperature-controlled environment with free access to a standard chow diet and water.

5

Creation of CKD and Sham Mice

A two-step process was used in the creation of a chronic kidney disease state in mice by the wide-used 5/6 nephrectomy as reported (Eddy et al., 2012, *Pediatr Nephrol* 27:1233-47). The left kidneys of 9-week old male mice were ablated through a 2 cm flank incision using electrocautery (Surgistat B Electrosurgical Generator, Valleylab, Covidien, Mansfield, MA). One week after this first procedure we performed a contralateral nephrectomy using a 2 cm flank incision. Again, one week post nephrectomy we performed a BUN analysis using reagents a kit from STANBIO Laboratory (Issaquah, WA). Sham control animals received sham operations that included the de-capsulation of both kidneys during the same time periods as the CKD mice. One week later after these initial steps, WT CKD, caspase-1^{-/-} CKD, and WT sham-surviving mice underwent carotid ligation.

10
15

Creation of Carotid Ligation

The WT CKD, caspase-1^{-/-} CKD and WT sham-surviving mice underwent common left carotid ligation as reported (Kokubo et al., 2009, *J Am Soc Nephrol* 20:1236-45). Under sterile conditions, a vertical incision was made in the left neck with the left common carotid artery and carefully dissected out. The carotid bifurcation was identified and a 7-0 prolene suture (Ethicon, Somerville, NJ) was used to ligate the common carotid artery at the level of the bifurcation. Three weeks after the creation of the arterial injury, we euthanized the mice and perfusion-fixed the left common carotid via a left ventricle puncture and perfusion of formalin at 100 mmHg for 15 minutes.

20
25

Histomorphometry

The left common carotid artery distal to the ligation extending all the way to the ostia at the level of the aortic arch was harvested at the time of sacrifice. Samples were processed and embedded in paraffin. Serial sections of 5 µm thickness every 100 µm were obtained throughout the entire left common carotid artery including the ligation injury, and Artery sections were stained with the Verhoeff elastic-van Gieson (VvG), hematoxylin and eosin (H&E) (Polysciences, Warrington, PA). For immunohistochemistry, adjacent sections

30

were stained for vascular smooth muscle cells (SM alpha-actin, 1:500 dilution; Sigma-Aldrich, St. Louis, Missouri). Volumetric measurements for NH lesion and thrombus were performed on digitizing images using Image J software (National Institutes of Health). As described in Figure 28, measurements were made of the vessel lumen area, neointimal area (enclosed by the black arrows), medial area and the adventitia. The percentage of luminal stenosis was calculated using the formula $(1-A/C) \times 100$. The ratio of intimal (I) area to medial area (M) was calculated using the formula $I \text{ area}/M \text{ area} = (B-A)/(C-B)$. The results of these parameters from each mouse group were averaged to obtain the mean values for luminal stenosis.

Statistics

The results were shown as the mean $\pm$ 2 standard deviations (SD). Excel statistical package was used for the quantitative analysis. The results were analyzed for statistical variance using an unpaired *t* test. The results were considered statistically significant at values of $p < 0.05$.

The results of the experiments are now described.

Caspase-1 inhibition partially corrects CKD patients' serum-induced downregulation of VSMC contractile gene markers

We hypothesized that the caspase-1 activation pathway in VSMC may be able to sense elevated uremic metabolic waste in CKD patients' serum and make VSMC undergo the phenotypic change from "contractile" to "synthetic" based on the newly identified role of the caspase-1 inflammasome pathway as a major sensor for endogenous metabolic waste-related DAMP (Yin et al., 2013, Front Biosci 18:638-49). To examine this novel hypothesis, we adopted an *in vitro* cultured human primary aortic VSMC (HAVSMC) treated with CKD patients' serum and focused on the detection of VSMC contractile gene marker downregulation. The results showed that the exposure of HAVSMC to pooled CKD patient sera significantly decreased the expression of contractile muscle markers to a relative quantification of 0.329 for alpha-actin and 0.394 for calponin compared to non-treated controls, which suggested that the *in vitro* model was valid. In addition, caspase-1 inhibition partially rescued the downregulation of CKD patient sera-induced contractile muscle markers and increased the relative quantification to 0.588 for alpha-actin and 0.601 for calponin, when compared to that of the non-treated controls (Figure 29). These results suggest that the

caspase-1 activation pathway in VSMC may be able to sense elevated uremic metabolic wastes in CKD patients' serum and make VSMC undergo the phenotypic change from "contractile" to "synthetic"; and that inhibition of caspase-1 activity in VSMC partially corrects the downregulation of CKD patients' serum-reduced VSMC contractile markers.

5

BUN level is not significantly different in wild-type CKD mice versus caspase-1 -/- CKD mice

In order to determine the role of caspase-1 in the development of neointimal hyperplasia in the carotid artery, the murine CKD model (Figure 30A) was established in 10 WT mice and 10 caspase-1 -/- mice. In addition, 10 WT mice were used to create a Sham-surgery model as controls. After the creation of the CKD model, the mice underwent serum biological analysis. The results showed that there were no significant differences in the tested biological measurement between the WT and caspase-1 -/- CKD mice (Figure 30B). Although the blood urea nitrogen (BUN) level in WT CKD mice was significantly higher than that reported for the WT mice (24.60 ± 2.62) (Lichtnekert et al., 2011, PLoS One 6:e26778), the BUN level did not show significant differences between WT CKD mice and caspase-1 -/- CKD mice (65.9 ± 11.64 mg/dL versus 71.43 ± 35.5 mg/dL; $p < 0.18$), and the BUN levels in WT CKD mice were similar to that of what we reported previously (Kokubo et al., 2009, J Am Soc Nephrol 20:1236-45), suggesting that the CKD model was established successfully. Moreover, there were no significant differences in body weight between the groups at the time of left common carotid artery (LCCA) ligation, and the body weights were in the reported range (Kokubo et al., 2009, J Am Soc Nephrol 20:1236-45). Of note, a previous report showed that neither inflammasome components NLRP3-, ASC- nor caspase-1-deficiency had any significant effect on renal histopathology nor the proteinuria of serum nephritis (Lichtnekert et al., 2011, PLoS One 6:e26778), which were all well correlated with our results that no significant change was found in the BUN level of WT CKD mice and caspase-1 -/- CKD mice. Taken all together, these analyses suggest that the caspase-1 inflammasome pathway may not play a significant role in the kidney pathogenesis caused by the trauma in the CKD model nor does it have a direct adaptive immune response in the serum/antibody-triggered nephritis model (Lichtnekert et al., 2011, PLoS One 6:e26778).

Caspase-1 deficiency significantly decreases CKD-promoted neointimal hyperplasia of the carotid artery

Based on our results that inhibition of caspase-1 activity in VSMC partially corrects CKD patients' serum-induced downregulation of VSMC contractile markers, we hypothesized that caspase-1 activation in VSMC may decrease the VSMC "contractile" phenotype, promote VSMC migration and accelerate neointima hyperplasia of the artery. In order to test this hypothesis, we established a mouse carotid ligation model as previously reported (Kokubo et al., 2009, J Am Soc Nephrol 20:1236-45). Six WT CKD mice, eight caspase-1 $-/-$ CKD mice and seven WT sham mice underwent carotid ligation procedure, and were kept three weeks for histophotometric analysis. After preparing and staining the histological samples with the Verhoeff–Van Gieson staining (elastic fibers), the neointimal hyperplasia in each of these sections was analyzed. The results showed that the neointimal hyperplasia volumes are increased significantly in WT CKD mice from 239,775.07 μm^3 to 1,440,023.70 μm^3 in the sham surgery mice ($p = 0.0196$) (Figure 31A). In addition, the results showed that the neointimal hyperplasia volumes are significantly reduced by 5 folds in caspase-1 $-/-$ CKD mice to 71,069.97 μm^3 from 1,440,023.70 μm^3 in WT CKD mice ($p = 0.035$) (Figure 31B). Moreover, no differences were found in the neointimal hyperplasia volumes between WT sham mice and CKD capase-1 $-/-$ mice. In order to consider the potential variations caused by the process of histological slides, we also calculated the neointimal hyperplasia to media ratio for each group of mice (Figure 31C). The results showed that the neointimal hyperplasia/media volume ratio of the WT sham mice was 18.50 while that of the WT type CKD mice was 88.03. There were statistical differences between the ratios of WT sham and WT CKD mice; $p = 0.025$. The neointimal hyperplasia/media volume ratio of the caspase-1 $-/-$ CKD mice was 17.98. Furthermore, there are statistical differences between WT CKD and caspase-1 $-/-$ CKD; $p = 0.023$. In addition, the percentages of stenosis in carotid arteries were also examined (Figure 31D). The results showed that WT sham mice were found to have lumen stenosis percentages of 19.24%. By comparison, WT CKD mice were found to have the lumen stenosis of 68.25 ($p < 0.001$). In contrast to that of WT CKD mice, the lumen stenosis percentage of caspase-1 $-/-$ CKD mice was 22.37% ($p < 0.001$). As the controls, no significant differences were found between the media volumes of WT CKD and that of caspase 1 $-/-$ CKD groups (Figure 31E). These results demonstrated that caspase-1 deficiency significantly decreases CKD-promoted neointimal hyperplasia of the carotid artery, which suggests that caspase-1 plays a critical role in accelerating CKD-promoted neointima hyperplasia of the carotid artery.

Caspase-1 deficiency rescues CKD-decreased expression of contractile vascular smooth muscle markers in NH lesion

In order to determine the molecular mechanism underlying the phenomenon we hypothesized that caspase-1 deficiency inhibits neointima hyperplasia by preserving the expression of contractile smooth muscle marker genes of VSMC based on our results that caspase-1 deficiency significantly decreases CKD-promoted neointimal hyperplasia of the carotid artery (Figure 31), and that caspase-1 inhibition partially corrects the CKD patients' sera-induced downregulation of VSMC contractile gene markers (Figure 29). To examine this hypothesis, we extracted RNAs from carotid samples and performed reverse transcription followed by quantitative PCR to measure the expressions of contractile smooth muscle markers that include alpha actin, calponin, SM22, and smoothelin (Figure 32). The results showed that the relative quantification of alpha actin in caspase-1 $-/-$ CKD mice was 1.4 fold when compared to that of WT CKD mice. The relative expressions of calponin (1.28 folds), SM22 (1.22 folds), and smoothelin (1.41 folds) were all elevated in caspase-1 $-/-$ CKD mice when compared to that of the carotid artery samples of WT CKD mice. The results suggest that caspase-1 deficiency inhibits neointima hyperplasia via the preservation of the contractile VSMC marker genes expression.

Caspase-1 deficiency decreases $\alpha v \beta 3$ integrin expression

As we pointed out in our previous review, $\alpha v \beta 3$ integrin blockade led to a significant reduction in neointimal lesion formation (Kokubo et al., 2007, J Vasc Surg, 45:A33-8), which suggested that $\alpha v \beta 3$ integrin and its ligand vitronectin mediate VSMC migration in NH formation. We hypothesized that caspase-1 promotes the expression of $\alpha v \beta 3$ integrin, the vitronectin receptor, in order to determine a mechanism underlying VSMC migration into the neointima. To test this hypothesis, we wanted to determine whether the expression of $\alpha v \beta 3$ integrin is decreased in any caspase-1 deficient tissues. By the analysis of the microarray data deposited in the NIH-GEO Profile database, we found that caspase-1 expression in WT mouse tissues is 22 folds higher than that of caspase-1 gene knock-out tissue ($p < 0.01$) (Figure 33), which suggests that 1) the tissue mRNA sample preparations of caspase-1 $-/-$ mice and WT control mice are correct; 2) the expressions of the three house-keeping genes (gapdh, aldoA, and nono) in the microarrays of caspase-1 $-/-$ mice versus WT control mice are very similar with a confidence interval ($\bar{x} \pm 2$ standard deviations) of 1.07 ± 0.08 that further suggests that the tissue mRNA sample preparations of caspase-1 $-/-$ mice and WT control mice are of high quality; and 3) the expression of αv integrin in WT

mouse tissue is 1.53 folds higher than that in caspase-1 $-/-$ mouse tissues ($p < 0.0247$) whereas the expression of the $\alpha v \beta 3$ integrin ligand vitronectin in WT tissue is -1.19 folds higher than that in caspase-1 $-/-$ mouse tissues ($p < 0.1910$). Importantly, $\alpha v \beta 3$ integrin is a heterodimer of αv and $\beta 3$ subunits (Desgrosellier et al., 2010, Nat Rev Vancer 10:9-22). We did not find

5 significant changes of $\beta 3$ integrin expression induced by caspase-1 depletion. However, when we analyzed the DNA sequence data in the NIH/NCBI-UniGene database, we found that $\beta 3$ integrin RNA transcripts are expressed at a relative high level in human vessels (not shown). This finding suggests the possibility that highly expressed $\beta 3$ integrin can associate with caspase-1 promoted αv integrin in order to upregulate the functional $\alpha v \beta 3$ integrin to mediate

10 VSMC migration. In addition, αv integrin is a ubiquitously expressed protein in most tissues (see the RNA transcript expression profile at the NIH-NCBI-UniGene database Hs.436873). Thus, αv integrin expression is not significantly regulated by tissue differentiation signals but may possibly be regulated by pathological inflammatory signals. Since there are no microarray data sets from vessels available, our database mining results of $\alpha v \beta 3$ integrin

15 RNA transcript expression with the microarray data set of GSE25205 from epididymal white adipose tissue in the NIH-Geo Database were justified based on these considerations and manipulations. The results suggest that caspase-1 may promote the expression of $\alpha v \beta 3$ integrin, but the effect of caspase-1 on the expression of the $\alpha v \beta 3$ integrin ligand vitronectin is not statistically significant. These results suggest that caspase-1 potentially promotes

20 neointima hyperplasia by enhancing the expression of the VSMC migration driving molecule $\alpha v \beta 3$ integrin.

Caspase-1 pathway plays a critical role in NH formation and serves as a novel therapeutic target for the suppression of CKD-promoted NH

25 It was reported that the bone marrow-derived inflammasome adaptor protein apoptosis-associated speck-like protein containing CARD (ASC) is critical for neointima formation after vascular injury (Yajima et al., 2008, Circulation 117:3079-87), which, however, did not report the role of vascular residential cell (for example, VSMC) expressed ASC. It has also been reported that caspase-1 inflammasome plays an important role in

30 pulmonary vascular remodeling (Villegas et al., 2013, Antioxid Redox Signal 18:1753-64), atherosclerosis (Düwell et al., 2010, Nature 464:1357-61) and the pathogenesis of kidney disease (Kumar et al., 1997, Circulation 96:4333-42). However, an important question remains to be addressed: whether caspase-1 plays a critical role in promoting CKD-induced VSMC phenotypic switch from “contractile” to “synthetic” and the development of NH. The

combination of CKD mouse model and the left carotid artery ligation-induced NH model, caspase-1 $-/-$ mice and CKD patients sera-stimulated HVSMC were used to determine whether caspase-1 plays any role in NH formation. We made the following findings: 1) Caspase-1 inhibition partially corrects CKD patients' sera-induced downregulation of VSMC contractile markers; 2) BUN level is not significantly different in WT CKD mice versus caspase-1 $-/-$ CKD mice; 3) Caspase-1 deficiency significantly decreases CKD-promoted neointimal hyperplasia of the carotid artery; 4) mechanistically, Caspase-1 deficiency rescues CKD-induced downregulation of VSMC contractile markers in NH lesion; and 5) Caspase-1 deficiency decreases the expression of the VSMC migration molecule $\alpha\beta 3$ integrin. Our results suggest that the caspase-1 pathway senses CKD-elevated metabolic wastes and promotes the switch from the VSMC "contractile" phenotype to "synthetic" phenotype both *in vitro* and *in vivo*. CKD promotes caspase-1 dependent NH formation in the left carotid artery via a decrease in the expression of VSMC contractile phenotypic markers and an increase in the expression of VSMC migration molecule $\alpha\beta 3$ integrin.

Our results suggest that caspase-1 depletion significantly decreases CKD-promoted neointima hyperplasia but does not cause significant changes in the media volumes of the NH lesion arteries. Once again, our results demonstrate that CKD-promoted NH is an inward remodeling process involved in the migration and proliferation of VSMC primarily in the tunica intima, that are adjacent to the intima but not distal to the intima, which results in the thickening of arterial walls and a decreased arterial lumen space. The mechanisms underlying the initiation of VSMC migration and the switch from "contractile" to "synthetic" phenotype in response to CKD still remain unknown. Recent reports demonstrated that TLR work in synergy with cytosolic sensing receptor families such as NLR in recognizing endogenous DAMP and in mediating the upregulation and activation of a range of inflammatory genes (Yin et al., 2013, Front Biosci 18:638-49). Our results presented here have clearly demonstrated that the caspase-1 pathway serves as the mechanisms underlying the initiation of VSMC migration and the switch from "contractile" to "synthetic" VSMC phenotypes that are responsive to CKD-elevated metabolic danger signals since caspase-1 deficiency completely inhibits CKD-promoted NH formation. Since the two processes of VSMC phenotypes switch, e.g., it can be inferred that a decrease in the VSMC "contractile" phenotype and increase in the VSMC "synthetic" phenotype is linked (Alexander and Owens, 2012, Annu Rev Physiol 74:13-40), which further justifies our focus on caspase-1 inhibition of CKD-induced decrease in VSMC "contractile" phenotype. Our results have also elucidated the detailed molecular mechanisms and demonstrated that caspase-1 enhances CKD-

decreased expressions of VSMC contractile markers and CKD-increased expression of VSMC migration molecule $\alpha v\beta 3$ integrin. Our new working model presented in Figure 34 highlights these significant findings.

Patients that undergo hemodialysis-utilizing AVF often need to be surgically re-intervened in order to correct stenotic lesions (Lee et al., 2009, Adv Chronic Kidney Dis 15:329-38). These surgically repeated interventions increase the morbidity and mortality in CKD patients that receive dialysis (Lee et al., 2002, Am J Kidney Dis 40:611-22). The major cause of vascular access failure in AVF is due to neointimal hyperplasia (Lee et al., 2009, Adv Chronic Kidney Dis 15:329-38), which is accelerated by the uremic state in CKD (Langer et al., 2010, Kidney Int 78:1312-21; Kokubo et al., 2009, J Am Soc Nephrol 20:1236-45). However, no effective therapies are available to inhibit the initiation and progression of NH associated with CKD. For the first time, our results have demonstrated that the caspase-1 pathway plays a critical role in NH formation, and that caspase-1 serves as a novel therapeutic target for the suppression of CKD-promoted NH and various vascular pathologies including atherosclerosis, hypertension and post-angioplasty restenosis (Regan et al., 2000, J Clin Invest 106:1139-47; Owens et al., 2004, Physiol Rev 84:767-801).

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

CLAIMS

What is claimed is:

1. A method for treating or preventing a disease or disorder associated with at least one of endothelial activation, inflammation and atherogenesis in a subject in need thereof comprising administering to the subject an inhibitor of caspase-1-Sirt1-AP-1 pathway.
2. The method of claim 1, wherein the inhibitor is an inhibitor of at least one of the group consisting of caspase-1 activity and caspase-1 expression.
3. The method of claim 1, wherein the inhibitor is a non-cleavable Sirt1 peptide inhibitor.
4. The method of claim 3, wherein the inhibitor is a human non-cleavable Sirt1 peptide inhibitor.
5. The method of claim 3, wherein the non-cleavable Sirt1 peptide inhibitor comprises a cell membrane permeable protein transduction sequence.
6. The method of claim 3, wherein the non-cleavable Sirt1 peptide inhibitor is at least one of:
 - a) Mouse nc-Sirt1:
RQIKIWFQNRRMKWKKGYRDNLLLTAGLLTNGFHSC (SEQ ID NO: 1);
or
 - b) Human nc-Sirt1:
RQIKIWFQNRRMKWKKGYRDNLLFGAEIITNGFHSC (SEQ ID NO: 2).
7. The method of claim 2, wherein the inhibitor is selected from the group consisting of a nucleic acid, a siRNA, an antisense nucleic acid, a ribozyme, a peptide, a small molecule, an antagonist, an aptamer, and a peptidomimetic.
8. An inhibitor of caspase-1 activity comprising a non-cleavable Sirt1 peptide inhibitor.

9. The inhibitor of claim 8, wherein the inhibitor is a human non-cleavable Sirt1 peptide inhibitor.

10. The inhibitor of claim 9, wherein the non-cleavable Sirt1 peptide inhibitor comprises a cell membrane permeable protein transduction sequence.

11. The inhibitor of claim 9, wherein the non-cleavable Sirt1 peptide inhibitor is at least one of:


a) Mouse nc-Sirt1:

RQIKIWFQNRRMKWKKGYRDNLLLTAGLLTNGFHSC (SEQ ID NO: 1);

or


b) Human nc-Sirt1:

RQIKIWFQNRRMKWKKGYRDNLLFGAEIITNGFHSC (SEQ ID NO: 2).




Figures 1A – 1E

A.



B.




C.


	Cholesterol (mg/dl)		Triglyceride (mg/dl)	
	Normal Chow	HF3w	Normal Chow	HF3w
ApoE ⁺	220 ± 67.5 (n=6)	587 ± 120.5 (n=3)	257.2 ± 55.5	289 ± 13.7
ApoE ⁺ /Casp-1 ⁺	320.4 ± 64.6 (n=5)	623.25 ± 85.5 (n=4)	303 ± 28.2	328 ± 99.3

(P>0.05, no statistical differences between the groups)


Figures 2A – 2C




Figures 3A – 3B




Figures 4A – 4C




Figures 5A – 5D



Figures 6A – 6G



Figures 7A – 7D




Figures 8A – 8C


A.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	PC																							PC
B	CXCL13	C5a	G-CSF	GM-CSF	CCL1	CCL11	siCAM-1	IFN- γ	IL-1 α	IL-1 β	IL-1ra	IL-2												
C	IL-3	IL-4	IL-5	IL-6	IL-7	IL-10	IL-13	IL-12p70	IL-16	IL-17	IL-23	IL-27												
D	CXCL10	CXCL11	CXCL1	M-CSF	CCL2	CCL12	CXCL9	CCL3	CCL4	MIP-2	CCL5	CXCL12												
E	CCL17	TIMP-1	TNF- α	TREM-1																				
F	PC																							NC

B.



C.



Figures 9A – 9C





Figure 10


A.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	PC																							PC
B	CXCL13	C5a	G-CSF	GM-CSF	CCL1	CCL11	sICAM-1	IFN- γ	IL-1 α	IL-1 β	IL-1 τ	IL-2												
C	IL-3	IL-4	IL-5	IL-6	IL-7	IL-10	IL-13	IL-12p70	IL-15	IL-17	IL-23	IL-27												
D	CXCL10	CXCL11	CXCL1	M-CSF	CCL2	CCL12	CXCL9	CCL3	CCL4	MIP-2	CCL5	CXCL12												
E	CCL17	TIMP-1	TNF- α	TREM-1																				
F	PC																							NC


B.



C.



Figures 11A – 11C

A**B**

1	MADEVALALQAAGSPSAAAA-MEASQPADEPLRKRPRRDGPGLGRSPGEPsAA----V	54
MADE	ALALQ GSPsAA A EAAS PA EPLRKRPRRDGPGL RSPGEP A V	
1	MADEAALALQPGGSPSAAAGADREAAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREV	60
55	APAAAGCEAASAAAPAAALWREAAGAAASAEREAPATAVAGDGDNGSGLR---REPRAADQ	111
	AA GC A+AAA A AA + ATA AG+GDNG GL+ REP AD+	
61	PAAARGCPCGAAAAALWREAEEAEEAAAAGGEQEAQ-ATAAAGEGDNGPGLQGSPSREPPLADN	119
Mouse SIRT1		
112	FDDDEGEEDDEAAAAAAGIYRDNLLITDGLLTNGFHSCESDDDDRTSHASSSSDWTPR	171
	D++ ++E E AAAAAIGYRDNLL D ++TNGFHSCESD++DR SHASSSSDWTPR	
120	LYDEDDDDDEGEEDDEAAAAAAGIYRDNLLFGDIIITNGFHSCESDEEDRASHASSSSDWTPR	179
Human SIRT1		
172	PRIGPYTFVQOHLMIGTDPRTILKOLLPETIPPELDOMTLWQIVINILSEPPKRRKKRKD	231
	PRIGPYTFVQOHLMIGTDPRTILKOLLPETIPPELDOMTLWQIVINILSEPPKRRKKRKD	
180	PRIGPYTFVQOHLMIGTDPRTILKOLLPETIPPELDOMTLWQIVINILSEPPKRRKKRKD	239
232	INTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRGGIYARLAVDFPDLDPQAMFDI	291
	INTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRGGIYARLAVDFPDLDPQAMFDI	
240	INTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRGGIYARLAVDFPDLDPQAMFDI	299
292	EYFRKDPRPFFKFAKEIYPGGQFQPSLCHKFIALSDKEGKLLRNYTQNIOTLEQVAGIQRI	351
	EYFRKDPRPFFKFAKEIYPGGQFQPSLCHKFIALSDKEGKLLRNYTQNIOTLEQVAGIQRI	
300	EYFRKDPRPFFKFAKEIYPGGQFQPSLCHKFIALSDKEGKLLRNYTQNIOTLEQVAGIQRI	359
352	LQCHGSFATASCLICKYKVDCEAVRGDIFNQVPRCPRCPADEPLAIMKPEIVFFGENLP	411
	+QCHGSFATASCLICKYKVDCEAVRGDIFNQVPRCPRCPADEPLAIMKPEIVFFGENLP	
360	LQCHGSFATASCLICKYKVDCEAVRGDIFNQVPRCPRCPADEPLAIMKPEIVFFGENLP	419
412	EQFHRAKMYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELL	471
	EQFHRAKMYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELL	
420	EQFHRAKMYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELL	479
472	GDCDVIINELCHRLGGEYAKLCNPFVKLSEITEKPPRPQKELVHLSELPTPLHISEDSS	531
	GDCDVIINELCHRLGGEYAKLCNPFVKLSEITEKPPR QKEL +LSELPTPLH+SEDSS	
480	GDCDVIINELCHRLGGEYAKLCNPFVKLSEITEKPPRTQKELAYLSELPTPLHISEDSS	539
532	SPERTVPQDSSVIAITLVDQATNNNVNDLEVSES-SCVEEKQEVQTSRNVENI--NVENP	588
	SPERT P DSSVI TL+DQA +N +DL+VSES C+EEKQEVQTSRNVE+I +ENP	
540	SPERTSPPDSSVIVTLTDQAASN-DDLDVSESKGCEEKQEVQTSRNVESIAEQMENP	598
589	DFKAVGSSTADKNERTSVAETVRKCPNRLAKEQISKRLEGNYLFVPPNRYIFHGAEVY	648
	D K VGSST +KNERTSVA TVRKCPNR+AKEQIS+RL+GNQYLF+PPNRYIFHGAEVY	
599	DLKAVGSSTGEKNERTSVAGTVRKCPNRAKEQISRRLDGNQYLFPPNRYIFHGAEVY	658
649	SDSEDDVLSSSSCGSNSDSGTCQSPSLEEPLEDESEIEEFYNGLEDTERPECAGGSIGFG	708
	SDSEDDVLSSSSCGSNSDSGTCQSPSLEEP+EDESEIEEFYNGLED+ + PE AGG+GFG	
659	SDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDSEIEEFYNGLEDPEDPVPERAGGAGFG	718
709	ADGGDQEVVNEAIATRQELTDVNYPsDKS 737 (SEQ ID NO: 33)	
	DG DQE +NEAI+ +QE+TD+NYPs+KS	
719	TDGGDQEAINEAISVKQEVTDNNYPsNKS 747 (SEQ ID NO: 34)	

Species**Casp1 Cleavage Site**

Mouse SIRT1 D142 (Chalkiadaki, A et al., Cell Metab, 2012)

Human SIRT1 D150 (BLAST search and conformation by previously published method: Shen, J et al., Atherosclerosis, 2008)

Figures 12A – 12B

SUBSTITUTE SHEET (RULE 26)





Figure 13



Figures 14A – 14C
SUBSTITUTE SHEET (RULE 26)





Figure 15

A.

VEGFR-2 (Flk1) depletion increases caspase-1 and
ASC expressions

Genes	Dataset(GSE3757)		Dataset(GSE3757)	
	Flk1(-) vs. Flk1(+) 84Hrs		Flk1(-) vs. Flk1(+) 95Hrs	
	Fold Change	p value	Fold Change	p value
Caspase1				
Activation Complex				
Casp1	1.48	0.06443	1.28	0.29813
PYCARD (Asc)	2.45	0.00014	1.14	0.37271
Caspase1 Related				
Cytokines				
IL1 ^β	1.14	0.31305	1.23	0.31558
IL18	1.12	0.46793	1.09	0.58626
Housekeeping Genes				
Gapdh	1.08	0.41967	1.02	0.82283
Aldoa	1.09	0.47737	1.12	0.33900

B.




Legend CTRL – Control (Grey) LPC- Lysophosphatidylcholine (Blue) SU -VEGFR-2 inhibitor (Red)

Figures 16A – 16B


A. Caspase-1 depletion increases VEGFR-2 expression

Gene	Dataset (GSE25205)		WT vs. Casp1 KO		
	WT Value	Casp1KO Value	ΔValue	Fold Change	p value
VEGFR-2					
Vegfr -2 (Flk1/Kdr)	7.97	8.86	-0.68	0.62	0.01021
Caspase-1 Activation Complex					
Casp1	9.32	4.85	4.47	22.23	0.00000
Caspase-1 Related Cytokines					
IL-18	3.98	4.17	-0.20	0.87	0.23650
IL-18	7.99	8.14	-0.16	0.90	0.37939
House keeping genes					
Gapdh	12.47	12.54	-0.07	0.95	0.55139
Nono	11.23	11.13	0.10	1.07	0.98092
Aldoa	12.58	12.64	-0.06	0.96	0.90721


B.





C.



D.




Figures 17A – 17D



Legend: CTRL- Control (Gray) LPC- Lysophosphatidylcholine (Blue) C-1 Caspase-1 Inhibitor (Green)

Figures 18A – 18B



Figures 19A – 19C





Figure 20



Figures 21A – 21C


cDNA expression microarray experiments

Figure 22






Figure 24



Figures 25A – 25E

SUBSTITUTE SHEET (RULE 26)



Figures 26A – 26B

SUBSTITUTE SHEET (RULE 26)




Figure 27




Figure 28







Figure 29



Figures 30A – 30B



Figures 31A – 31E





Figure 32

A.

Genes	Dataset (GSE25205)	
	WT Vs. Casp1 -/-	
	Fold Change	P.Value
Casp1 (Caspase 1)	22.23	2.59E-07
Itgav (Integrin alpha V)	1.53	0.0247
Vtn (Vitronectin)	-1.19	0.1910
Housekeeping Genes (HG)		
Gapdh	1.12	0.3250
Aldoa	1.03	0.6990
Nono	1.07	0.2760
Confidence Interval of HG	1.07 $\pm$ 0.08	

(# analyzed from the microarray data set GSE25205
from epididymal white adipose in the NIH -Geo Database)



Figures 33A – 33B




Figure 34

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/15964

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/64; 45/06, 39/395 (2016.01)

CPC - A61K 38/217; 45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) Classification(s): A61K 31/64; 45/06, 39/395; CPC Classification(s): A61K 38/217; 45/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPTO Web Page; PatSeer (US, EP, WO); Google; Google Scholar; EBSCO: Entrez Pubmed; NCBI BLAST (protein); Lens.org; ENA; Search terms -- inflammation, caspase-1, sirtuin, sirt1, inhibitor, siRNA, 'membrane permeability', 'non-cleavable inhibitor'

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2014/0314746 A1 (PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE) October 03, 2014; abstract; paragraphs [0006], [0007], [0010], [0011], [0013], [0016], [0045], [0093]; figure 7	1-2, 7 ----- 3-5
X -- Y	(CHALKIADAKI, A. et al.) High-Fat Diet Triggers Inflammation-Induced Cleavage of SIRT1 in Adipose Tissue To Promote Metabolic Dysfunction. Cell Metabolism, 08 August 2012, Vol. 16, pages 180-188; page 185, second column, first and second paragraphs; page 186, first column, second paragraph; figures 4E, 5A	8, 9 ----- 3-5, 10
Y	US 2012/0329721 A1 (CHAUVIER, D et al.) December 27, 2012; paragraphs [0029], [0106], [0222]	4, 9, 10
Y	US 2010/0137345 A1 (LEO, O et al.) June 03, 2010; abstract; paragraphs [0001], [0060], [0091]	5, 10
A	US 2005/0222034 A1 (HSU, SI-H) October 06, 2005; paragraphs [0064], [0094], [0108], [0143]; SEQ ID NO: 8	6, 11
A	US 2010/0210692 A1 (FARMER, SR et al.) August 19, 2010; entire document	1-11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 June 2016 (14.06.2016)

Date of mailing of the international search report

11 JUL 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/15964

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

-***-Continued Within the Next Supplemental Box-***-

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-11; SEQ ID NO: 1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US16/15964

Continued from Box III: Lack of Unity of Invention

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups I+, Claims 1-11 and SEQ ID NO: 1 (Sirt1 peptide inhibitor) are directed toward a method for treating or preventing a disease or disorder associated with at least one of endothelial activation, inflammation and atherogenesis in a subject in need thereof comprising administering to the subject an inhibitor of caspase-1-Sirt1-AP-1 pathway; and an inhibitor of caspase-1 activity therefor.

The method and inhibitor will be searched to the extent that they comprise a peptide inhibitor encompassing SEQ ID NO: 1 (first exemplary Sirt1 peptide inhibitor). Applicant is invited to elect additional inhibitor(s), with specified SEQ ID NO: for each, to be searched. Additional inhibitor sequence(s) will be searched upon the payment of additional fees. It is believed that claims 1-5, 6 (in-part), 7-10 and 11 (in-part) encompass this first named invention and thus these claims will be searched without fee to the extent that they encompass SEQ ID NO: 1 (Sirt1 peptide inhibitor). Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group (s) will result in only the first claimed invention to be searched/examined. An exemplary election would be a Sirt1 peptide inhibitor encompassing SEQ ID NO: 2 (first exemplary elected Sirt1 peptide inhibitor).

No technical features are shared between the sequences of Groups I+ and, accordingly, these groups lack unity a priori.

Groups I+ share the technical features including: a method for treating or preventing a disease or disorder associated with at least one of endothelial activation, inflammation and atherogenesis in a subject in need thereof comprising administering to the subject an inhibitor of caspase-1-Sirt1-AP-1 pathway; and an inhibitor of caspase-1 activity comprising a non-cleavable Sirt1 peptide inhibitor.

However, these shared technical features are previously disclosed by US 2014/0314746 A1 to Philadelphia Health and Education Corporation, d/b/a Drexel University College of Medicine (hereinafter 'Philadelphia') in view of the article 'High-Fat Diet Triggers Inflammation-Induced Cleavage of SIRT1 in Adipose Tissue To Promote Metabolic Dysfunction' by Chalkiadaki et al. (hereinafter 'Chalkiadaki').

Philadelphia discloses: a method for treating or preventing a disease or disorder associated with inflammation in a subject in need thereof (a method for treating or preventing a disease or disorder associated with inflammation in a subject in need thereof; abstract) comprising administering to the subject an inhibitor of caspase-1-Sirt1-AP-1 pathway (comprising administering to the subject an inhibitor of caspase-1; paragraphs [0006], [0007], [0010]). Philadelphia further discloses wherein the inhibitor is a peptide aptamer or peptidomimetic (wherein the inhibitor is a peptide aptamer or peptidomimetic; paragraphs [0010], [0055]).

Philadelphia does not disclose an inhibitor of caspase-1 activity comprising a non-cleavable Sirt1 peptide inhibitor.

Chalkiadaki discloses wherein SIRT1 is cleaved by caspase-1 (wherein SIRT1 is cleaved by caspase-1; abstract), and wherein a modified form of SIRT1 is resistant to caspase-1 cleavage (wherein D142A SIRT1 is resistant to caspase-1 cleavage (wherein a modified form of SIRT1 is resistant to caspase-1 cleavage); page 186, column 1, paragraph 2); and wherein said cleavage is inflammation-induced (wherein said cleavage is inflammation-induced; abstract).

It would have been obvious to a person of ordinary skill in the art at the time of the invention was made to have modified the disclosure of Philadelphia to have provided a peptide inhibitor of Caspase-1, including a peptide including at least a fragment of SIRT1 comprising a D142A mutation which was resistant to caspase-1 cleavage, as disclosed by Chalkiadaki, as a competitive inhibitor of caspase-1, potentially further including additional protease-resistant moieties, such as non-canonical amino acids that further enhance the protease resistance of the peptidomimetic in order to enhance the lifetime thereof in a subject, in order to provide an effective means of inhibiting caspase-1, as well as the inflammation-associated cleavage of at least one target molecule, SIRT1, as disclosed by Chalkiadaki, as a part of the method of treating or preventing a disease associated with inflammation disclosed by Philadelphia.

Since none of the special technical features of the Groups I+ inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by a combination of the Philadelphia and Chalkiadaki references, unity of invention is lacking.